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ABSTRACT 
An acetonitrile based protein extraction method was developed that demonstrated high 
efficient and effective removal of high abundant proteins from both human and murine 
serum. The protein content of the extract was characterised using gel electrophoresis, the 
Bradford assay and liquid chromatography – tandem mass spectrometry (LC-MS/MS) with 
database searching. Selected reaction monitoring (SRM) analysis was used to quantify the 
levels of high abundant serum proteins to further validate the extraction methodology. The 
ACN depletion method, in combination with artificial neural networks (ANNs) data 
mining software, was applied to a murine growth hormone (GH) gene doping study with 
the aim of identifying biomarker ions capable of detecting gene doping. The LC-MS and 
ANNs analysis approach failed to conclusively identify a biomarker to gene doping in the 
mouse model. However, the application of the same technique to serum from a rhGH 
administration study in humans, returned models capable of discriminating between rhGH 
treated placebo states. The ion identified as being the most discriminatory was 
characterised using mass spectrometry, and was derived from the protein leucine-rich α-2-
glycoprotein (LRG). Multiple LRG related tryptic peptides were identified as being up-
regulated upon dosing with recombinant human GH (rhGH).  
 
A high throughput LC-MS/MS and SRM approach was developed to quantify proteins in 
human serum. The approach was validated by comparison of LC-MS/MS derived APO A1 
concentrations with those obtained using established clinical analyser technologies. The 
LC-MS/MS methodology was applied to a large cohort of 257 serum samples from two 
rhGH administration studies performed at Royal Free Hospital . The two administrations 
included serum samples from 15 individuals who had been dosed daily with rhGH. Serum 
concentrations of the established rhGH biomarker insulin-like growth factor-I (IGF-I) were 
quantified by LC-MS/MS and compared well with those determined using two different 
immunoassay-based methodologies. Serum concentrations of the LRG protein were 
measured simultaneously with IGF-I and appeared to increase in 14 of the 15 rhGH dosed 
individuals. Combining the LRG and IGF-I data further increased the separation of rhGH 
treated and placebo states within each individual, and the application of ANNs analysis 
showed that the combination of the two proteins increased the discrimination 
characteristics over using IGF-I alone. 
 
 
iii 
The murine equivalent of the LRG protein was identified and SRM transitions for a  
tryptically derived peptide were developed, along with transitions for monitoring a peptide 
from the murine IGF-I protein. These transitions were used to quantify the two proteins in 
the remaining aliquots from a murine GH gene doping experiment, however neither protein 
appeared to increase in the GH +ve plasmid samples that were analysed.  
 
 
Keywords. 
Serum proteomics, Quantitative proteomics, recombinant human growth hormone abuse, 
Gene doping,  
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1. INTRODUCTION 
1.1 A BRIEF HISTORY OF DOPING IN SPORTS 
Competitive athletics is an ancient tradition and has evolved as human cultures have 
changed over the millennia. The most famous sporting event of all is the Olympics, 
which is believed to have started in the year 776 BC and was held regularly until 393 
AD, lasting some 1200 years (1). In the modern Olympics (1896-present), the degree of 
sophistication of the Olympic sports has increased significantly. This has been matched 
with an increase in athletic performance, either through scientifically driven training 
regimes or artificially by doping. The world of competitive sports has always involved 
great rewards and prestige for the winning athletes and their respective countries where, 
in recent times, successful athletes can receive large amounts of money in the guise of 
multi-million dollar sponsorship deals. The possibility of gaining such rewards is so 
alluring to some competitors that the temptation to cheat can be overwhelming and can 
result in a “win at all costs” attitude. Cheating could involve either a physical break of 
the rules, such as running in a walking event, or the use of performance enhancing 
compounds, the latter being significantly harder to detect. Therefore, athletes are more 
likely to use performance enhancing agents to gain advantages over fellow competitors.  
 
In the ancient Olympics, performance enhancement was achieved by eating a diet of 
figs, or through the use of hallucinogenic mushrooms (2). Modern athletes have the 
benefit of the immense improvements in the field of science and technology that have 
been accomplished over the last fifty years. In particular, the advances in the chemical 
and biological sciences has lead to the understanding of the function of many 
endogenous compounds and how they can be used to manipulate specific biological 
pathways. Furthermore, current chemical and biochemical engineering processes have 
enabled the production of synthetic analogues of specific compounds, such as 
stanozolol (3). This has lead to the situation that any member of the public, not just 
competitive athletes, can obtain synthetically produced, biologically active compounds 
(4). 
 
The combination of the ready availability of synthetically produced and bioactive 
performance enhancing compounds, and the apparent desire of athletes to use them, 
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demanded the establishment of anti-doping testing regimes. The first systematic testing 
at an Olympic games was performed at Munich in 1972 where stimulants were tested 
for, and found, using gas chromatography (5). Since 1972, doping has been discovered 
on a regular basis. One notorious case was that of the Canadian 100 meter sprinter, Ben 
Johnson, who broke the world 100m sprint record in the 1988 Olympics at Seoul, 
earning him the title “The fastest man on earth”. A subsequent urine test detected the 
synthetic steroid stanozolol, therefore he was stripped of his Olympic gold medal, and 
title.  
 
Synthetic drugs, such as stanozolol, can be detected using current analytical techniques, 
however the knowledge of their existence is essential for their detection. Armed with 
the particulars of current testing regimes, unscrupulous chemical engineers have 
specifically designed drugs that would be undetectable. Tetrahydrogestrinone (THG), is 
a recent case where the testing authorities were unaware its widespread abuse (6), and 
the drug had even been dubbed “The clear” by athletes and trainers using the 
compound. Its chemical structure was designed so that it would not derivatise using 
standard reagents prior to gas chromatography mass spectrometry (GC-MS) analysis 
(6). After a brief investigation, the analysis of the drug was subsequently switched to a 
liquid chromatography tandem MS based (LC-MS/MS) method, enabling its detection 
for future sample analysis. This synthetic steroid was then tested for retrospectively and 
a number of athletes tested positive for the steroid. The most notorious of whom was 
Marion Jones, who admitted to abusing THG in October 2007 and was stripped of all 
medals back to September 2000, which included 5 golds and two bronzes. 
 
The abuse of THG highlights the extents to which athletes will go to in order to gain an 
advantage over their peers. At that time, THG was a new chemical entity and very little 
was known about its toxicological and pharmacokinetic properties. Despite this, it was 
taken by athletes for its performance enhancing properties over a sustained period of 
time. This disregard for an athlete’s own health is not unexpected and was highlighted 
in a poll devised by Bob Goldman (7), which included two questions specifically related 
to abuse of performance enhancing substances. The first question was: 
 
“If you were given a performance enhancing substance and you would not be caught 
and win, would you take it?” 
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The result from the 1995 poll of 198 elite US athletes was that 195 (98%) said that they 
would take the substance. The second question was: 
 
“If you were given a performance enhancing substance and you would not be caught,  
win all competitions for 5 years, then die, would you take it?” 
 
Over 50% of the participants of the questionnaire answered yes, and similar results were 
seen on a biannual basis. This disregard for the safety of athletes has been documented, 
where evidence of physical damage caused by regular abuse of anabolic steroids in 
young female Olympic athletes was uncovered after the collapse of the German 
Democratic Republic (GDR) in 1990 (8). Furthermore, deaths occurring in athletes 
doping with performance enhancing substances have occurred over the last 120 years. 
The first documented incidence was in 1886, when the English cyclist Arthur Linton 
overdosed on “tri-methyl” during a 600 km race (2).  
 
Advances in medical sciences have lead to the production of protein based drugs like 
recombinant human erythropoietin (rhEPO) and recombinant human growth hormone 
(rhGH). In 1989, Amgen developed rhEPO to aid patients suffering from diseases such 
as anaemia, and has been used to help AIDS sufferers (9) and rhGH was developed by 
Genentech in 1981 to treat growth deficiencies (10). These protein therapeutics came to 
the attention of athletes and their trainers due to the ability of the proteins to possibly 
increase performance through increasing endurance (rhEPO) or muscle and bone 
structure (rhGH).  
 
The detection of protein therapeutics, and proof of their abuse, is significantly more 
complicated than for small molecules. Current detection methods use antibody based 
techniques, which although highly sensitive, are not confirmatory. In 2004, both A and 
B bottles from a Belgian triathlon athlete (Rutger Beke) tested positive for rhEPO. 
However, the result was overturned in 2005 when he successfully proved that bacterial 
contamination had caused the false positive. Another complication is that these proteins 
are produced endogenously, although rhEPO has slightly different glycosylation 
patterns to its endogenously produced equivalent, which is exploited to detect its abuse 
(11,12). However, rhGH is identical to the endogenous form of GH, and therefore a 
detection strategy must take a quantitative approach to determine if levels are outside 
the established normal range. Further complications to detecting rhGH abuse are that 
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endogenous GH is released in a pulsatile fashion, and has a high clearance rate from the 
body, leading to natural peaks and troughs throughout the day (13). GH is also released 
after exercise, where one study demonstrated that after an exercise bout, serum GH 
levels in individuals dosed with placebo reached approximately 50% of that seen in 
individuals administered with rhGH (14). The abuse of rhGH in athletics is believed to 
be widespread, including amateur and even young athletes (15). This apparent level of 
abuse in the sporting community has forced WADA to develop a test for its abuse.    
 
1.1.2 Future doping threats 
The abuse of protein therapeutics such as rhEPO and rhGH is well documented. The 
administration route of these proteins involves subcutaneous injection of the product on 
a regular basis. This regular injection means keeping stocks of the protein. In fact, 
athletes have been caught in possession of the recombinant protein, e.g. a group of 
Chinese swimmers were caught with vials of rhGH en-route to the 1998 world 
swimming championships. A possible alternative to repeat dosing is through the 
relatively new science of gene therapy.  
 
Gene therapy is the practice of introducing a gene into an organism in order to alter its 
phenotype through the expression of a specific protein. The technique has primarily 
been developed to cure human genetic diseases by introducing a specific gene in order 
to produce a functional protein in the event it is either absent, or an ineffective version 
is being produced (discussed in detail in Section 1.2). To date, a single gene therapy 
product has been licensed: Gencidine, which produces p53, a tumour suppressor protein 
instrumental in the control of a normal cell’s growth cycle (16). The drug was licensed 
by the State Food and Drug Administration of China in October 2003 after five years of 
clinical trials. It was initially designed to treat head and neck squamous cell carcinoma, 
but has since been used to treat other cancers such as hepatocellular carcinoma (17). 
There are currently no Food and Drug Administration (FDA) licensed gene therapy 
products, possibly because the safety of current gene therapy techniques is highly 
questionable. A gene therapy was developed to cure X-linked severe combined 
immunodeficiency disease (X-SCID) and was successful in nine of the eleven infants 
given the treatment. However, the trial was halted when three patients developed clonal 
T-cell leukaemias. The onset of leukaemia was believed to have been from an 
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insertional mutagenesis event, where the viral vector used in the therapy integrated the 
gene into the sequence of a known oncogene (18). 
  
Gene therapy is still in its infancy, but the technique has already been recognised by 
trainers and athletes. For example, in February 2006, a German athletics coach (Thomas 
Springstein) was accused of attempting to obtain Repoxygen™, an EPO gene therapy 
treatment from Oxford Biomedica, for use in his athletes (19). The EPO gene therapy 
had not been put through any clinical testing, which highlights the lengths individuals 
will go to gain a competitive edge, even using unproven gene therapy. WADA 
identified the development of genetic therapies as a serious threat to the integrity of 
sports and incorporated gene doping into its prohibited list in 2003. The then president 
of WADA, Richard Pound, released this statement: 
     
"By introducing the notion of genetic doping into the list at this time, we at WADA 
and the IOC are taking into account the important changes occurring in doping 
techniques. New medical technologies may pose new challenges in the fight against 
doping, but we, together with the scientific and medical communities, are ready to 
meet those challenges." 
 
1.1.3 Challenges in detecting gene and protein doping 
The detection of the abuse of protein doping is a challenging task, and the ability to 
detect gene doping is likely to be equally challenging. As new protein targets are 
produced for therapeutic purposes (and their possible abuse), new methods will be 
needed for their detection. Historically, antibody based techniques have been used to 
detect and quantify proteins and their downstream effectors (biomarkers). Most 
physiological conditions manifest themselves through protein expression or the levels of 
small molecules and their metabolites, thus disease progession / regression can be 
assessed by monitoring these compounds. Zolg et al (20) describe a biomarker as: 
 
“A molecule that indicates an alteration of the physiological state of an individual in 
relation to health or disease state, drug treatment, toxins, and other challenges of the 
environment” 
 
However, this highlights that the identity of the protein and its surrogate biomarkers 
must be known, so that they can be monitored. Research into identifying new 
biomarkers has traditionally been performed using intelligence driven hypotheses and 
specific antibodies to known proteins, which is an inefficient and slow process. Taking 
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GH as an example, the protein has been available in recombinant form since Genentech 
first produced it in 1981. However, there is still no validated method to detect its abuse, 
which has so far gone unproven. Therefore the detection of the abuse of therapeutic 
proteins or gene therapy, either by direct measurement of the entity or through its 
downstream biomarkers, could require a radically different approach.  
 
The field of proteomics (study of all proteins within a specific matrix) in combination 
with mass spectrometry and bioinformatics has developed into a very powerful 
technique, which can characterise large numbers of proteins within complex mixtures 
(21). This has been achieved through improvements in computing power, 
characterisation of genomes, and improvements in MS instrumentation. Using this 
approach, approximately 10,000 proteins have been identified in serum and plasma 
(22). Furthermore, MS is also a quantitative technique, and has been applied to the 
quantification of proteins in serum, where similar results were generated compared with 
the standard immunochemistry based technique (23). Studies into the detection of 
disease biomarkers are generally performed on blood based matrices because it perfuses 
throughout the body, coming into contact with all organs and tissues. Furthermore, 
serum and plasma can be obtained relatively easily, and are already taken for doping 
control purposes (24). The application of mass spectrometry based proteomics to the 
identification of biomarkers to gene and protein doping should therefore be attempted 
using plasma and / or serum as a source of such biomarkers. 
 
This thesis focuses on the current state of the art of gene and protein therapeutics, 
current and developing proteomic technologies, and how the latter can be applied to 
detect the abuse of the former. Both these fields are evolving at a high rate, and have 
changed significantly since the commencement of the project in February 2005. 
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1.2 GENE THERAPY. 
Gene therapy is the process of introducing an exogenous gene into an organism, so that 
the host can express a specific protein using its own translational machinery. The 
overall aim of gene therapy intervention is to produce the wild type variant of a specific 
gene product to either assuage the effects of producing a mutant form, or to correct for 
its absence in the host organism. The presence of mutant genes (or the complete absence 
of the correct gene) can occur by either inheriting a defective or missing gene from the 
parental generation, or through a spontaneous mutation of the DNA within the genome 
and its subsequent transmission to later generations through cell division. In order to 
correct a genetic disorder by therapeutic intervention, the gene coding for the specific 
protein has to be well characterised, and its DNA sequence and upstream regulatory 
region established. The completion of the human genome project in 2003 has enabled 
significant increases in the understanding of genetic diseases and how errors in the 
DNA sequences cause them.  
 
A major challenge of a successful gene therapy treatment is the integration of the 
correct gene into a target organ and the continued production of the protein without 
inducing potentially harmful side affects in the host organism. A number of approaches 
to deliver therapeutic DNA have been investigated, some of which have reached clinical 
trial status (Figure 1.1). The majority of gene therapy approaches involve the use of 
viral organisms as DNA delivery vehicles (or vectors), as they have evolved specifically 
to introduce foreign DNA into host cells. Plasmid DNA has also been investigated as a 
possible vector for introducing target genes. The current state of the art of gene therapy 
will be discussed, including some examples of clinically successful gene therapy events. 
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Figure 1.1. Different vectors used in gene therapy clinical trials as of March 2008 (25). 
 
1.2.1 Viral vector based gene therapy 
Over the millennia, viruses have evolved highly efficient methods for delivering genes 
into host cells for the purpose of self-replication. There are a large number of different 
viral species that can infect a variety of cell types, ranging from single cellular 
prokaryotes such as E.coli, to high order eukaryotic organisms like H. sapiens. Viruses 
have evolved to target specific host cells via the interaction of their capsid proteins and 
specific host cell surface receptors (26). The two main species of virus used for gene 
therapy will be discussed, including the adenovirus (Adv), and adeno-associated virus 
(AAV).  
 
1.2.1.1 Adenoviral vectors 
The Adv is a non-enveloped icosahedral virus (Figure 1.2), which mainly infects cells in 
the upper respiratory tract and the small intestines. The virus has been chosen as a gene 
therapy vector because of its highly efficient nuclear entry mechanism (27) and its 
ability to transfer large amounts of DNA (up to 36 kb) (28). In fact, 24.8% of all gene 
therapy clinical trials up to March 2008 have used Adv as their DNA vector, making it 
the most commonly used gene therapy technique (25). The Adv infiltrates cells through 
the interaction of its capsid fibres with the Coxsackie and Adenoviral receptor (CAR) 
protein, triggering a clathrin mediated endocytosis of the viral particle. 
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Figure 1.2. Diagram of an Adv, showing configuration of constituent proteins and 
packaged DNA. Image taken from Volpers et al. (28). 
 
After entry, the coated vesicle containing the virus is degraded, releasing the virus into 
the cytoplasm (Figure 1.3), where the virus utilises the dyenin transport mechanism, 
bringing it to the phospholipid bilayer of the cell nucleus. The viral particle is then 
disassembled and its DNA transported into the nucleus via a nuclear pore, where the 
host cell’s DNA replication machinery is used to produce more viral DNA (29).  
The wildtype Adv does not incorporate its DNA into the host genome like retroviruses, 
therefore in proliferating cells, viral DNA is not included in the progeny following 
mitosis. However, modification of the transgene DNA with elements from other viruses 
has enabled scientists to force the incorporation of foreign DNA into the host genome, 
therefore enabling prolonged transgene expression (30). Removing the majority of the 
viral DNA allows a significantly larger transgene (DNA coding for target protein) to be 
inserted into the viral particle. These are known as high capacity, or “gutless” vectors, 
and have also proved to be less immunogenic as they contain very few viral genes, 
therefore producing fewer viral proteins (31). Gutless vectors allow longer expression of 
the transgene (32), believed to be due to fewer transduced cells being targeted by T-cell 
lymphocytes (33). 
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Figure 1.3 Key stages of adenoviral endocytosis from the extracellular matrix to 
importation of viral DNA into the host cell nucleus. Image taken from Meier et al. (29). 
 
The type of cells that the Adv can infect is dependent on the configuration of the protein 
fibres incorporated into the viral capsid. The modification of this fibre or substitution 
with a protein fibre from an alternative Adv serotype can allow the virus to infect a 
different cell type (34). This is important for targeting diseases that affect cells which 
wild type virus won’t interact with.  
Adv vectors have been used in a number of clinical trials, with mixed results. One 
infamous case is that of a 19 year old American male, Jesse Gelsinger, who suffered 
from a partial deficiency of ornithine transcarboxylase. Jesse was given gene therapy in 
September 1999, however it transpired that the dose formulation had an extremely high 
viral titre. He rapidly developed serious side affects and died from multiple organ 
failure. However, despite this setback, the use of Adv for gene therapy is still being 
investigated, with the development of gutless vectors and the modification of the viral 
DNA insertional properties looking like promising avenues of research.  
 
1.2.1.2 Adeno-associated virus (AAV) vectors  
As their name suggests, AAVs have links with the Adv viral family. This is because 
AAVs do not contain genes coding for its self-replication, and needs a helper virus 
(Adv) for proliferation and release from the host cell (35). The AAV family is currently 
composed of 11 different serotypes, with AAV2 being the most commonly used for 
gene therapy trials (36). AAV is a small virus, with space for approximately 5 kb of 
DNA available for transfection (35). This 5 kb restriction might limit the use of AAVs 
to gene therapy for smaller proteins than Adv and other viral vectors, however in some 
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cases it is possible to reduce the size of the expressed protein to its core functional 
regions and still retain full functionality. This has been successfully performed with the 
dystrophin gene, where the gene was reduced from 14 kb to approximately 3.6 kb, and 
gene therapy using an AAV vector resulted in the successful treatment of the disease in 
mice (37).  
Despite the gene size limit, AAVs have a large number of positive traits, including low 
immunogenicity, low pathogenicity, and the ability to transfect acquiescent cells, which 
makes them ideal for use as vectors for gene therapy.  
 
1.2.2 Plasmid based gene therapy. 
Plasmids are double stranded DNA molecules that exist in a closed loop (circular) 
configuration, and are mainly found in prokaryotes, although few eukaryotes, such as 
yeasts, also contain plasmids (38). Plasmids contain the genetic elements necessary for 
their self-replication within a host organism, allowing their copy number to vary greatly 
(from a single copy up to thousands). Their size (in base pairs) ranges from 1 to 200 kb, 
therefore a single plasmid can code for a large number of genes, making them ideal 
vectors for gene therapies. Plasmid DNA can be manipulated using restriction enzymes 
to introduce genetic material coding for therapeutic proteins e.g. growth hormone 
(Figure 1.4). These restriction enzymes cleave DNA at specific recognition sequences 
leaving so-called “sticky ends”. An exogenous gene with compatible sticky ends can 
then be incorporated into the plasmid, and the DNA loop reformed using a ligase 
enzyme (Figure 1.4). Producing large amounts of the modified plasmid DNA is a 
relatively simple process, as they replicate continually within the bacteria, generating 
large copy numbers over time as the bacteria themselves replicate. However, as 
mentioned earlier, bacteria can contain a large number of different plasmids, therefore a 
means of selecting bacteria that contain high copy numbers of the specifically modified 
plasmid is essential. This process is simplified if genetic material contained in the 
modified plasmid gives the host cell an advantage over its competitors. For example, if 
an antibiotic resistance gene is present on a plasmid, this enables the host cell to live in 
media containing antibiotic compounds. Bacteria without the modified plasmid will not 
multiply, and therefore be unable to compete with the resistant strain. Once a large 
number of the antibiotic resitant bacteria has been produced, the target plasmid can 
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easily be isolated with low endotoxin contamination (39). The purified plasmid can then 
be used for gene therapy. 
 
 
Figure 1.4. Cloning of ovine GH gene into a plasmid vector using restriction enzymes. 
The final plasmid (pAROGH) also contains ampicillin and chloramphenicol resistance 
genes. Image modified from Appa Rao et al (40). 
 
 
The major challenge for a plasmid based gene therapy is delivering the genetic material 
into the target host cells for protein production. The chemical structure of DNA was 
identified in 1953 by Watson and Crick and includes a phosphate sugar backbone (41). 
This makes DNA highly negatively charged, polar and water soluble, and therefore 
prevents it from diffusing across a cell’s hydrophobic phospholipid bilayer. Direct 
injection of plasmid vectors into tissues has resulted in the expression of the transgene 
(42), however this approach is inefficient. More efficient plasmid delivery techniques, 
including electroporation and hydrodynamic cell entry, have been developed to increase 
transfection efficiency. 
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1.2.2.1 Electroporation  
The application of a potential difference across a cell generates small, transient pores 
that appear in the phospholipid bilayer (43). These small holes are sufficient for the 
DNA to enter the cell without the need for active transfer (Figure 1.5). 
 
 
Figure 1.5. Process of DNA entry into a cell using electroporation (a-c), showing pore 
formation in the phospholipids bilayer (d-e). Image taken from Neumann et al (43). 
 
Delivery systems using the electroporation principle have been developed for 
introducing gene therapy plasmids into large animal models. The VGX™ Cellectra® 
electroporator system (formally ADViSYS) has been used to administer plasmids to 
animals of many different sizes, ranging from mice to horses, and achieved a detectable 
increase in circulating levels of the transgene product (44).  
 
1.2.2.2 Hydrodynamic cell entry 
Electroporation and direct injection of DNA involves targeting a specific area of an 
organism. Hydrodynamic delivery of DNA involves injecting a large volume of liquid 
(approximately 8-12% of the hosts body weight) into the circulatory system (45). This 
enables the plasmid DNA to travel around the whole body and gain entry into a number 
of tissues throughout the organism. This technique has demonstrated high efficient entry 
into the liver, where transgene expression was detected for at least five days after 
therapy was administered (45,46).   
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1.2.3 Reasoning for using plasmid based gene delivery for gene doping study. 
The gene doping study performed for this project will involve the use of a plasmid 
based gene therapy. There were a number of valid reasons for choosing this technique 
over a viral based technique. Firstly, the production of large amounts of bacteria, and 
therefore plasmids, can be performed in low technology environments. Access to 
specific reagents and chemicals, the ability to work aseptically, and some microbiology 
training is all that is required to be able to produce high-grade plasmids for gene therapy 
purposes. Production of viral vectors for gene therapy protocols is significantly more 
complicated. This would therefore make plasmid based gene therapy the most likely 
route of abuse for athletes. Furthermore, once a bacterial production strain has been 
established, large quantities of the gene therapy plasmid can be produced regularly, for 
repeat administrations.  
 
1.3 PRODUCTION OF THERAPEUTIC PROTEINS FROM BACTERIAL 
SOURCES. 
The aim of gene therapy is the transfection of a host organism with a specific gene, such 
that the target protein can be produced. Transfection of bacterial organisms with 
recombinant DNA plasmids can also be used to produce a target protein in large 
quantities. Once the plasmid is introduced into the cell, the bacteria can then be forced 
to produce the recombinant protein in large quantities using specific gene promoting 
compounds such as isopropyl-β-D-thio-galactopyranoside (IPTG) (40). In this example, 
the bacteria cannot metabolise IPTG, therefore the compound constitutively promotes 
transcription of genes governed by the “lac operon” in the bacterial system, ensuring 
continued expression of the gene. A large number of therapeutic proteins are produced 
using this approach, including recombinant human GH (47). However, this technique 
cannot be used to artificially produce all human proteins, as prokaryotic organisms are 
unable to add post-translational modifications such as glycosylation or phosphorylation, 
which are vital for some proteins functional characteristics.  
 
If a target protein must have post-translational modifications, it can be produced in a 
eukaryotic cell system, such as Chinese Hamster ovary (CHO) cells (48). However, in 
the case of EPO, the glycan moieties added within the CHO cell line have a different 
pattern to the human wild type protein, and these differences can be detected (11,49). 
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This has lead to the development of human cell lines that produce EPO with more 
humanised glycosylation patterns, although these proteins are still not identical to wild 
type human EPO (50). The belief that the production of EPO via a gene therapy 
approach would correct the glycosylation pattern differences was recently proven to be 
incorrect, where EPO produced after plasmid gene therapy in primates displayed 
different glycosylation patterns to the endogenous EPO glycoforms (51).  
Recombinant human proteins such as GH and EPO have been available since early 
eighties, and are now accessible from disreputable websites on the Internet. One such 
example is http://www.hardcoregrowth.eu which offers rhGH, the synthetic IGF-I 
analogue Long R3-IGF-I and the IGF-I Ec splice variant proteins. Athletes can therefore 
obtain high quality protein therapeutics for performance enhancing purposes. 
Furthermore, as the characterisation of proteins in the human body improves, more 
potential doping targets will emerge and become available for abuse.  
 
1.4 POTENTIAL GENE AND PROTEIN DOPING TARGETS 
1.4.1 Growth Hormone 
GH is a 191 amino acid, 22 kDa protein produced in the anterior pituitary. A second 
isoform is also produced, which has 176 amino acids and has a mass of 20 kDa (52). 
The protein interacts with the growth hormone receptor, which is expressed mainly in 
the liver, and induces the production of IGF-I (53). Figure 1.6 displays the hormonal 
effects and feedback mechanisms of the GH / IGF-I axis in the body.  
 
The protein therapeutic rhGH was initially developed for the treating infants with 
growth deficiency (10). This disease was originally treated with GH extracted from 
human pituitary glands. However, this practice was abandoned when it was discovered 
that pituitary gland extract was implicated with the transmission of infectious agents 
that caused Creutzfeldt-Jakob disease (54). GH is not constitutively produced within the 
body, but released in pulses, which creates peaks and troughs in its plasma 
concentration throughout the day.  
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Figure 1.6. The GH and IGF-I axis and the related feedback mechanisms. Arrows 
indicate stimulatory effects and parallel lines indicate inhibitory actions. Image taken 
from Florini et al (55). 
 
GH is believed to promote muscle growth and studies have identified that it also inhibits 
the production of myostatin (a potent myogenesis inhibitor) in GH deficient subjects 
and in vitro (56). Administration of rhGH also increases the rate of lipolysis, leading to 
a decrease in abdominal fat mass in obese men (57). The combination of increased 
myogenesis and fat metabolism has made rhGH an ideal target for abuse by athletes and  
the difficulty in detecting abuse of rhGH has lead to its abuse being widespread. 
Furthermore, the prevalence of plasmids containing the GH gene for producing the 
recombinant protein makes GH a likely target for gene doping. 
 
The fact that GH is an endogenous compound, and that it has a plasma half-life less than 
30 minutes, severely complicates the identification of rhGH abuse by direct detection 
and has lead to a biomarker derived test for rhGH abuse. A number of biomarkers of 
GH action have been identified which include IGF-binding protein 3 (IGFBP3) (Section 
1.4.1.1), procollagen III N terminal peptide (PIIINP) (Section 1.4.1.2) and IGF-I 
(Section 1.4.2). 
 
1.4.1.1 GH related biomarker – IGFBP3. 
IGF binding protein 3 (IGFBP3) is produced by the liver (shown schematically in 
Figure 1.6) and circulates in the plasma in a complex with the acid labile subunit protein 
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(58). A number of other IGF binding proteins are present in serum, however IGFBP3 is 
the most abundant and has a plasma concentration in the region of 1-4 μg/mL (59). 
IGFBP3 is upregulated when GH levels increase, and therefore has as an inhibitory 
effect on IGF-I by sequestering increased free IGF-I from the circulation. Free IGF-I in 
plasma is less than 1% of total concentration; Dr Frank Vitzthum, Head of Pre-
Development, Siemens Diagnostics (personal communications). Immunoassays are 
available to measure IGFBP3 in plasma and levels of the protein are routinely used to 
aid in the diagnosis of GH related disorders. 
 
1.4.1.2 GH related biomarker – PIIINP  
Collagen is a structural protein and a major component of skin, tendons, ligaments, 
cartilage and bone. The protein is initially expressed in an immature form, procollagen, 
of which there are 17 main variants (60). The post-translational processing of the 
collagen related to rhGH abuse, collagen alpha 1, involves the cleavage of 130 and 245 
amino acids from the N and C terminal ends of the protein respectively (61). The 
relation of PIIINP to rhGH abuse was discovered because GH directly affects bone 
growth (Figure 1.7), where excess protein results in clinical symptoms such as 
acromegaly (62). Therefore increased production of procollagen results in an increase in 
the release of the PIIINP peptide.  
 
 
Figure 1.7. GH/IGF-I axis effects on bone production and turnover. A = Immature 
Osteoclast, B = Immature Osteoblast, C = Mature Osteoclast, D = Mature Osteoblast,   
E = Collagen Synthesis, F = Mineralisation of new bone. Image taken from Ueland (62). 
 
 
18 
The plasma concentration of PIIINP is very low, in the region of 0.1 to 1 ng/mL, and is 
measured by radioimmunoassay (63). Detection of this protein by mass spectrometry 
based techniques will be extremely challenging within the limits of current methods and 
instrumentation. 
 
1.4.2 Insulin-like growth factor-I (IGF-I) 
IGF-I is a 7649 Da, 70 amino acid protein, mainly produced in the liver (Figure 1.6), 
and is involved in muscle growth (myogenesis) (55). Research into muscle wasting 
diseases, such as muscular dystrophy, has led to the development of gene therapies to 
increase levels of IGF-I (64). Barton-Davis et al. demonstrated that IGF-I gene therapy 
resulted in a 15% increase in muscle mass and a 14% increase in muscle strength in 
young mice. The study also showed a 27% increase in muscle strength in older mice, 
which has reinforced the belief that GH (which increases circulating IGF-I 
concentrations) is an anti-aging drug. Circulating levels of IGF-I decreases 35% per 
decade (65), suggesting that the administration of GH might combat age related loss of 
muscle strength. Because the link of IGF-I to muscle growth is well-established, it has 
become a target for abuse within competitive sports. The laboratory head responsible 
for the Barton-Davis research has reported being contacted regularly by athletes and 
trainers attempting to obtain the IGF-I gene therapy construct (66). 
 
Recombinant IGF-I has also been produced for therapeutic purposes, and is marketed in 
the USA by Tercica (licensed as “Increlex”). A modified version of the protein (Long-
R3-IGF-I) is produced by Novozymes, which was designed to have a higher efficacy for 
muscle promotion than the endogenous IGF-I. This protein can allegedly be purchased 
in a highly purified form online from a number of websites, along with dosing 
instructions.  
  
1.4.3 GH releasing Hormone (GHRH) and associated agonists. 
GHRH is a 5036 Da; 44 amino acid protein, produced in the hypothalamus (Figure 1.6), 
and its main function is to stimulate the production and secretion of growth hormone by 
the pituitary. In conjunction with the peptide hormone somatostatin, GHRH is 
responsible for the pulsatile secretion of GH (67). The physiological effects of GHRH 
means it is an ideal compound for increasing circulating GH levels in patients with GH 
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deficiency. GHRH gene therapy has already been demonstrated in large animal models 
such as pigs to increase GH levels (44), to treat laminitis in horses (68) and to improve 
the immune system in cattle (69).  
 
Endogenous GHRH analogues (ghrelin) have shown to increase GH production in a 
number of in-vivo and in-vitro studies (70). The possibility of ghrelin abuse has been 
noted by WADA, and the incorporation of ghrelin levels into the GH abuse biomarker 
panel was considered. However, ghrelin levels temporarily decrease after exercise, 
where a 21% drop was detected in athletes (71), which could complicate any test 
attempting to detect for its abuse. 
 
1.4.4 Peroxisome Proliferator Activated Receptor delta (PPARδ) 
PPARδ was identified in the early 1990’s, although its function was not fully 
understood until mid 2004. PPARδ is involved in the production of slow twitch muscle 
(type I fibre), which is rich in mitochondria, and therefore more energy efficient than its 
fast twitch muscle (type II b) counterpart. Wang and co-workers performed experiments 
where the PPARδ gene was transfected into mice, and demonstrated that the genetically 
modified mouse could run twice as far as wild type litter mates before reaching 
exhaustion (72). These mice were subsequently dubbed “marathon mice”. The 
introduction of this gene had an unexpected side effect; the transgenic mice fed on a fat 
rich diet did not increase in weight, unlike wild type mice fed on a similar diet. This 
discovery could lead to the protein being used for the treatment of obesity, and therefore 
a valid target for gene therapy. Wang hinted at this possibility in his 2004 paper, stating: 
 
 “This work demonstrates that complex physiologic properties such as fatigue, 
endurance, and running capacity can be genetically manipulated”. 
 
The subsequent clinical interest in PPAR δ has lead to the discovery that its production 
can be manipulated using small molecule therapies. The Salk Institute has demonstrated 
that the compound GW1516 enhances muscle fiber growth by upregulating PPARδ 
(73). WADA were notified about GW1516 and the compound was included on the 2009 
prohibited list (74). A method for the detection of GW1516 in human plasma has 
recently been developed, well before the compound has been licensed for use in humans 
(75). 
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1.4.5 Myostatin  
Myostatin is a member of the transforming growth factor β superfamily (76), and was 
originally named growth/differentiation factor 8. The protein has been identified as a 
negative regulator of muscle growth, and therefore has drawn attention as a therapeutic 
target for reducing muscle wasting in duchene muscular dystrophy sufferers (76). The 
protein is initially secreted in an immature form, consisting of 352 amino acids, and is 
processed to a mature form of 109 amino acids in length. Myostatin’s inhibitory effect 
on muscle growth means that manipulating this biochemical pathway would require 
removal of the protein from circulation. This has been achieved through selective 
breeding in cattle through the generation of the double recessive gene in the Belgian 
Blue breed. These cattle are myostatin null, which results in a “double muscle” 
phenotype (Figure 1.8A). Similar musculature differences between wild type and 
myostatin null forms have also been seen in mice and dogs (Figure 1.8 B & C). The 
complete loss of myostatin production is not fatal, or harmful, and these animals live 
relatively normal lives. To date, only a single human male has been identified as being 
myostatin null, however his identity was kept a secret although he is known to have 
been born in Germany in 2000 (77). The complete removal of myostatin results in 
increased muscle mass, however this does not come with increased performance 
although whippets heterozygous for the mutant gene have demonstrated improved 
athletic ability (78). 
 
Figure 1.8. A = Myostatin null Belgian Blue, displaying “double musculature”. B = 
Wild type and myostatin null mice, figure on right displays increased musculature 
(Images taken from Mc Pherron et al (79)). C = Wild type, heterozygous and myostatin 
null whippets. Heterozygous animals display improved musculature over wild type. 
(Images taken from Moscher et al (78)).   
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In order to block myostatin’s activity the protein must either be removed, or its binding 
to a target receptor disrupted. Wyeth pharmaceuticals have developed an anti-myostatin 
antibody with the specific aim to inhibit its activity (80). This appeared to be 
unsuccessful at treating muscular dystrophy, although it did increase muscle mass in the 
patients, which is the ideal outcome for bodybuilders.  
 
Inhibition of myostatin activity would be a more suitable route for genetic modification 
of athletes rather than over-expressing IGF-I. Significantly increased IGF-I levels have 
been linked to cancer, therefore uncontrolled over-expression of the protein is unwise 
(81). The myostatin null phenotype has a similar, but harmless muscle building effect, 
therefore manipulating the myostatin pathway would be a more likely approach than 
using IGF-I therapy.  
 
1.5 PROTEOMICS AND PROTEIN SEPARATION TECHNOLOGIES 
The term “proteome” was originally coined by Marc Wilkins in 1994 (82) and 
“proteomics” is the study of all proteins in a specific organism or matrix. In a review 
published in Electrophoresis in 1998 (83), Anderson and Anderson described 
proteomics as:  
 
“The use of quantitative protein-level measurements of gene expression to 
characterize biological processes (e.g., disease processes and drug effects and 
decipher the mechanisms of gene expression control”. 
 
The “quantitative protein-level measurements” statement in the quote can be performed 
using an array of techniques, including sodium dodecyl sulphate poly acrylamide 
electrophoresis (SDS-PAGE), high performance liquid chromatography (HPLC) and 
mass spectrometry. 
 
1.5.1 SDS-PAGE 
Traditionally, the application of proteomics to biomarker discovery has involved using 
2D SDS PAGE. The first dimension separates proteins dependent on their charge, using 
isoelectric focusing (IEF), where proteins migrate along an immobilised pH gradient 
until they have no net charge. The IEF strip is then transferred to a polyacrylamide gel, 
where the proteins migrate into the gel under voltage and are then separated by size 
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(84). 2D gel analysis significantly increases the separation power over one dimensional 
SDS PAGE since over 1100 proteins can be separated on one gel (84). However, a 
major drawback to 2D SDS-PAGE is that only one sample can be analysed per gel, 
therefore multiple experiments need to be performed in order to compare levels of 
proteins in different samples. Furthermore, this approach is complicated by poor gel to 
gel reproducibility of the 2D SDS-PAGE, mainly due to the variability in the 
immobilised pH gradient strips in the first dimension of separation. Also, proteins of 
high molecular weight, hydrophobicity, or with pKa’s in the high and low range, do not 
separate well on a 2D gel therefore these types of proteins will be under represented on 
the gel image (85).  
 
Theoretically, identical proteins within two samples would migrate to the same relative 
position in two separate gels and therefore give relative quantitation information 
relating to the spot size and density. This approach has been used to compare protein 
expression levels in diseased and healthy samples in order to identify possible 
biomarkers (86,87). The development of the differential gel electrophoresis technique 
(DIGE) enables up to three samples to be run on the same gel, removing the gel to gel 
running differences. DIGE involves labelling proteins within each sample with different 
fluorescent dyes prior to combining all three differently labelled samples and loading 
onto the IEF strip. Once the gel has run, proteins are visualized using a fluorescence 
scanner, and the image processed by software to give relative protein concentrations 
(86). This new technology has dramatically improved the reproducibility of the 2D 
SDS-PAGE technique. However, the throughput of the technique is still very low. 
 
The separating power of the 2D SDS-PAGE technique has been used in conjunction 
with mass spectrometry to enable identification of protein spots within a gel. Protein 
spots can be excised and the immobilised protein digested using trypsin, resulting in 
peptide fragments that can be analysed by mass spectrometry (discussed in more depth 
in Sections 1.6 and 1.7). This approach has been applied to human serum, where a total 
of 3700 protein spots were visualized, and mass spectrometric analyses were performed 
on 1800 spots identifying 325 distinct proteins (21). Although this is a very powerful 
technique, the timescales involved to separate and identify large numbers of proteins is 
prohibitive.  
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1.5.2 High Performance Liquid Chromatography 
Chromatography was invented by the Russian Mikhail Semyonovich Tswet in 1901, 
during his research into chlorophyll pigments (88). The science has progressed 
significantly since inception, and has developed into a technique that can separate and 
detect thousands of compounds. High Performance Liquid Chromatography (HPLC) 
has become one of the main techniques used for protein and peptide analysis, especially 
since it has been interfaced with mass spectrometry. HPLC involves the use of two 
distinct phases, a liquid mobile phase and a solid stationary phase. The stationary phase 
is contained within a solid support (usually a column) through which the mobile phase 
is passed at high pressure. The outlet of the column is connected to a detector, which 
can be of many types, some of which are described in a Section 1.6.3. Analyte is 
introduced into the mobile phase and as it reaches the stationary phase, it interacts with 
specific chemical groups on the surface of the solid support. The analyte is released 
from the stationary phase when the chemical properties of the mobile phase are such 
that the analyte has lower entropic energy when dissolved in the mobile phase. This 
movement between the two phases is called partitioning and the rate at which the 
analyte moves between the stationary and mobile phases determines its 
chromatographic properties within a given experiment. 
 
The most common form of HPLC used for protein and peptide analysis is reversed-
phase mode (RP-HPLC), in which the mobile phase is a polar solution and the solid 
phase non-polar / hydrophobic. Over a chromatographic run, the percentage of organic 
solvent in the mobile phase is increased, which causes proteins and peptides to elute 
from the column. The addition of solvent modifiers to the mobile phase, such as ion 
pairing agents (trifluoracetic (TFA)) or acids (formic acid / acetic acid), increase the 
hydrophobicity of dissolved analytes and enhances their interaction with the solid 
phase. This is because the acidic ion pairing agents interact with charged groups on the 
amino acid residues, reducing their overall hydrophilicity (89). The elution of analyte 
from the column, in ideal conditions, will appear as a gausian peak in a detector. 
Adding TFA at a level of 0.01 to 0.1% (v/v) significantly improves peak shape for 
proteins and peptides. However TFA causes significant ion suppression effects in the 
electrospray ionisation process, reducing sensitivity (90). Formic acid is the most 
commonly used solvent modifier when performing LC-MS analyses (normally at 0.1% 
v/v), mainly because it does not cause ion suppression.  
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1.5.3 Two-dimensional HPLC. 
The application of HPLC to protein and peptide analysis has enabled the separation of 
large numbers of peptides in complex mixtures. However, pre-fractionation of a peptide 
or protein sample using strong cation exchange (SCX) chromatography and a 
subsequent analysis by RP-HPLC, significantly increases the number of peptides that 
can be separated and detected (91). Tryptic digestion of proteins will result in the C-
terminal amino acid of each fragment being either arginine or lysine. These peptides 
will be have a net positive charge in an acidic environment and will ensure good 
retention on SCX media. The interactions between the peptide and the solid phase is an 
ionic bond, and peptides are only released when the conditions of the mobile phase are 
such that the concentration of the salt in the mobile phase has a higher affinity for the 
solid phase bound ionic moiety. Selective release of peptides can be achieved by 
passing solutions of increasing ionic strength over the solid phase, either in step or 
gradient form, which can be collected into less complicated fractions for later analysis 
(92). These fractions can then be analysed by RP-HPLC to greatly increase the number 
of peptides detected by LC-MS/MS compared with an identical sample being analysed 
without SCX fractionation. SCX fractionation adds another dimension of separation to 
HPLC and its use (in combination with tandem mass spectrometry) has been dubbed as 
multi-dimensional protein identification technology (MudPIT) (93). This additional 
dimension has resulted in higher protein coverage of complex samples by significantly 
increasing the peak capacity over single dimensional analysis with hundreds of proteins 
being detected in a 2D LC-MS/MS experiment (94,95). A drawback of performing 
MudPIT experiments is that they are extremely time-consuming, depending on the 
number of fractions generated in the first dimension. For example, Nägele et al 
performed an analysis which took 820 minutes to complete, which corresponds to a 13.6 
hour LC-MS/MS experiment for a single sample (92). 
 
1.6 MASS SPECTROMETRY BASED PROTEOMICS 
Historically, the western blot was the foremost technique used to confirm the presence 
of a protein within a complex mixture. The application of mass spectrometry to protein 
and peptide analysis, in conjunction with bioinformatics, has had a significant impact on 
the field of proteomics. However, mass spectrometry requires an analyte to be both in 
the gaseous phase and ionised, so that the ion can be manipulated and subsequently 
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detected by the instrument. Proteins are non-volatile compounds, therefore techniques 
were needed to force the proteins into a gaseous state, without causing degradation of 
the analyte. Matrix Assisted Laser Desorption / Ionisation (MALDI) and Electrospray 
Ionisation (ESI) have evolved into the two main techniques for introducing proteins and 
peptides into a number of different mass spectrometers. This project uses the ESI 
approach, and therefore MALDI is discussed briefly in Section 1.6.2. 
   
1.6.1 Electrospray ionisation (ESI) 
John Fenn invented ESI in the late 1980’s for which he was awarded the Nobel Prize for 
chemistry in 2002. He demonstrated that large biomolecules such as DNA, peptides, 
proteins and even biopolymers such as polyethylene glycol (PEG), acquired multiple 
charges when analysed using ESI, forming a “charge envelope” (96). These multiple 
charges bring the m/z ratio of biomolecules within the range of bench-top mass 
spectrometers.  
 
1.6.1.1 Basic principles of ESI 
The ESI process begins with the formation of a jet of mobile phase, known as a Taylor 
cone, created through the application of a very high electric field within the electrospray 
source. The field is applied to the end of a capillary, through which the mobile phase 
flows, and is opposite to the charge applied to the orifice of the mass spectrometer. The 
transmission of this charge to the mobile phase requires there to be a sufficient 
concentration of ions in the solution (97). The polarity of the applied charge can be 
either negative or positive, where the correct polarity is dependent on the pKa of the 
analyte and the modifiers added to the mobile phase. If a positive charge is applied to 
the capillary, positive ions in the solution will be repelled from the tip of the capillary 
and pulled towards the negatively charged orifice. This applied charge, combined with 
the surface tension of the liquid, forms the Taylor cone (97,98). The Taylor cone 
eventually destabilises into a spray of fine droplets, with a high density of positively 
charged ions. In conventional high flow rate ESI analysis a drying gas is introduced to 
the source along with the mobile phase, which in conjunction with high source 
temperatures, increases the evaporation rate of the solvent in the droplets. As the droplet 
volume decreases, the effective concentration of positively charged analytes and 
positive ions increases, until a critical level is reached at which coulombic explosion 
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occurs (the Rayleigh limit). This is caused by the close proximity of like charges, which 
generates a repulsive force exceeding the surface tension of the droplet. This coulombic 
explosion generates droplets of smaller sizes, allowing the desolvation process to 
continue until analytes are in a gaseous state. Figure 1.9 displays the principles of ESI in 
positive mode. The exact mechanism of the final desolvation step is not fully 
understood but there are currently two main hypotheses: the charge residue model and 
the ion evaporation method, neither of which has been proved (97).  
 
Figure 1.9. demonstration of the electrospray principle in positive ion mode. a = Taylor 
cone, b = first droplet, c = subsequent droplets, d = desolvated ions. 
 
1.6.1.2 Application of ESI to protein and peptide analysis. 
The ESI process generates multiply charged species (Section 1.6.1) through the addition 
of two or more charges, generating a mass spectrum with a “charge envelope”. Adjacent 
m/z peaks (in a protein’s charge envelope) differ by a single charge. However, the 
difference in the m/z value between the two charge states is related to the protein’s 
intact mass. Multiplying the m/z value by the charge state, then subtracting the charge 
state value gives the molecular weight of the peptide or protein. Charge state 
determination of a particular m/z ion can be performed in two ways. The simplest is by 
identifying the relationship of the m/z ratios of two adjacent ions of a charge envelope 
within a mass spectrum. This approach can be performed on any bench top MS system 
(99). The other approach requires a high mass accuracy MS system, which can resolve 
the 13C isotopic pattern of a single charge state (100). The reciprocal of the difference 
between two 13C isotopic peaks gives the charge state for that cluster of ions. Figure 
1.10 displays examples of the two methods for assigning the molecular weight of IGF-I 
using ESI mass spectrometry.  
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Figure 1.10. ESI mass spectra of IGF-I. Panel A is from a low resolution system, 
displaying the charge envelope and isotope pattern of the IGF-I [M+6H]6+ ion. 
Deconvolution of the spectra generates a molecular weight of 7651 Da. Panel B shows 
the 13C isotope pattern of the same IGF-I [M+6H]6+ ion using a high resolution MS 
system (spectra taken from Bredehoft et al (100)). Deconvolution of the isotope cluster 
generates a mw of 7648.6. 
 
The ESI technique has transformed the analysis of proteins and peptides within the 
proteomics community. Furthermore the application of protein digestion coupled with 
ESI and tandem mass spectrometry has developed into a quantitative technique to rival 
western blotting, and even the ELISA. This approach is described in more detail later 
(Chapter 5) 
 
1.6.1.3 Tryptic digestion of proteins 
ESI based analysis of intact proteins can determine their molecular weight accurately, 
and therefore their possible identity. However, the sensitivity of intact protein analysis 
is low, as the signal recorded by the mass spectrometer is spread over a number of 
charge states. Furthermore, proteins of similar molecular weights and hydrophobicities 
do not separate well using RP-HPLC. Trypsin, a serine protease, specifically cleaves 
proteins on the C terminal side of Lysine (K) and Arginine (R) residues except if R or K 
precede a proline (P) residue. These two amino acids are well represented in most 
proteins and tryptic digestion results in an average peptide length of approximately 15 
amino acids. The benefit of tryptically digesting proteins prior to ESI based MS analysis 
is three fold. Firstly, a gain in sensitivity is obtained by reducing the charge states down 
to two or three, depending on the length of the peptide. Secondly, peptides can be 
chromatographically separated far more efficiently than proteins. Finally, peptides can 
be fragmented using collision induced dissociation (CID) to generate amino acid 
sequence information for protein database searching (discussed further in Section 1.7.2).  
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An important consideration when performing tryptic digestion of a protein, or a 
complex protein mixture, is the presence of disulphide bridges. These are covalent 
bonds that link two cysteine residues through the sulphur molecule on the amino acid’s 
side group. Disulphide bonds help to stabilise the “globular” tertiary, and in some cases 
the quaternary, structure of proteins (described in more detail in Section 1.8.3.2). 
Proteins can have multiple internal disulphide bonds, such as IGF-I which contains six 
cysteines, all of which are linked. These linkages consist of residues 6 to 48, 18 to 61 
and 47 to 52 (101). If these covalent linkages are not broken prior to tryptic digestion, it 
will result in the release of peptides linked together with disulphide bonds, which 
severely complicates the analysis of the protein digest. In the case of IGF-I, tryptic 
digestion generates four peptides linked together with three disulphide bonds. Two 
simple chemical reactions can be applied to solve the problem of disulphide bridges. 
The first reaction involves the use of dithiothreitol to reduce the disulphide bonds, 
generating two free thiol groups. Over time, these thiol groups would reform, possibly 
not to their original conformation, therefore they must be capped. The addition of 
iodoacetamide, or iodoacetic acid, alkylate the free thiol groups and prevent the 
reformation of the disulphide bridge. This reduction and alkylation reaction results in a 
specific modification to the peptide, but does not inhibit its fragmentation patterns, 
therefore is fully compatible with database searching programs.  
 
One major drawback to using tryptic digestion when analysing complex protein 
mixtures such as serum or plasma, is that it significantly increases the complexity of the 
sample. For example, albumin (the main component of serum and plasma) is a 67 kDa 
protein, which upon treatment with trypsin generates 79 peptides. However, 100% 
tryptic efficiency is not guaranteed and missed cleavages are common, further 
complicating the resultant mixture (up to 157 peptides with 1 missed cleavage 
included). The issue of incomplete digestion can be mitigated by the inclusion of the 
intact target protein into any quantitative assay in an identical matrix. The efficiency of 
digestion of the protein standard should then be mirrored in the calibration standards 
and the samples of interest. In the event of using a surrogate peptide to quantify a 
protein, complete digestion of a protein to the specific tryptic would be essential, or the 
assigned concentration of the protein would be different from its true value.  
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1.6.2  Matrix Assisted Laser Desorption / Ionisation (MALDI) 
MALDI involves the co-deposition of a target analyte with a solid matrix, and its 
subsequent vaporisation by irradiation with a pulsed laser of a specific wavelength in 
order to generate gas phase ions (102). There are a variety of matrices that can be used 
for MALDI. Selecting the correct matrix depends on the size of the protein or peptide 
being targeted for analysis. α-cyano-4-hydroxycinnamic acid (CHCA) works well for 
low molecular weight proteins and peptides, whilst sinapinic acid (3,5-dimethoxy-4-
hydroxycinnamic acid) is used for higher molecular weight proteins. A highly 
concentrated matrix solution containing an acidic modifier is mixed with sample and 
left to dry on a target plate. The high concentration of matrix is believed to be necessary 
to isolate proteins and peptides from each other (103). The matrix spots are then 
targeted with a high energy pulsed laser, most commonly a nitrogen laser (337 nm), 
which is absorbed by the matrix causing it to volatilise in the form of a plume or “gas 
jet”, taking the embedded analytes with it. The acid present in the matrix enables charge 
to transfer to the proteins or peptides. Once ionised and in gaseous form, the analytes 
can be manipulated by a mass spectrometer, which in most cases contains a time-of-
flight (TOF) mass analyser (Section 1.6.3.4).  
 
1.6.3 Mass analysers 
Several commercially produced mass analysers are regularly used for proteomics-based 
analyses, including 3D and linear ion traps, quadrupoles, TOF, fourier transform ion 
cyclotron resonance (FT-ICR) and the latest addition, the Orbitrap. Instruments 
incorporating either the Orbitrap or FT-ICR analysers were not used in this project, 
however they have been proven as highly capable systems for proteomics analysis 
(104), therefore a brief description of their workings is included. The instruments 
available for this project included the hybrid triple quadruple linear ion trap 4000 Qtrap 
system (Applied Biosystems / MDS Sciex) and a quadrupole TOF system, the Q-TOF 
premier (Waters). A brief description of the different mass analysers will be discussed. 
 
1.6.3.1 3D and linear ion traps  
The 3D ion trap mass spectrometer consists of three hyperbolic electrodes; a ring 
electrode and two end cap electrodes (Figure 1.11). Ions in a gaseous state enter the trap 
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and are held in the inter electrode space by radio frequency (RF) voltage applied to each 
of the ring electrodes (105). Once inside the trap, ions oscillate within a specific radius, 
which is governed by their m/z value, and the RF voltage applied to the ring electrode. 
Changing the applied voltages causes the path of ions of a given m/z to become unstable 
and the ion is then ejected from the trap and detected using an electron multiplier. 
 
 
Figure 1.11. Schematic of an ion trap, showing ring and end cap electrodes. 
 
The ion trap can store a large number of ions before releasing for detection, making the 
device highly sensitive in full scan mode (106). Application of specific RF voltages to 
the electrodes enables ions of a given m/z to oscillate in a stable manner within the trap, 
whilst all other ions are ejected. This isolates an ion with a specific m/z, so it can be 
selected for further study such as tandem mass spectrometry (MS/MS). This involves 
the trapped ion being fragmented by forcing it to collide with an inert gas such as 
helium. The resulting fragment ions are indicative of the precursor compound and 
enable the user to obtain structural information on the trapped analyte. The MS/MS 
capability of ion trap MS systems can be used for protein identification by sequencing 
MS/MS spectra of peptides generated by proteolytic digestion (explained further in 
Section 1.6.1.3).  
 
Further development of the 3D ion trap has resulted in the introduction of linear ion trap 
MS systems, where the ring and end cap electrodes are replaced by a quadrupole. This 
enables a larger volume of ions to be trapped, which increases sensitivity approximately 
ten times over the 3D ion trap.  
 
 
31 
1.6.3.2 Quadrupole 
The quadrupole mass analyser consists of four symmetrically arranged parallel rods, 
where opposite rods have the same polarity. Changing the polarity of the voltages 
applied to the paired rods at RF causes ions entering the quadrupole to oscillate 
perpendicular to their flight path. If only RF modulation is used, all ions travel through 
the quadrupole in a stable path. Applying a DC voltage superimposed on the RF 
voltages allows ions of only one specific m/z value to oscillate in a stable manner and 
reach the detector at the end of the analyser (Figure 1.12). The paths of the remaining 
ions in the quadrupole are unstable and do not reach the detector. The specific RF and 
DC voltages applied to the quadrupole can be changed very quickly, either in gradual 
amounts, which is used for its scanning function, or to values which allow only user 
defined m/z values to pass through the analyser. 
  
Figure 1.12. Schematic of a quadrupole mass analyser showing the configuration of the 
four rods and the position of the detector. 
 
The major strength of the quadrupole analyser is its ability to isolate specific m/z ranges 
from the total ion current, giving high sensitivity in selected ion monitoring (SIM) 
mode. However, in full scan mode, the ion current must be scanned out of the 
quadrupole, which results in low duty cycle and poor sensitivity compared with the ion 
trap mass analysers. 
 
1.6.3.3 Time-of-flight mass spectrometers (TOF) 
The TOF mass analyser works on the principle that in a high vacuum, ions with 
different mass to charge ratios accelerated with the same kinetic energy will arrive at a 
detector at different times. In order to give all ions the same amount of energy, ions 
enter the mass analyser in the form of an ion beam and are accelerated in a direction 
orthogonal to their current motion. This acceleration is performed by the application of 
a quick pulse of an electric field applied to a plate and a metal grid. The ions are 
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repulsed from the plate through the grid and into the flight tube. Because the ions 
already have movement in the direction of the ion beam, they continue to move in this 
direction. Furthermore, the orthogonal acceleration does not affect this velocity in any 
way (107). Figure 1.13 shows a schematic of a linear and a reflectron TOF mass 
analyser, demonstrating the continued velocity of the ion packets.  
 
Figure 1.13. Schematics of linear and reflectron mass analysers, showing the directions 
of ion travel, and the subsequent orthogonal acceleration towards the detector. The 
reflectron TOF has an ion mirror, which effectively doubles the flight path. Image taken 
from Guilhaus et al (107). 
 
Ions of a lower m/z value arrive at the detector first, as their velocity is greater in a 
vacuum than ions with a higher m/z value. The TOF mass analyser is ideal for intact 
protein analysis, as it can assign a mass to large proteins in MALDI mode, whilst its 
high mass accuracy significantly improves the assignment of a proteins molecular 
weight when deconvoluting ESI based protein mass spectra.  
 
1.6.3.4 FT-ICR  
The principle of an FT-ICR mass analyser is similar to that of a quadrupole ion trap, in 
that it traps ions within a specific space before analysis. The fundamental difference 
between the two analysers is that the ion cyclotron mass spectrometer uses very high 
strength magnetic fields (of between 3 and 12 teslas) to trap the ions as apposed to 
applying electronic fields. The analysis cell of the ICR can be many different shapes 
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and sizes, however the most common is a cube consisting of six metal plates (108). 
Once in the cell, ions cycle in stable orbits until they are excited through the application 
of a sinusoidal voltage on the excitation plates (109). This increases the kinetic energy 
of the trapped ions and increases the radius of their orbit, bringing them into close 
proximity to the detection plates. This induces an electric current in each detection plate 
as the ion travels on its circular path within the cell (Figure 1.14).  
 
 
Figure 1.14. Diagram of an ion cyclotron resonance cell showing the excitation effect 
(left) and the detection phase (right). Diagram taken from Marshall et al (108). 
 
The data output from the ion cyclotron resonance mass analyser are in the guise of a 
waveform, which is converted into a typical spectrum (m/z and intensity) using a fourier 
transform algorithm. A hybrid LTQ-FTICR machine has been produced by 
ThermoFinnigan, which enables highly accurate mass measurement of a precursor 
peptide ion as well as MS/MS fragmentation and product ion scanning.  
 
1.6.3.5 Orbitrap mass analysers 
The Orbitrap mass spectrometer was developed by Thermofinnigan and Purdue 
University in early 2005 and represents the newest addition to the list of mass analysers. 
The instrument is a hybrid system, employing an LTQ linear ion trap as the primary 
mass filter before the injection of ions into the Orbitrap analyser. Two end cap 
electrodes enclose a central electrode and a static electric field is applied to trap the ions 
within the system. Ions enter the Orbitrap, and rapidly form a tight packet of ions which 
oscillate axially in a figure of eight pattern at a specific radius along the central 
electrode (110). As the ion packets come into close proximity to the end cap electrodes, 
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they generate an electric current in a similar fashion to that observed in an FT-ICR 
analyser. The data collected from the Orbitrap are then fourier transformed into a 
classical mass spectrum. The Orbitrap has already proved useful for both peptide and 
intact protein analysis (111). It has also recently been used to detect recombinant bovine 
growth hormone abuse in cattle (112), and recombinant human IGF-I and its isoforms in 
human plasma (100).  
1.7 TANDEM MASS SPECTROMETRY (MS/MS) 
Tandem mass spectrometry (MS/MS) involves the selection of a specific ion for 
fragmentation, so that the products from the selected ion species can be scanned using a 
mass analyser. Instrument manufacturers have produced a number of hybrid mass 
spectrometers, which usually contain two types of mass analysers, such as the Q-TOF. 
The combination of a quadruple with a time-of-flight analyser enables high mass 
accuracy measurements of product ions from specifically fragmented ions. This is 
achieved through the ability of the quadrupole to select ions of a specific m/z value from 
the total ion current for subsequent collision induced dissociation (CID) based 
fragmentation. The instrumentation used in this project used CID fragmentation, which 
is discussed in greater detail (1.7.2). The product ions generated by CID fragmentation 
are then scanned using a high resolution, time-of-flight mass analyser. The ion selected 
for MS/MS fragmentation can be performed manually, or automatically selected from a 
list generated from a full scan spectrum, called information dependent acquisition (IDA) 
or data dependent acquisition (DDA).  
 
Another example of a hybrid MS system is the 4000 QTRAP from Applied Biosystems 
/ MDS Sciex, which is a triple quadrupole system, where the third mass analyser is also 
a linear ion trap. This instrument was the main system available for this project, and is 
discussed in more depth.  
 
1.7.1 4000 QTRAP hybrid triple quadrupole  
The 4000 QTRAP is based around a triple quadrupole, but the third quadrupole has 
been converted into a linear ion trap (106). Triple quadrupole instruments comprise of 
three quadrupoles arranged in parallel (Figure 1.15). They are ideally suited for tandem 
mass spectrometry based analyses, where RF and DC voltages in Q1 are set such that a 
specific precursor m/z is allowed to pass into Q2, where it is fragmented using CID in 
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the presence of an inert gas. After fragmentation has occurred, the product ions pass into 
Q3, which is set either to scan the product ions or set such that only a given m/z can 
pass through to reach the detector.  
This latter approach is highly specific, because the MS system will detect only ions of a 
narrow m/z range originating from the fragmentation of a precursor of a specific m/z 
value. Because the RF and DC voltages in Q1 and Q3 can be changed very quickly, this 
enables triple quadrupoles to monitor large numbers of precursor to product ion 
“transitions”, in a short time period (in the region of 30-60 per second). This approach 
has been called Selection Reaction Monitoring or SRM. The technique is well placed 
for quantitative MS analysis, and has been used for small molecules for a number of 
years. It was only applied to tryptically digested proteins more recently (2004) when 
Kuhn and co-workers employed LC-MS/MS and SRM to detect and quantify c-reactive 
protein (CRP) peptides in a tryptically digested serum protein extract (23). 
 
The 4000 Qtrap system has the high sensitivity and specificity of a triple quadrupole, 
with the high full scan sensitivity of a linear ion trap. The 4000 QTRAP is also capable 
of performing neutral loss and precursor ion scans, which enables the machine to 
identify post-translationally modified peptides (113).  
 
 
Figure 1.15. Image taken from Leblanc et al (106) displaying the configuration of the 
QTRAP triple quadrupole instrument with a linear ion trap as the third quadrupole. 
 
 
1.7.2 Collision induced dissociation (CID) 
CID fragmentation is performed by the interaction of an accelerated ion with an inert 
collision gas atom (usually Ar, N2 or He) within a higher pressure region of the mass 
spectrometer. The fragmentation of the precursor ion occurs when kinetic energy (eV) is 
imparted to the ion within the fragmentation chamber, so that when a collision with an 
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inert gas molecule occurs, the compound becomes unstable and fragments. In peptides, 
this fragmentation occurs at specific areas along the peptide backbone causing it to 
break apart into characteristic fragments. Once the fragmentation event has occurred, 
the instrument can then either scan the product ions to generate an MS/MS spectrum of 
the precursor ion, or monitor specific fragment ions in an SRM based approach. 
1.7.3 Peptide CID based MS/MS fragmentation. 
The application of CID based fragmentation of a peptide, and full scan MS analysis of 
its products, enables the characterisation of the peptides amino acid composition. Low 
energy CID fragmentation occurs at multiple sites along the peptide backbone, 
generating predictable and consistent spectra. The nomenclature for peptide 
fragmentation patterns was coined by Roepstorff and Fohlman in 1984 and designated 
as a\b\c and x\y\z ion series (114) (Figure 1.16A). The main site of fragmentation is 
between the carbonyl group and the nitrogen of the peptide bond, generating y and b 
fragment ion molecules. Other fragmentation events do occur along the backbone, but at 
a lower frequency. The fragmentation event will generate product ions with at least one 
charge, which enables the fragments to be manipulated in the mass analyser and 
subsequently detected (Figure 1.16B). 
 
A B  
Figure 1.16. A displays sites of peptide backbone fragmentation using CID showing 
a\b\c\x\y and z ions. B displays charge retention of the fragments in positive ESI-
MS/MS. Figures taken from Matrix Science website www.matrixscience.com. 
  
Because peptides fragment in a reproducible and specific fashion, the pattern of 
fragment ions from any given amino acid sequence can be predicted. Assigning an 
amino acid sequence to a full scan peptide MS/MS spectrum can be performed in two 
ways, database searching or de novo sequencing. 
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1.7.3.1 Protein database searching  
The identification of a specific peptide’s amino acid sequence from an MS/MS 
spectrum is a highly complicated task and requires the use of bioinformatics software 
packages.  These software packages are available from instrument manufacturers and 
third party companies. In this project, the Mascot software package (Matrix Science, 
UK) was used for protein identification purposes. The bioinformatics software performs 
an in silico enzymatic digestion of a protein database, which can contain hundreds of 
thousands of protein entries. This digestion generates a list of peptide sequences, each 
of which have a known precursor mass and an associated theoretical CID fragmentation 
pattern. The bioinformatics software then compares the experimentally acquired 
peptide’s precursor mass, and subsequent fragment ions (Figure 1.17A) against the in 
silico data (Figure 1.17 B & C) in order to generate a possible match. 
 
 
Figure 1.17. Database matching of experimentally acquired MS/MS spectra of a peptide 
from Lectithin-cholesterol acyltransferase (A). B displays the matching of the peptides 
theoretical fragment masses (C) to the acquired spectrum for comparison purposes. 
 
1.7.3.2 De novo sequencing 
The acquisition of a full scan MS/MS spectrum from a peptide that originated from a 
unsequenced protein renders database sequencing a redundant exercise, and could even 
result in a false positive match for an unrelated protein. However, the MS/MS spectra of 
the peptide can be submitted for de novo sequencing. This approach involves using the 
differences in the m/z values of adjacent y or b ions in the peptide MS/MS spectrum to 
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identify a specific amino acid residue. This method is best attempted on high resolution 
MS systems such as Orbitraps, FT-ICR or TOF instruments, where the high mass 
accuracy enables unambiguous determination of fragment masses for sequencing 
purposes (115). 
 
1.7.4 SRM analysis of peptides 
The application of an SRM based detection technique to peptide analysis enables a 
quantitative and targeted LC-MS/MS based approach for protein quantitation. If a 
protein’s primary sequence is known, tryptic digest fragments can be identified using 
in-silico digestion programs. The fragmentation products of the peptides can also be 
identified in-silico allowing SRM transitions to be generated that link a peptide 
precursor ion to a number of product ions. An alternative approach to identifying SRM 
transitions is to use experimentally generated product ion spectra. This could either be 
performed on a pure protein digest, or from data acquired in IDA based protein 
identification experiments. The benefit of identifying transitions through experimentally 
acquired data is that this specifically targets peptides that were definitively generated 
when trypsin is added to the precursor protein, and furthermore, that the peptide is 
detectable by ESI based LC-MS experiments. Peptides that fulfil these specific criteria 
have been coined “proteotypic peptides” (116). A recent publication by the University 
of Cranfield describes an online software package that searches a database of 
experimentally acquired tryptic peptide MS/MS spectra, from a multitude of proteomics 
experiments. The software package (MRMaid) enables the user to identify prototypic 
peptides and choose specific peptide fragments that could be used to generate SRM 
based assays (117). 
 
SRM analysis is inherently quantitative because, in combination with LC based 
separation, monitoring specific precursor to product ion transitions generates a highly 
specific signal as a function of time. Therefore as a peptide elutes from an HPLC 
column, signal is generated in the mass spectrometer which can be integrated to obtain 
quantitative information for that peptide within a given sample. SRM based approaches 
to protein quantitation, in combination with tryptic digestion and stable isotope labelled 
tryptic peptide analogues, as internal standards, have been demonstrated to be effective 
and comparable to immunoassays (23). In their study, Kuhn et al quantified serum 
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levels of CRP using standard curves of synthetically produced (and unlabelled) tryptic 
peptides. They generated peak area ratios of unlabelled and stable isotope labelled 
variants of each peptide and used the equation of the line to back calculate 
concentrations of endogenous CRP protein in human serum samples. However, they 
demonstrated significantly different serum CRP concentrations when using different 
tryptic peptides and surmised that these differences occur from variable tryptic digestion 
efficiencies. Therefore, to develop an accurate and quantitative LC-MS/MS protein 
assay, a pure and intact source of the target protein is required to account for tryptic 
digestion errors. The best approach to quantitation would involve the use of stable 
isotopically labelled proteins with the pure unlabelled form, which would take into 
account errors in tryptic digestion. Two approaches, SILAC (118) and QconCAT (119), 
have been developed that involve expressing proteins in in-vitro biological systems 
where the growth media contains stable isotope labelled amino acids, usually lysine and 
arginine, exchanged for their unlabelled equivalents. Tryptic digestion of all the proteins 
produced in this environment would generate labelled peptides for quantitative 
purposes.     
 
1.8 THE PLASMA / SERUM PROTEOME 
Circulating blood comes into contact with every organ within an organism, making it an 
ideal medium to distribute signalling molecules throughout the body. It is believed that 
every cell in an organism releases compounds into the blood, even in the case of 
damage or death (120). When an organism enters into a disease state, for example 
cancer, specific proteins or peptides are released into the bloodstream as a biomarker of 
a clinical condition (121). The detection of these biomarkers can be used to identify 
early stages of diseases, even if clinical symptoms are not apparent (122,123). Plasma 
(the cell free content of blood) and serum (the solution left after clotting has occurred) 
have been the main biological matrices for diagnosing a myriad of diseases, because of 
the presence of disease biomarkers, and the ease of which it can be obtained.  The 
plasma and serum proteomes are very similar in terms of protein content, the differences 
are mainly due to the clotting process, which removes a low number of proteins (such as 
fibrinogen) from the solution (124).  
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It is believed that there are at least 10,000 proteins in human plasma, the majority of 
which are present in low concentrations (125,126). Furthermore, the dynamic range of 
plasma protein concentrations span 10 orders of magnitude from the high mg/mL to low 
pg/mL (124). A further complicating factor is that 99% of the total protein content 
originates from 22 proteins, with the vast majority (50%) attributed to albumin (Figure 
1.18). This suggests that the remaining 1% of the plasma proteome contains many 
proteins, which are present in vastly different concentrations (Figure 1.19).  
 
 
Figure 1.18. Pie charts demonstrating numbers of proteins present in human plasma, and 
their relative proportions. Taken from Tirumalai et al (121). 
 
The application of mass spectrometric based techniques to study plasma proteins is 
extremely challenging, as the high abundance proteins mask the presence of the lower 
abundant protein constituents (121,125). Therefore, the depletion of these high 
abundance proteins is regarded as essential (126). A number of approaches to the 
depletion of high abundance proteins from plasma or serum have been investigated, 
including immuno-depletion, dye-based depletion, protein precipitation and molecular 
weight discrimination.   
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Figure 1.19. Concentrations of proteins in plasma. Taken from Anderson et al (124). 
1.8.1 Immuno-depletion 
The application of immunochemistry based technologies to the removal of specific 
proteins from plasma has proved to be highly effective and has been adopted by a 
number of commercial suppliers. The first available immuno-depletion device was the 
Multiple Affinity Removal System (MARS) from Agilent, which contained antibodies 
to the top six plasma proteins (albumin, IgG, IgA, α1-antitrypsin, transferrin, and 
haptoglobin) immobilised to a solid matrix in the form of HPLC columns or spin 
columns (126). When a sample is added to the device, the selected proteins are bound 
by the immobilised immunoglobulins, allowing unretained proteins and peptides to pass 
through. The bound proteins are then eluted, so the device can be re-used. This 
approach removes the high abundance proteins, significantly reducing the total protein 
concentration in the plasma or serum, which enables the detection of lower abundant 
proteins by LC-MS/MS or SDS-PAGE analysis. Using these devices, a ten-fold increase 
in loading capacity is possible, increasing the amount of the low abundance proteins for 
analysis (126). This technology has been used in conjunction with protein identification 
experiments, where immuno-depleted plasma resulted in 181 proteins being identified 
as apposed to only 40 in crude serum (127). A significant drawback with this 
technology is that albumin transports small proteins, peptides and other compounds 
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around the body, therefore its removal (without disruption of this binding) could result 
in the loss of possibly important proteins (121,125,126,128).  
 
Immuno-depletion relies on the highly specific antigen-antibody interaction to deplete 
high abundant proteins. This approach renders each device as species specific, as human 
antibodies would not interact with their equivalent protein targets in serum or plasma 
from a different species, such as mouse or rat. As a consequence of this species 
specificity, Agilent released the “Mouse 3” immuno-depletion device. However, this 
project involves both human and murine serum protein analysis, requiring a method that 
would work in both species. 
 
1.8.2  Dye-based affinity depletion 
Another approach to removing high abundance proteins is by using cibacron-blue-3G-A 
(a triazine dye) immobilised to a polymeric based solid matrix. The dye is structurally 
analogous to nicotinamide adenine dinucleotide and binds proteins with dinucleotide 
binding sites (129). The binding of proteins to the dye was found to be pH dependent, 
with the charge on the protein being the crucial factor. Li et al (130) investigated the use 
of cibacron-blue-3G-A to remove albumin and transferrin from cerebrospinal fluid 
(CSF). They demonstrated that the immobilised dye could remove a large quantity of 
the two proteins from the CSF proteome. However, Lascu et al. indicated that cibacron-
blue-2G-A bound a number of proteins other than albumin and transferrin (129), which 
could result in the inadvertent removal of possible biomarkers from the serum or plasma 
matrix.  
 
1.8.3  Protein precipitation 
Protein precipitation techniques exploit the physicochemical properties of proteins in 
solution, which are imparted through a protein’s three-dimensional structure. This 
structure is ultimately determined by the sequence of amino acids of each protein, and 
the nature of how the amino acid residues interact. The different levels of protein 
structure are described in further detail.  
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1.8.3.1 Protein primary structure 
Proteins are biopolymers comprising long chains of amino acids of which the majority 
are selected from a pool of 20 common residues. These residues can be grouped into 
four classes based on their chemical properties; polar uncharged, acidic, basic and non-
polar. Active proteins can consist of large numbers amino acids, ranging from small 
peptides like Bradykinin (9 amino acids) to titin (~ 27,000 amino acids). The order in 
which these amino acids are linked, via peptide bonds, is known as the primary 
structure, and is predetermined by the sequence of the DNA coding for the protein in 
question.  
 
1.8.3.2 Protein secondary and tertiary structure. 
A protein’s primary structure is extremely flexible, allowing the chain of amino acids to 
rotate freely and interact with itself, forming secondary structures such as α-helices and 
β-pleated sheets (Figures 1.20 A & B). Additional secondary structures include di-
suphide bridges (Figure 1.20 C), which are formed between cysteines residues within 
(or between) a protein’s primary structure. These secondary structures aid the formation 
of the proteins globular or tertiary structure by introducing stable and folded regions of 
the protein.  
 
A protein’s tertiary structure enables it to perform its designated function through the 
generation of catalytic or binding sites. Tertiary structure is stabilised by internal and 
external forces such as hydrogen bonding, disulphide bridges and van der Waals forces. 
It is believed that the processes involved in correct protein folding in a given solution is 
derived from a combination of enthalpic and entropic factors (131). In its folded state, 
the outer regions of globular proteins consist of mainly hydrophilic amino acids (Figure 
1.20 D), such as asparagine, glutamine, lysine and arginine which comprise on average 
27% of a protein surface area, but only 4% of interior residues. A protein’s interior 
contains mainly hydrophobic residues, with valine, leucine, isoleucine, phenylalanine, 
alanine and glycine comprising 63% of interior residues (131).  
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Figure 1.20. IGF-I tertiary structure. A=β-pleated sheet, B=α-helices, C=Disulphide 
bond. D=Albumin tertiary structure showing hydrophobicities of amino acid residues. 
Non-polar residues are grey (e.g. phenylalanine), changing to dark blue as they become 
more polar (e.g. arginine). 
 
The hydrophilic amino acids on the outer surface of the protein interact with water 
molecules and co-solvents within a “hydration shell”, which enables the protein to keep 
its tertiary structure intact, and remain in solution (132,133). Electrostatic repulsion 
between like charged objects (proteins) also prevents proteins from aggregating, 
resulting in precipitation (131). Therefore, modifying the hydration shell by adding non-
compatible co-solvents such as chaotropic salts (urea), organic solvents or acids can 
cause proteins to become insoluble and precipitate from solution.  
 
1.8.3.4 Precipitation agents: ammonium sulphate 
Ammonium sulphate causes protein precipitation because the ammonium and sulphate 
ions sequester the ‘water of hydration’ from dissolved proteins. This reduces the 
proteins solubility, resulting in precipitation; this process is called “Salting out”. The 
loss of hydrating water causes the proteins to interact with each other and form 
aggregates, and therefore precipitate from the solution (134). Larger proteins require 
larger hydration shells to remain soluble, with a general rule of 2 water molecules per 
amino acid (131). Therefore, albumin (585 aa) requires approximately 1170 molecules 
of water, whilst APO A2 (77 aa) requires only 154.  
 
Ammonium sulphate has been used to purify antibodies from serum because the 
precipitation event does cause proteins to denature and lose their function (131,135). 
Therefore, the addition of ammonium sulphate to serum could be used to precipitate the 
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high molecular weight proteins in order to study the remaining proteins in the 
supernatant. However, the use of ammonium sulphate would require an additional clean 
up stage prior to analysis by LC-MS due to the high salt content in the supernatant. 
 
1.8.3.5 Precipitation agents: organic solvents 
The addition of organic solvents to aqueous solutions lowers the dielectric constant of 
the solution, increasing the attraction between charged molecules and facilitates 
electrostatic protein interactions, causing protein aggregation (133). The addition of 
ACN to serum causes protein precipitation and releases proteins and peptides that are 
bound to albumin, allowing their subsequent detection by LC-MS (121,128). Since 
ACN is miscible with water in all ratios, and proteins and peptides are also soluble in 
ACN containing buffers (136), this approach could prove useful in developing a method 
for removing high abundance proteins from serum / plasma, whilst retaining those 
proteins and peptides bound to albumin. Organic solvents have also been used to 
deplete high abundance proteins from serum for biomarker studies into B cell 
lymphomas (136).  
 
Organic solvents can be removed from the supernatant after the precipitation event has 
occurred by evaporation, thus enabling a concentration step in the extraction process. 
Polson et al investigated the use of organic solvents as precipitants in plasma from a 
number of species and measured total protein remaining after precipitation, Table 1.1 
(133). They demonstrated that the efficiency of protein precipitation was very high, with 
a ratio of 2 volumes of ACN to 1 volume of plasma obtaining 92% total protein 
removal. 
 
Table 1.1. Protein precipitation efficiency. Values are ([total plasma protein - protein 
remaining in supernatant] / total plasma protein) x100. Selected data taken from human 
plasma experiments from Polson et al (133). 
 
 Ratio solvent : plasma  (RSD in brackets n=3) 
Organic solvent 0.5:1 1:1 1.5:1 2:1 2.5:1 3:1 
Acetonitrile 3 (3.6) 89 (2.5) 92 (3.6) 92 (3.1) 93 (5.2) 94 (5.9) 
Methanol 13 (0.9) 64 (3.1) 88 (3.5) 90 (3.5) 90 (2.8) 91 (5.1) 
Ethanol 0 (2.8) 78 (2.4) 87 (1.6) 88 (9.5) 90 (9.6) 92 (2.5) 
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1.8.4  Molecular weight discrimination 
Serum and plasma biomarkers tend to be low molecular weight proteins or peptides, 
examples of which are the interleukins, which vary from 10 kDa to 30 kDa (137). These 
proteins are significantly lower in mass than the more abundant proteins in plasma, for 
example, albumin (67 kDa) and the immunoglobulins (~ 150 kDa). This large difference 
in mass can be exploited through the use of molecular weight cut off (MWCO) devices. 
These devices come in a number of mass cut off sizes, from 200 to 100,000 Da. MWCO 
devices have been used to remove high abundance proteins from serum/plasma 
(121,128). There have been counter arguments against the use of ultrafiltration, 
suggesting that they did not retain all the high molecular proteins in the device, letting a 
significant portion through into the filtrate (138). However Georgiou et al only used one 
MWCO device. Unpublished work carried out at Quotient Bioresearch on equine 
plasma using 10 and 30 kDa devices demonstrated that all traces of high molecular 
weight proteins were removed from the filtrate (data not shown).  
 
A number of approaches to the removal of high abundance proteins from plasma or 
serum have been discussed, all of which have strengths and weaknesses. The methods 
tested in this project were protein precipitation and MWCO devices. The reproducibility 
of these methods was investigated, and the LC-MS data was analysed using 
bioinformatics programs.  
1.9 BIOINFORMATICS FOR BIOMARKER IDENTIFICATION 
The analysis of a serum/plasma extract digest by LC-MS generates an immense amount 
of data. Full scan spectra are acquired approximately once a second for the entire 
analysis, which lasts for at least 60 minutes (totalling approximately 3600 spectra). 
Each spectrum contains data in the form of m/z and intensity (usually in increments of 
~0.1 m/z from 400-1600 m/z). Therefore, a 60-minute LC-MS experiment will generate 
in the order of 40 million m/z and intensity measurements. Detecting differences in m/z 
and intensity values from multiple LC-MS analyses would be impossible “by eye”, 
therefore the application of bioinformatics techniques is essential for this task. 
Bioinformatics approaches that have been applied to biomarker discovery include 
artificial neural networks (ANNs) and principal components analysis (PCA). 
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1.9.1 Artificial Neural Networks 
Artificial neural networks mimic the workings of biological neural networks, in their 
design and function, allowing them to learn and adjust to identify patterns within 
complicated data sets. A comparison between biological and ANNs will be discussed. 
 
1.9.1.1 Biological neural networks 
The human brain contains approximately 10 billion interconnecting memory cells called 
neurons. Furthermore, any one neuron can be connected to between 1,000 and 10,000 
other neurons within the brain. A neuronal cell consists of four key parts; a cell body 
(soma), an axon, dendrites and axon terminals (Figure 1.21). The dendrites accept input 
from the synapses of other neuronal cells and propagate the electronic pulse into the 
soma for data processing. Multiple signals are being transferred to the soma at any one 
time, however, signal only propagates along the neurons axon if the total input into the 
soma reaches a pre-determined threshold. The electronic input transfers along the axon 
in the form of a depolarisation wave which, upon reaching the synapse, causes 
neurotransmitters to be released from vesicle stores into the post-synaptic cleft. The 
neurotransmitters diffuse across the short distance between two neurons, and if in a 
sufficient concentration, trigger a new depolarisation wave in the connected neuron.  
 
 
Figure 1.21. A typical neuronal cell, showing dendrites, cell body, axon and axon 
terminals. 
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1.9.1.2 Artificial neural networks 
An artificial neural network simulates the basic functions of the four basic components 
of a neuron. Information is received, processed and an output signal is propagated if the 
total input passes a threshold. Figure 1.22 shows the basic structure of an artificial 
neuron, which was described as a “perceptron” by Frank Rosenblatt in 1958.  
 
 
Figure 1.22. Schematic of an artificial neuron, showing inputs x, weights w, and 
processing element. Taken from www.psych.utoronto.ca/users/reingold/courses/ai/ 
cache/neural2.html. 
 
Input data (Xn) are initially weighted by random amounts (Wn) prior to training of the 
artificial neural network. The processing element takes all the input values, multiplies 
them by their weights and calculates a summed value. If this summed value exceeds a 
specific threshold value, the ANN designates the output as a binary integer (1), if the 
value is below the threshold the ANNs assigns the output as 0. Training ANNs involves 
manipulation of the weight values for each input until the desired outcome (correct 
prediction of a state) is achieved. This involves using training sets of data, which are 
processed by the network multiple times in an iterative fashion. During each training 
cycle, the trained network is used to predict the state of randomly selected blind test 
samples. The prediction errors obtained from each analysis of a test set is then fed back 
into the system for another training iteration, where the weighting of the input data is 
refined in order to achieve the correct output. This process is called backpropagation 
(139). Once the network has been trained, the weightings can be “frozen” so as to 
prevent the network being over trained. 
 
49 
Neural networks can be extremely powerful techniques for detecting patterns within 
large datasets (140). However they can only provide useful data if they have been 
correctly trained as the output from a model might not be genuine, which can result 
from a network memorisation of a training set rather than true prediction (139). To 
overcome the problem, the test set must be sufficiently large (preferably n=50 for each 
state) for the network to reach a successful outcome.  
 
1.9.2 Principal components analysis 
Principal components analysis (PCA) is another bioinformatics approach that can be 
used to identify trends within highly dimensional data sets. The technique was 
developed by Karl Pearson in 1901 (141) and involves determining how specific 
datasets correlate with each other. PCA uses highly complicated mathematical functions 
to transform potentially correlating data into uncorrelated variables called principal 
components. These components (essentially specific data inputs) are selected such that 
they explain as much variance within the data set as possible.  
 
A good analogy of the PCA technique is to envisage a data set as a currant bun, where 
data are expressed as vectors designating the x,y and z coordinates of each currant in the 
bun. If an attempt is made to position a needle into the bun, such that it is as close to all 
the currants as possible, this is declared as a principal component. If the bun is flattened, 
it turns three dimensional data to two dimensions, so that the distances of each currant 
from the needle can be calculated. This generates a value for each data point relative to 
the first principal component. The aim of the first principal component is to account for 
as much variability as possible. If a second needle is introduced perpendicular to the 
first, it generates a second principal component. Values obtained from each principal 
component for each data point are then displayed in a scatter plot for comparison 
purposes (Figure 1.23).  
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Figure 1.23. Example PCA plot showing PC1 (x axis) and PC2 (y axis). The majority of 
data points show no differences within the data set, and are tightly clustered at the 
origin. Specific proteins such as Actin 1 and 2 show significant differences mainly in 
PC1 (circled), whilst patient state as mutated (M) or unmutated (UM) for a specific IgG 
locus display large differences in PC2. Image taken from Cochran et al (142). 
 
This approach enables the user to identify components of large and highly complex 
datasets that differ between a specific set of samples. PCA has been used in the field of 
proteomics to identify differentially expressed proteins within a population of patients 
with different forms of leukaemia (142).  
 
PCA is a powerful technique for identifying differences within a complex dataset. 
However the approach is not capable of learning and adapting. The approach requires 
all data to be submitted in one analyses, whilst using ANNs allows the user to develop a 
model, then apply that model to future samples for classification purposes. Furthermore, 
a direct comparison of ANNs and PCA approaches demonstrated that ANNs performed 
better at classification tasks than PCA (143).  
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1.10 PROJECT OVERVIEW 
The aim of this project is to apply LC-MS and bioinformatics approaches to identify, 
characterise and validate biomarkers to GH gene therapy in a murine model, and rhGH 
administration to humans. The thesis contains four experimental chapters: 
 
1. Chapter 2 describes the development of an ACN depletion method for removing high 
abundant and high molecular weight proteins from serum, and the characterisation of 
extracts using SRM and 2D LC-MS/MS analyses. 
 
2. Chapter 3 describes the application of the ACN depletion method to murine serum 
and the extraction and analysis of serum samples from an administration of GH gene 
therapy to a murine model. Data from the LC-MS analyses were submitted to stepwise 
ANNs analysis for biomarker identification purposes.  
 
3. Chapter 4 describes the LC-MS analysis of ACN extracted serum samples from an 
rhGH administration to human subjects performed at Royal Free University College 
London. A possible biomarker capable of discriminating between rhGH and placebo 
treated individuals was identified using ANNs and identified as Leucine-rich α-2-
glycoprotein (LRG). 
  
4. Chapter 5 describes the development of a high throughput uHPLC-MS/MS and SRM 
based analysis for serum protein quantitation. The combination of the ACN depletion 
method and uHPLC-MS/MS approaches were applied to a large rhGH administration 
sample cohort for validation of LRG. This analysis was performed concordantly with a 
quantitative analysis of IGF-I in the same uHPLC-MS/MS analysis. The analysis of 
IGF-I and LRG was also performed in the murine GH gene therapy samples to assess if 
the murine LRG protein was also GH dependent. 
 
 
 
 
52 
CHAPTER 2. DEVELOPMENT OF AN ACETONITRILE DEPLETION 
METHOD TO REMOVE HIGH ABUNDANT, HIGH MOLECULAR WEIGHT 
SERUM PROTEINS FOR BIOMARKER DISCOVERY AND VALIDATION 
EXPERIMENTS 
2.1 INTRODUCTION 
The serum/plasma proteome has been extensively studied in order to identify and 
quantify protein and peptide biomarkers in a number of species. A major goal of these 
proteomics studies is to discover protein or peptide targets that can aid the diagnosis and 
detection of physiological conditions, for example, the detection of protein biomarkers 
following growth hormone administration (144). However, identifying and detecting 
changes in protein and peptide concentrations is constrained by the complexity of the 
serum proteome. The dynamic range of protein concentrations within serum is in the 
region of 10 orders of magnitude, with an approximately 50% contribution from 
albumin. Proteomics studies on serum and plasma have shown that the concentrations of 
potentially important biomarkers, such as tissue leakage proteins, are likely to be at 
concentrations of five to ten orders of magnitude lower than albumin (124). Current 
analytical techniques cannot detect changes in concentration of proteins over this 
dynamic range without some degree of pre-fractionation prior to analysis (121). 
  
A common approach to simplifying the serum proteome is through the use of immuno-
depletion using a MARS column, which removes specific high abundant proteins such 
as albumin, transferrin, immunoglobulin (Ig) G and IgA (21). However, there are a 
number of disadvantages with this technique, such as low sample throughput, non-
specific loss of albumin bound proteins and species specificity issues. The sample 
throughput is low because extractions are performed sequentially and proteins in the 
column eluates require concentration following extraction using molecular weight filters 
(145). Albumin is a known carrier protein for hormones, lipoproteins and other 
circulating signalling molecules (146), therefore the removal of the protein without 
prior disruption of its structure can result in the loss of potential biomarkers (121). 
Lastly, due to the highly specific nature of the antibody-antigen interaction, immuno-
depletion devices may not be viable for use in matrices from a multitude of different 
species. For example, different antibodies are required for the extraction of high 
abundant proteins from rodent and human sera.  
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The addition of organic solvents to serum results in the precipitation of high molecular 
weight proteins, leaving a low molecular weight protein fraction in solution (128,136). 
The use of organic solvents as plasma protein precipitants has been investigated in a 
number of species, although the intent of the study by Polson et al was to remove as 
much protein as possible (133), rather than only the high abundant protein species. Of 
the solvents tested, ACN was found to be the most reproducible and effective solvent 
(133). ACN depletion is a high throughput technique, which is amenable to automation 
and is used regularly in bioanalytical laboratories for extracting small molecules from 
plasma or serum prior to analysis. The addition of ACN to serum at a final volume of 
20% has also been shown to disrupt the association of proteins with serum albumin, 
reducing the possible loss of biomarkers (121). An acetonitrile based protein depletion 
method is also low cost with regard to reagents.. 
 
This chapter describes the development of an ACN based serum protein depletion 
method for biomarker discovery and validation experiments. The serum proteins left in 
the supernatant post-depletion were assessed using SDS-PAGE, the Bradford assay and 
LC-MS/MS based analyses. LC-MS/MS techniques used included both SRM based 
analyses, to give relative concentrations, and an information dependent scanning 
method in order to characterise the proteins in the supernatant using protein database 
searching. 
  
2.2 MATERIALS AND METHODS 
2.2.1 Chemicals 
Acetonitrile (ACN, LC grade) was purchased from Romil (Cambridge, UK) and 18.2 
MΩ water was produced by a Maxima water purifier (Elga, High Wycombe, UK). 
Ammonium bicarbonate, β-mercaptoethanol, brilliant blue R250, dithiothreitol (DTT), 
iodoacetamide and formic acid were purchased from Sigma Aldrich (Poole, UK). Acetic 
acid was purchased from BDH (Poole, UK). Trypsin gold was from Promega 
(Southampton, UK). Ethanol was sourced from Hayman (Witham, UK). Human serum 
was obtained from a healthy male consenting adult. 
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2.2.2 Assessment of serum pre-dilution prior to ACN depletion 
Ten aliquots of human serum (20 μL) were transferred to Lo-Bind micro centrifuge 
tubes (Eppendorf, Cambridge, UK) and increasing amounts of water added prior to the 
addition of ACN at a ratio of 1.5 volumes to the combined volume of serum and water. 
An undiluted serum was also extracted for comparison. Samples were sonicated for 10 
minutes in a U300 ultrasonic water bath (Ultrawave Ltd, Cardiff, UK). The tubes were 
vortexed briefly then sonicated for a further ten minutes. The protein precipitate was 
pelleted by centrifuging at 12,000 x g for 10 minutes at room temperature in a fixed 
rotor EBA 12-R centrifuge (Hettich, Tuttlingen, Germany). The supernatant was 
transferred to clean LoBind tubes, and evaporated to dryness in an HT-4 centrifugal 
evaporator (Genevac, Ipswich, UK) with no heating. Following evaporation, the extract 
was reconstituted into 30 μL of water and 15 μL was added to 15 μL of SDS-PAGE 
loading buffer containing 4.2% β-mercaptoethanol  (v/v) (Sigma-Aldrich, Poole, UK) 
and protein disulphide bonds were reduced by heating at 95 °C for 5 min. Samples were 
cooled and 15 μL loaded onto a 15% polyacrylamide gel and analysed alongside 10 μL 
of a Precision Plus protein unstained molecular weight markers (Biorad, Hemel 
Hempstead, UK). Electrophoresis was performed at 200 V for 45 min, and the gel fixed 
in 30% ethanol (v/v) (Hayman, Witham, UK) and 5% acetic acid (v/v) (BDH) for 30 
min. Protein bands were stained using 0.1% (w/v) brilliant blue R250 (Sigma-Aldrich) 
with shaking for 45 min before destaining in fixing solution. The gel image was 
captured using a UVP gel cupboard (Cambridge, UK) and stored as jpeg files. 
 
2.2.3 Selection of ACN:diluted serum ratio 
Following the identification of the optimum serum pre-dilution factor, the ratio of ACN 
to diluted serum was assessed. This involved dilution of human serum (20 μL) with 
water (40 μL), and adding 30, 60, 90 and 120 μL of ACN, corresponding to ratios of 
1:0.5, 1, 1.5 and 2 respectively. The supernatant was removed and evaporated in a 
genevac rotary evaporator and the extract analysed using SDS PAGE as described in 
Section 2.2.2. 
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2.2.4 Assessment of reproducibility of final ACN depletion method. 
Human serum aliquots (20 μL, n=7) were transferred to Lo-Bind tubes, diluted with two 
volumes of water (40 μL) and vortexed to mix. ACN was added at a ratio of 1.5 
volumes of total diluted serum (90 μL) and the samples extracted and evaporated as 
described in Section 2.2.2. In order to assess the reproducibility of the method, the dried 
extract was reconstituted into 30 μL and split into two equal fractions, one for SDS 
PAGE analysis and the second for total protein quantitation using the Bradford assay.  
  
The concentration of protein in the human serum extract was quantified using the 
Bradford assay (Dojindo, Kumamoto, Japan). A BSA standard curve (31.25 – 2000 
μg/mL) was generated by performing seven doubling dilution steps in phosphate 
buffered saline. Three 6 μL aliquots of each standard and two 6 μL aliquots of the 
remaining protein extract were transferred to 96 well microtitre plates, and 300 μL of 
coomassie brilliant blue solution was added. The plate was shaken for 60 seconds 
before reading at 595 nm in a Spectrofluor plate reader (Tecan, Theale, UK). 
 
2.2.5 Reduction, alkylation and tryptic digestion of ACN extract for proteomic analysis. 
Five serum samples were ACN depleted using the method described in Section 2.2.4 
and the supernatant transferred to fresh Eppendorf tubes. Following evaporation of the 
supernatant, 16 μL of 50 mM ammonium bicarbonate, pH 8.2, and 2 μL of 100 mM 
DTT in water were added and vortexed to reconstitute the extract. Samples were 
incubated at 60 °C for 1 hr and allowed to cool to room temperature before the addition 
of 2 μL of 100 mM iodoacetamide in water. Samples were incubated at room 
temperature for 30 minutes in the dark prior to the addition of 3 μL of 100 μg/mL 
Trypsin Gold in 50 mM acetic acid. Samples were digested overnight at 37 °C and the 
reaction was quenched by the addition of 2.5 μL of 1% formic acid in water (v/v). 
Samples were transferred to plastic autosampler vials for nanoflow LC-MS/MS 
analysis. 
 
2.2.6 Nanoflow LC-MS/MS analysis of human serum extract 
Nanoflow LC-MS/MS was performed on an Ultimate 3000 LC system (Dionex, San 
Francisco, CA, USA) coupled to a 4000 QTRAP hybrid triple quadrupole mass 
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spectrometer with a NanoSpray II ® ion source and a Microionspray II® device 
(Applied Biosystems / MDS Sciex, Concord, ON, Canada). ACN depleted serum 
samples prepared in 2.2.5 were analysed in duplicate. Sample (2 μL) was injected onto a 
C18 PepMap (Dionex) 0.3mm x 5 mm trap and washed with 100% mobile phase A (2% 
ACN in 0.1% formic acid in water, v/v) at 25 μL/min for five minutes. Following valve 
switching, peptides were separated on a C18 PepMap (Dionex) 75 μm x 150 mm column 
at a constant flow of 300 nL/min using a gradient from 0 to 40% mobile phase B (90% 
ACN in 0.1% formic acid in water, v/v) over 55 minutes and then to 90% B over a 
further ten minutes. After reaching 90% B, the column and trap were switched out of 
line and the column washed for 12.5 mins before returning to original conditions, whilst 
the trap was washed for the same time at 50 μL / min to clean the remaining sample off 
the reversed phase material. The total analysis time of the LC separation was 95 min. 
Positive ion electrospray was performed using an uncoated 20 μm id SilicaTip (New 
Objective, Cambridge, MA, USA) with a voltage of 2.2 kV applied to the needle. The 
MS analysis method included the 113 SRM transitions (Appendix I) relating to 57 
proteins used by Anderson and Hunter in their 2006 publication (147).  The collision 
energy was set at 40 eV for each SRM transition, collision gas at 12 psi, and dwell times 
at 30 milliseconds. The peptide peak area from the overlaid SRM chromatograms was 
calculated using Analyst v1.4.1 (Applied Biosystems).  
  
 
2.2.7 2D LC-MS/MS analysis of a large serum extract 
2.2.7.1 Serum extraction 
Serum (500 μL) was diluted with 1 mL of water, and protein depleted with 2.25 mL of 
ACN. The extract was sonicated and vortexed as described in 2.2.2 and the solution 
aliquoted into four 1.5 mL LoBind tubes for centrifugation. The supernatant was 
transferred to clean tubes and evaporated in a centrifugal evaporator. Following 
evaporation, 80 μL of 50 mM ammonium bicarbonate pH 8.2, and 10 μL of 100 mM 
DTT in water were added to each of the four LoBind tubes, vortexed to reconstitute the 
extract and the samples pooled. The extract was incubated at 60 °C for 1 hr, then 
allowed to cool to room temperature before the addition of 40 μL of 100 mM 
iodoacetamide in water. Samples were incubated at room temperature for 30 minutes in 
the dark prior to the addition of 80 μL of 100 μg/mL Trypsin Gold in 50 mM acetic 
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acid. Samples were digested overnight at 37°C and the reaction quenched by the 
addition of 48 μL of 1% formic acid in water (v/v).  
 
2.2.7.2 Initial 1D LC-MS/MS analysis 
The tryptic digest was analysed using nanoflow LC-MS/MS as described in Section 
2.2.6 with an IDA based analysis method to assess the peptide content of the serum 
extract. IDA analysis involved performing a full scan analysis from m/z 400-1600 at 
1000 amu/second, and the three most intense ions selected for MS/MS fragmentation. 
The charge state of the three selected ions were identified using an enhanced resolution 
scan which monitored a region ± 15 m/z around each targeted ion at 250 amu/second. 
Scans displaying multiply charged 13C isotopic clusters triggered a full scan MS/MS 
analysis (m/z 100-1700, 4000 amu/second) on the target ion. Multiply charged peptide 
ions selected for full scan product ion analysis were added to a dynamic exclusion list 
for 4 minutes before further ions with the same m/z value could be selected for repeated 
MS/MS fragmentation.  
 
The acquired LC-MS/MS file was searched against the Swissprot database (05-03-
2008) with a human species filter, semi-trypsin enzyme setting, a fixed modification of 
carbamidomethylated cysteine, with variable modifications of deamidated asparagine 
and glutamine residues, and an oxidised methionine. Precursor and product ion 
tolerances were set at 1.6 and 0.8 respectively. The Mascot peptide score cut-off was set 
at 35, with a p value of <0.05, and all peptides required a bold red match (where only 
the top hit for each peptide was used for protein identification). A total of 31 proteins 
were identified using a 1D LC-MS/MS analysis (Appendix II). 
 
2.2.7.3 SCX based fractionation of digested serum extract 
SCX fractionation was performed on an HP1100 HPLC system (Agilent, Santa Clara, 
USA) with UV detection and an automated fraction collector (Gilson, Middleton, USA). 
The digest sample was made up to a total volume of 1mL using Solvent A, which 
consisted of 25 mM ammonium formate pH 3.0, 10% ACN (v/v). Sample (1 mL) was 
manually injected into a sample loop before switching in-line with a 4.6 x 100 mm 
PolySULFOETHYL Aspartamide SCX column (Nest group, Southborough, USA). The 
initial solvent conditions were held at 100% A for 20 minutes before increasing to 
100% B (1M ammonium formate, pH3, 10% ACN (v/v)) over 25 minutes. The UV 
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detector recorded absorbance values at 280 nm during the fractionation, which 
corresponds to the wavelength absorbed by tryptophan and tyrosine. A wavelength of 
214 nm was not monitored because ammonium formate absorbs strongly at this 
wavelength. One-minute fractions were collected into LoBind tubes for 20 minutes, and 
each fraction was split into two equal aliquots before evaporation. 
 
2.2.7.4 Nanoflow LC-MS/MS analysis of SCX fractions 
Dried SCX fractions were reconstituted into 25 μL of solvent A (2% ACN in 0.1% 
formic acid (v/v) and 10 μL injected onto the Ultimate 3000 LC system. Peptides were 
separated using the LC method described in Section 2.2.6, with an IDA based MS/MS 
analysis as described in Section 2.2.7.2.  
 
Acquired data files were assessed for peptide content; only fractions 1 to 15 displayed 
data consistent with the presence of peptides. The LC-MS/MS files were combined for 
protein database searching using Mascot and the Swissprot database (settings as 
described in 2.2.7.2). A protein list was generated which included the proteins 
identified, number of peptides matched per protein, percent coverage and the proteins 
molecular weight. Protein molecular weights were calculated without the signal peptide 
(identified using the Expasy website http://www.expasy.ch) and did not include PTM’s 
such as glycosylation or phosphorylation. 
 
2.2.8 Nanoflow LC-MS/MS analysis for IGF-I in serum extract. 
The 2D LC-MS/MS analysis resulted in a match for the IGF-I T1 tryptic peptide. An 
experiment was carried out to assess if the peptide could be detected in a targeted 1D 
nanoflow LC-MS/MS analysis. A 20 μL serum extract was analysed using the same 
nanoflow LC-MS/MS conditions as described in Section 2.2.6, using four SRM 
transitions specific for the triply charged ([M+3H]3+) precursor ion of the IGF-I T1 
tryptic peptide. The amino acid sequence of this peptide is 
GPETLCGAELVDALQFVCGDR, which contains two carbamidomethylated cysteine 
residues. The transitions used for this analysis were 769.7 / 881.4, 769.7 / 994.5, 769.7 / 
1065.5 and 769.7 / 1180.5 targeting the y7, y8, y9 and y10 fragment ions respectively.   
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2.3 RESULTS AND DISCUSSION 
2.3.1 Initial assessment of acetonitrile depletion on the human serum proteome 
Method development was performed entirely on human serum, as the human serum / 
plasma proteome has better annotation than that of the murine. Early assessments of the 
effect of ACN on human serum indicated that it was extremely efficient at removing 
proteins. However, SDS PAGE gel analysis of the supernatant showed that almost all 
proteins were being depleted, rendering the technique inappropriate for proteomic 
studies. An initial experiment investigated the dilution of serum with water prior to 
ACN depletion and this significantly increased the protein content of the supernatant. 
An experiment was therefore performed to assess the optimum dilution factor of serum 
prior to the addition of ACN. 
 
2.3.1 Serum pre-dilution and ACN:sample ratio experiments 
The effect of diluting serum prior to ACN depletion clearly increased the protein 
content in the supernatant, and higher dilution factors gave higher protein recovery after 
depletion (Figure 2.1). The optimum dilution factor was chosen as two volumes of 
water to one volume of serum (lane 6 Figure 2.1). These conditions were selected as a 
compromise between protein recovery and the volume of supernatant. Higher serum 
pre-dilution ratios required significantly increased volumes of ACN for protein 
depletion, therefore generating large volumes of supernatant to evaporate prior to 
downstream sample handling.  
 
The assessment of different volumes of ACN added to diluted serum is displayed in 
Figure 2.2. Lanes 2 and 3 display the protein content of depleted serum extracts using 
ratios of 1:0.5 and 1:1 respectively, where significant warping of the gel has occurred 
due to the high albumin content of the extracts (~70 kDa). The SDS PAGE gel image 
clearly demonstrates that adding 1.5 volumes of ACN to diluted serum (lane 4) most 
effectively removes abundant proteins, whilst retaining the majority of the low 
molecular weight protein fraction. Lane 5 (2 volumes of ACN to sample) shows almost 
complete removal of all protein below the 25 kDa mw range, making it unsuitable for 
proteomics experiments. 
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Figure 2.1. 1D SDS PAGE analysis of serum diluted with increasing volumes of water 
and precipitated with ACN. Precipitation was performed with 1.5 volumes of ACN 
(corresponding to final volume of diluted serum) and 25% of the supernatant was 
loaded onto the gel (equivalent to 5 μL neat serum). Lane 1= molecular weight markers, 
2= undiluted serum, 3= 0.5 volumes of water added before precipitation, 4= 1 volume, 
5= 1.5 volumes, 6= 2 volumes, 7= 2.5 volumes, 8= 3 volumes, 9= 3.5 volumes, 10= 4 
volumes, 11= 9 volumes, 12= molecular weight markers. 
 
 
 
Figure 2.2. SDS PAGE image of serum diluted with 2 volumes of water and the 
addition of increasing volumes of ACN to assess protein depletion. 1= molecular weight 
markers, 2= 0.5 volumes, 3= 1 volume, 4= 1.5 volumes, 5 = 2 volumes. 
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The two SDS page experiments demonstrated that the optimum dilution of serum prior 
to ACN depletion was the addition of 2 volumes of water, and that adding 1.5 volumes 
of ACN removed a significant amount of high abundant serum protein, whilst retaining 
lower molecular weight proteins. These parameters were chosen for all future 
experiments. 
2.3.2 Bradford assay of ACN depleted serum extracts 
The ACN depletion approach demonstrated high efficiency for removing high abundant 
and high molecular weight proteins from serum. However, if the ACN depletion 
technique is to be applied for biomarker discovery, a high degree of reproducibility will 
be essential. Therefore an experiment was devised to assess the reproducibility of the 
method, which involved using both the Bradford assay and SDS-PAGE analysis. 
 
A standard curve of BSA from 32 to 2000 μg/mL was generated (Figure 2.3A) and the 
equation of the calibration line used to calculate the concentration of protein in the ACN 
depleted serum extracts (Figure 2.3B). Using a Bradford assay approach, the 
concentration of protein in the reconstituted extract gave a mean concentration of 0.25 
mg/mL with a coefficient of variation of 15% (n=7). The protein concentration of crude 
serum was calculated as 70 mg/mL, corresponding to removal of an average of 99.64% 
(± 0.1) total protein mass following extraction. 
A
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mg / mL
% protein 
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1 230 99.67
2 270 99.61
3 210 99.7
4 320 99.54
5 220 99.69
6 280 99.6
7 240 99.66
Mean 252 99.64
SD 39 0.06
%CV 15 0.06  
Figure 2.3. A = BSA calibration line from 32 to 2000 μg/mL in PBS, error bars indicate 
1 standard deviation (n=3). B displays concentration of protein in seven replicate 
extractions of human serum using the ACN depletion method, as determined by 
Bradford assay. 
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2.3.3 SDS PAGE assessment of optimised extraction method. 
The protein content of the supernatant from the seven serum aliquots extracted using the 
optimised ACN depletion method is displayed in Figure 2.4. The 1D SDS image 
indicates the protein content of the extracts is highly reproducible, where all seven lanes 
have very similar protein content and relative intensities of Coomassie stained protein 
bands. Following depletion, no proteins greater than 75 kDa in mass are visible, 
confirming the ability of the extraction method to remove high molecular weight 
proteins, whilst retaining a low molecular weight protein fraction. 
 
Figure 2.4. 1D SDS PAGE analysis of seven identical aliquots of 20 μL of human 
serum extracted using the ACN depletion method. Equivalent volume of serum loaded 
onto the gel was 5 μL. Lane 1= Protein molecular weight markers, lanes 2-8= seven 
extracts of identical serum aliquots, lane 9= molecular weight markers. 
 
The combination of the Bradford assay and SDS PAGE analyses indicates the ACN 
depletion approach generates depleted extracts with reproducible protein concentrations 
and protein content. A direct comparison of the reproducibility of the ACN depletion 
method with the MARS immunodepletion approach was not performed in this study. 
However the reproducibility of the MARS device was investigated by Sitnikov et al 
(148), where they extracted 10 aliquots of plasma per day for ten days and analysed the 
levels of proteins in the flow through volume compared with the pre-extraction protein 
concentration. Over the 100 repeat analyses, total protein depletion efficiency was 
measured at 78%, with a CV of 0.9%. SDS PAGE analysis of the depleted serum 
extracts was performed, although the data were not shown, but implied as similar to 
those seen in an Agilent application note (Figure 2.5) (149).  Comparing the protein 
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content after extraction using ACN (5 μL serum, Figure 2.4) and MARS  (10 μL 
plasma, Figure 2.5), a significant increase in the relative levels of low molecular weight 
proteins was visible using ACN depletion compared with MARS, even though 50% less 
protein was loaded onto each well in the ACN depletion experiment. Comparing the 
protein band patterns within each of the two SDS-PAGE analyses (Figures 2.4 and 2.5) 
suggests that the ACN depletion method has a similar reproducibility compared with the 
Agilent MARS system. The main source of variation in protein bands in the ACN 
depletion figure appears to be in the higher molecular weight region.  
 
The MARS methodology used by Sitnikov et al involved sequential extraction using the 
same device, taking 5 hours of HPLC time per 10 samples (148), furthermore samples 
underwent a significant dilution, with 10 μL of plasma generating in the region of 750 
μL of extract, requiring dialysis or evaporation (149). In direct contrast to the MARS 
approach, the ACN depletion technique can be performed in parallel, using multiple 96 
well plates, with minimal dilution (20 μL serum generates a total volume of 150 μL of 
supernatant). In terms of reproducibility, the MARS technique demonstrates better 
results, however this was achieved by sacrificing throughput.   
 
The combination of the 1D SDS PAGE analysis and protein quantification shows that 
the ACN depletion method is a reproducible and effective extraction technique. The 
main time limiting factor in the process is the solvent evaporation stage, where a larger 
volume of supernatant leads to increased drying time. However, parallel processing of 
samples is possible in 96 well plates, allowing the procedure described to be used as 
part of a high throughput analysis of low molecular weight proteins in serum. 
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Figure 2.5. SDS PAGE analysis of unbound proteins from 200 serum extractions on the 
Agilent MARS column. 1.4 mg of protein loaded in each well, corresponding to ~10 μL 
of plasma. Image taken from Zhang et al (149).  
 
2.3.4 Nanoflow LC-MS/MS and SRM analysis of ACN depleted serum extracts. 
The SDS-PAGE analysis of the ACN extract indicated a large number of proteins were 
present up to approximately 65 kDa. The identities of these proteins were not known, 
furthermore, proteins would be present at levels below the sensitivity of the Coomassie 
blue stain. In order to characterise the proteins present (and lost) following ACN 
extraction, an SRM based LC-MS/MS analysis was performed. This required reduction 
and alkylation to be performed prior to tryptic digestion and subsequent LC-MS 
analysis.  
 
ACN depleted serum extracts (n=5) were analysed in duplicate following tryptic 
digestion using a nanoflow LC-MS/MS method with SRM detection. The majority of 
the SRMs were taken directly from the paper by Anderson et al (147). An initial 
analysis of an ACN depleted serum extract using the transitions reported by Anderson 
gave disappointing results, with many proteins not being detected. An information 
dependent acquisition (IDA) resulted in the identification of proteotypic peptides for a 
number of proteins that the initial transitions failed to detect (denoted by X in Table 
2.1). Furthermore additional proteins not reported by Anderson were identified, and 
SRM transitions were devised from the full scan MS/MS peptide spectra (denoted by 
N). Molecular weight values of proteins are derived from the Swissprot database, where 
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the signal peptide is removed, but does not include post-translational modifications e.g. 
glycosylation. * denotes a carbamidomethylated cysteine residue. SRM transitions for 
peptides different from Anderson are identified by an “X” for an alternate peptide or 
transition, and an “N” for a new protein added as a result of an information dependent 
acquisition based analysis of an ACN depleted serum extract. Data includes %CV of 
peak areas obtained from 5 replicate extractions and duplicate injections. 
 
Table 2.1. List of SRM transitions corresponding to the 29 proteins detected in the ACN 
depleted human serum digest.  
 
Accession 
_Human mw Peptide Q1 m/z 
Q3 m/z  
(1) 
Q3 m/z  
(2) 
New (N) or 
changed (X) %CV 
APOC1 6626 TPDVSSALDK 516.8 620.3 719.4  6.4 
APOA2 8707 EPC*VESLVSQYFQTVTDYGK 1175.6 1221.5 1436.6 X 7.2 
APOC3 8759 DALSSVQESQVAQQAR 858.9 1417.7 1144.6  8.1 
APOC2 8909 STAAMSTYTGIFTDQVLSVLK 745.1 1149.7 1002.6  9.5 
SAA 11675 FFGHGAEDSLADQAANEWGR 726.6 803.7 931.4 N 2.7 
APOF 17413 SGVQQLIQYYQDQK 849.4 972.6 1085.5 N 9.3 
APOD 19290 NILTSNNIDVK 615.8 890.4 1003.5 N 12.0 
RETBP 21058 YWGVASFLQK 599.8 849.5 693.4  21.6 
APOM 21253 EFPEVHLGQWYFIAGAAPTK 754.4 875.9 615.5 N 7.9 
A1AG1 21546 NWGLSVYADKPETTK 570.3 575.3 1052.5  35.9 
APOA1 28078 DYVSQFEGSALGK 700.8 1023.6 808.4 X 33.7 
ZA2G 32124 EIPAWVPFDPAAQITK 891.9 1087.7 728.4  46.1 
A2GL 34325 TLDLGENQLETLPPDLLR 1019.6 710.4 924.5 N 11.6 
AMBP 37090 AFIQLWAFDAVK 704.9 836.4 949.5  32.4 
HPT 43321 TEGDGVYTLNDK 656.2 753.4 1081.6 X 17.5 
APOA4 43376 LGEVNTYAGDLQK 704.4 794.5 895.4 X 35.3 
A1AT 44296 DTEEEDFHVDQVTTVK 631.3 790.4 889.5  51.8 
Accession 
_Human mw Peptide Q1 m/z 
Q3 m/z  
(1) 
Q3 m/z  
(2) 
New (N) or 
changed (X) %CV 
LCAT 47053 SSGLVSNAPGVQIR 692.4 669.3 941.4 N 20.8 
HEMO 49263 NFPSPVDAAFR 610.8 959.6 775.3  11.5 
ANGT 49729 PKDPTFIPAPIQAK 508.3 556.4 724.4  20.5 
A1BG 51908 LETPDFQLFK 619.4 894.5 995.5  70.8 
VTNC 52244 SIAQYWLGC*PAPGHL 835.4 921.5 808.4 X 61.0 
TTHY 55008 AADDTWEPFASGK 697.8 606.4 921.4  23.7 
THRB 65266 LAVTTHGLPC*LAWASAQAK 665.7 761.4 575.3 X 58.0 
ALBU 66428 LVNEVTEFAK 575.4 694.4 937.4  75.6 
TRFE 75132 SVIPSDGPSVAC*VK 708.3 1116.4 817.4 X 37.7 
FIBA 95715 TFPGFFSPMLGEFVSETESR 755.6 708.3 807.4 X 32.7 
CO4A 194369 DDPDAPLQPVTPLQLFEGR 1054.5 1256.7 852.4 X 7.2 
FINC 255664 DLQFVEVTDVK 647.3 789.4 690.4  25.5 
 
 
A successful protein detection was confirmed when the two transitions specific for each 
tryptic peptide from the given protein gave a peak at identical retention times in both of 
the SRM chromatograms. The summation of the two transitions for each protein was 
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performed as this gave improved peak area %CV values compared with the use of a 
single SRM transition, as discussed by Anderson et al (147). The analysis of the serum 
extracts resulted in twenty-nine of the targeted proteins being successfully detected. 
Figure 2.6 shows the peak area data for each of the detected proteins and their relative 
intensities, which were distributed over three orders of magnitude, with APO C3 giving 
the highest peak area value and APO C1 the lowest, indicating the wide dynamic range 
of SRM based approaches.  
 
Nine of the 29 detected proteins were apolipoproteins, including seven of the ten most 
abundant proteins. The high molecular weight and high abundant APO B100 (512 kDa 
and 1 mg/mL respectively) was not detected in the extract, despite it being successfully 
detected in undepleted serum digests using the same SRM transitions (147). 
 
 
Figure 2.6. Average peak areas of peptides from the SRM analysis of depleted human 
serum. The white bar indicates data from the albumin peptide, where it is the 20th 
highest peak area recorded. The error bars indicate one standard deviation (n=10). 
 
The average molecular weight of the ten most abundant proteins in the ACN extract was 
18 kDa, further strengthening the SDS-PAGE evidence that the ACN depletion method 
enriches for low molecular weight proteins. The proteins not detected in the analysis 
had an average molecular weight of 94 kDa, whilst the average weight of the proteins 
that were detected was 50 kDa. These LC-MS/MS results demonstrate that high 
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molecular weight and high abundant proteins were removed from serum, confirming the 
gel electrophoresis data (Figure 2.4). Albumin was detected in the serum extract; ranked 
as the 20th most abundant peptide, indicating that the majority of the protein was 
removed by ACN depletion (Figure 2.6). Based on peptide peak area, the albumin 
concentration was reduced approximately 1000 fold from ~50 mg/mL to the level of 
proteins present at approximately 40 μg/mL, such as plasma retinol binding protein 
(Figure 2.6, RETBP_HUMAN) (150).  
 
The ten LC-MS/MS analyses generated quantitative data, enabling assessment of the 
reproducibility of the depletion technique for a number of targeted proteins. The %CV 
values of the peak areas of the 29 detected proteins were calculated and are displayed in 
Table 2.1, with the lowest reproducibility observed for albumin (75.6%), and the 
highest for serum amyloid A (2.7 %), where, on average, all the 29 proteins had a %CV 
of 27%. The high degree of variance from the albumin peptide was not unexpected. Due 
to albumin’s high serum concentration, small variances in the depletion efficiency 
would result in significant differences in the protein’s final concentration. Separating 
the proteins into molecular weight ranges, the average %CV’s for proteins up to 30, up 
to 50, and over 60 kDa were 14, 20, and 27% respectively, suggesting the ACN 
depletion method is more reproducible for the low molecular weight protein fraction. It 
was not possible to assess the degree of recovery of each protein as the pellet formed 
during centrifugation was highly insoluble, rendering the precipitated proteins 
inaccessible for tryptic digestion and subsequent nanoflow LC-MS/MS analysis. 
 
2.3.5 2D LC-MS/MS analysis of tryptically digested ACN depleted serum extract 
2.3.5.1 SCX fractionation 
Fractionation of tryptically digested peptides using SCX significantly increases the 
number of peptides that can be identified in a single sample. This approach was applied 
to the ACN depleted serum extract to identify and characterise additional and lower 
abundant proteins. The SCX fractionation of a large serum extract generated 20 1 mL 
fractions, which were split and evaporated for reversed phase nanoflow LC-MS/MS 
analysis on the 4000 QTRAP. The HPLC-UV trace for the analysis showed a large peak 
of unretained compounds eluting after approximately 1 minute (Figure 2.7). This would 
contain compounds which do not have a net positive charge such as phospholipids and 
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other fats present in the supernatant after ACN depletion (151). Monitoring the UV 
adsorption at 280 nm showed that peptides eluted from 22 to 35 minutes, and that this 
region was highly complex, indicating the presence of a large number of peptides.  
 
 
Figure 2.7. HPLC-UV trace of the SCX fractionation of an ACN depleted serum digest. 
The large peak at approximately 1 minute corresponds to unretained material. The 
ammonium formate gradient started at 20 minutes and is displayed in the inset. 
 
2.3.5.2 Reversed-phase nanoflow LC-MS/MS analysis of 15 SCX fractions. 
The SCX fractions collected in 1-minute intervals from 20 to 40 minutes were analysed 
by reversed phase LC-MS/MS, of which only the first 15 contained mass spectral data 
consistent with peptides. These 15 files were submitted to the Mascot protein 
identification software package as a combined data set, and searched against the 
Swissprot database. A total of 85 proteins were identified using the criteria outlined in 
Section 2.2.7.2 and included medium abundance proteins such as IGF-I and IGF-II 
(Appendix II). The peptide MS/MS spectrum used for the identification of the IGF-I T1 
peptide (GPETLCGAELVDALQFVCGDR), and the IGF-II T5 peptide (GIVEECCFR) 
is displayed in Figure 2.8, including the theoretical y and b ions matching ions in the 
acquired peptide MS/MS spectra. The IGF-I and IGF-II peptides were matched against 
the Swissprot databases with Mascot scores of 70 and 52 respectively (p <0.05).  
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Figure 2.8. MS/MS peptide spectra for the IGF-II T5 peptide GIVEECCFR and the 
IGF-I T1 peptide GPETLCGAELVDALQFVCGDR. Peptide y and b ions were 
identified using the Mascot search algorithm. 
 
Both IGF-I and IGF-II are downstream messengers of the GH metabolic pathway 
(Figure 1.6, Section 1.4.1), and have both been identified as GH abuse biomarkers 
(63,152). The detection of these two proteins suggests that the ACN depletion approach 
could be used to monitor multiple serum based biomarkers of GH abuse. 
 
The list of proteins identified in the 2D LC-MS/MS analysis of an ACN depleted serum 
extract was compared against a manually validated plasma protein list generated by 
Schenk et al (104). The study by Schenk et al involved removing the top 6 abundant 
proteins using immuno-depletion prior to digestion and analysis using both LTQ-FTICR 
and LTQ-Orbitrap instruments, which have far superior proteomics capabilities than the 
mass spectrometer system used in the 2D LC-MS/MS study (Section 2.2.7). The 
comparison of the two protein lists demonstrated that 78 of the 85 proteins identified in 
the ACN depleted serum 2D LC-MS/MS analysis were also present in the list compiled 
by Schenk et al. Further investigation of the seven proteins identified using ACN 
depletion that were absent from the larger list indicated that they were all low molecular 
weight proteins. The seven proteins ranged from a 5 kDa, 44 amino acid peptide (GR-
44 from Chromogranin A) to a 14.6 kDa, 131 amino acid protein (Serglycin). Of the 
seven proteins, six are listed as secreted on www.expasy.org, and would therefore be 
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expected to be present in plasma or serum. The protein not listed as excreted was 
TRML1_HUMAN, a 31 kDa transmembrane protein. The two peptides detected from 
the protein reside in the extracellular domain of the protein, and could therefore be 
released into serum from a cleavage event at the cell surface.  
 
Comparing the two protein lists on the basis of the molecular weight ranges of 
identified proteins, displays the bias of the ACN depletion method to low molecular 
weight proteins (Figure 2.9). The distribution of the molecular weights of proteins 
identified in both experiments is remarkably similar, however the ACN depletion 
experiment identified more proteins in the <10 kDa molecular weight range, further 
confirming its ability to enrich for low molecular weight proteins. 
 
 
Figure 2.9 Comparison of the percentage contribution of proteins in specific molecular 
weight ranges with the total number identified. Numbers on bars indicate actual number 
of proteins in given ranges. 
 
2.3.6 Nanoflow LC-MS/MS SRM analysis of ACN extract for IGF-I T1 tryptic peptide  
The ability of the ACN depletion method to separate proteins from their binding 
complexes, as well as enrich low molecular weight proteins, was demonstrated by the 
detection of IGF-I in serum at physiological levels. IGF-I is a 7.6 kDa protein that 
circulates in a complex with a variety of IGF binding proteins and the acid label subunit 
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protein. This protein complex totals between 125 and 150 kDa in mass (58). The 
spectrum from the 2D LC-MS/MS analysis enabled the identification of suitable SRM 
transitions for the IGF-I T1 peptide (Figure 2.8).  
 
A serum digest was analysed using three SRM transitions specific for the IGF-I T1 
peptide and all three extracted ion chromatograms displayed a peak at a retention time 
of 55.5 minutes (Figure 2.10). The presence of peaks at identical retention times in all 
four traces confirmed the detection of endogenous levels of IGF-I in the serum extract. 
This demonstrates the ACN depletion method is capable of detecting low molecular 
weight proteins present in protein complexes in serum in the 100 ng/mL range. The 
769.7 / 881.4 transition demonstrated the highest signal and would be the most suitable 
SRM for future quantitative IGF-I analyses. 
 
Figure 2.10. Four extracted SRM traces relating to the IGF-I T1 tryptic fragment. 
Significant peaks at 55.5 minutes are present in all four traces indicating the retention 
time of the T1 peptide.    
 
2.4 SUMMARY 
A reproducible and rapid procedure for depleting high abundance serum proteins prior 
to tryptic digestion and LC-MS/MS analysis has been developed. Reproducibility was 
demonstrated using SDS PAGE gel analysis, which also showed a high efficiency for 
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removing proteins over 75 kDa, and the majority of the albumin present in serum. The 
concentration of protein in the extracts was determined and showed that approximately 
99.6% of protein was removed from the serum with good reproducibility (%CV of 15, 
n=7).  
 
Levels of selected, medium to high abundance serum proteins were assessed in the 
ACN extract after depletion using LC-MS/MS with SRM detection. Fifty-seven proteins 
were monitored, of which 29 proteins were detected in the ACN extract and included a 
large number of apolipoproteins. These are hydrophobic proteins which circulate in the 
blood integrated into high, low and very low lipoprotein particles (153,154). The 
apparent bias towards apolipoproteins suggests that the extraction method selectively 
enriches proteins of a hydrophobic nature. However, it should be noted that 
apolipoproteins accounted for 100% of all the plasma proteins targetted by Anderson et 
al below 20 kDa and 63% of those below 30 kDa (147), which could explain the 
possible apolipoprotein bias.  A recent study investigating low molecular weight plasma 
proteins present in the filtrate obtained using ultrafiltration cartridges, also reported 
apolipoproteins as major contributors to the low molecular weight plasma proteome 
(155). This indicates that the majority of the abundant and low molecular weight 
proteins in serum or plasma are in fact members of the apolipoprotein family, and 
therefore would be enriched using ACN depletion, and detected using the targeted SRM 
approach designed by Anderson. However, APOB100, a highly lipophilic, high 
molecular weight (512 kDa) and high abundance apolipoprotein, was not detected in the 
extract, which implies that the ACN depletion process is mainly based on the size of the 
protein rather than its hydrophobicity. A 2D LC-MS/MS analysis and protein database 
searching experiment generated a list of 85 proteins identified in an ACN depleted 
serum extract (Appendix II), 90% of which are present in a manually validated plasma 
proteome list (104). A 1D LC-MS/MS analysis using an SRM-triggered IDA on the 
4000 QTRAP confirmed the presence of 63 of the 85 proteins in a newly prepared 20 
μL serum ACN extract digest (Appendix II).  
 
The ability to detect endogenous IGF-I in serum after ACN depletion demonstrates that 
proteins other than apolipoproteins are enriched, and indicates the sensitivity that can be 
achieved using this approach. The application of LC-MS to the detection of IGF-I in 
serum and plasma has been previously attempted, however two of the three studies used 
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antibody based analyte concentration and monitored levels of the intact protein 
(99,100). The third approach involved the use of tryptic digestion without any prior 
protein depletion, but involved spiking serum with levels of IGF-I significantly higher 
than physiologically expected, with the lowest spike at 2 μg/mL (156). Endogenous 
levels of IGF-I are in the region of 100 ng/mL, approximately five orders of magnitude 
lower in concentration than albumin. Previous studies using LC-MS/MS and SRM 
analyses for serum proteins have only achieved sub 1 μg/mL sensitivities using antibody 
depletion followed by extensive fractionation prior to analysis, including the use of 2D 
LC-MS/MS (157). This chapter demonstrates that medium abundance serum proteins 
such as IGF-I and IGF-II can be detected at endogenous levels using a simple, rapid and 
inexpensive protein depletion strategy.  
 
This chapter describes the development of an ACN based extraction technique, which 
demonstrates sufficient reproducibility and sensitivity to be used for an LC-MS based 
biomarker discovery experiment. Although the method was developed using human 
serum, the technique also successfully depleted high molecular weight proteins in 
murine serum, which is described in chapter 3 (Section 3.2.2). Because ACN extraction 
demonstrates high reproducible and throughput, the technique would also be ideally 
suited for extracting large sample cohorts, essential for validating newly identified 
biomarkers.  
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CHAPTER 3. APPLICATION OF MASS SPECTROMETRY AND ANNS 
ANALYSIS TO THE IDENTIFICATION OF BIOMARKERS TO GENE 
THERAPY ADMINISTRATION TO THE MURINE. 
 
3.1 INTRODUCTION 
Protein therapeutics were designed by the pharmaceutical industry to alleviate specific 
disease states, for example, rhGH is used to treat growth deficiencies. In the case of 
rhGH administration, patients require regular dosing because of its short plasma half-
life. A possible alternative to repeat administrations of a therapeutic protein is through 
gene therapy. Gene therapy is the correction of a genetic flaw, through the insertion of a 
correct copy of a mutant gene. A successful gene therapy treatment would make regular 
injections of a protein therapeutic redundant, effectively curing the individual of their 
disease. However, gene therapy requires the insertion of exogenous DNA into an 
organism and requires the use of vectors, such as plasmids or inactivated viral entities, 
which carry possible health risks to the host. Therefore the administration of gene 
therapy to humans is not yet possible for a number of ethical and safety issues. 
However, the administration of gene therapy vectors into an animal model is allowed, 
under strict ethical guidelines, and a number of such pre-clinical safety studies have 
been performed over the past 10 years.  
 
The abuse of rhGH has been well documented in athletics and is believed to be 
widespread, due to the difficulty in detecting and proving its misuse. Therefore the 
abuse of future GH gene therapies is a very real threat, if they are licensed for use in 
humans. A number of pre-clinical gene therapy trials have involved the introduction of 
the GH gene to host organisms via a plasmid based vector. Examples of pre-clinical 
gene therapy studies related to the GH axis are described further, with a particular 
emphasis on the use of plasmid based vectors, as they are likely to be the vector of 
choice for gene doping.   
 
3.1.1 GH Gene therapy studies in animal models. 
The majority of pre-clinical studies have involved rodent models because large numbers 
of animals are essential for obtaining statistically relevant data. Gene therapy expressing 
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an exogenous form of the growth hormone protein (human) has already been performed 
in a murine model (158). The study by Dagnæs-Hansen et al, involved introducing a 
plasmid containing the hGH gene into the tail vein of mice using the hydrodynamic cell 
entry based approach, and demonstrated expression of hGH for at least 59 days. 
Furthermore, the expression of hGH caused a concomitant rise in IGF-I levels, which 
was detectable one day post injection (Figure 3.1). Dagnæs-Hansen et al demonstrated 
that levels of a well characterised biomarker of GH administration increased in the 
mouse following the production of an exogenous GH through a genetic intervention, 
and suggests that any GH related biomarkers identified in a rodent model could translate 
into a human model and vice versa. 
 
  
Figure 3.1. The graph on the left displays levels of hGH in murine serum after 
administration of GH gene therapy compared with control animals. The graph on the 
right shows levels of IGF-I in the same animals, with error bars displaying standard 
error of the mean. Images taken from Dagnæs-Hansen et al (158). 
 
3.1.2 Gene therapy studies of upstream GH effectors 
Gene therapy experiments expressing upstream effectors of the GH protein have been 
performed in order to increase plasma GH levels. Plasmid DNA vectors expressing 
growth hormone releasing hormone (GHRH) was introduced into the rat, and 
demonstrated increased levels of both GH and IGF-I in the treated animals (159). Khan 
et al used an intramuscular injection followed by electroporation, a technique which has 
also been used in larger animal models. Plasmids expressing GHRH have been 
administered into canine, equine and bovine models, and all studies demonstrated 
successful transgene expression (44,68,160). The publication of successful (and safe) 
gene therapy experiments in large animal models indicates that the plasmid-based 
approach could be successful in a human model.  
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3.1.3 WADA’s research into detecting GH related gene therapies  
If a GH protein related gene therapy was licensed, the administration of a plasmid 
containing the GH gene might need to only be performed once for a long-term 
expression of the gene, therefore cutting the need, and cost, of regular injections (161). 
WADA has identified that athletes aiming to artificially enhance their performance are 
likely to abuse any GH related gene therapy licensed for therapeutic use. Therefore they 
have initiated a number of research programs to develop tests to detect gene doping, 
well in advance of any licensed therapies.  
 
One avenue of gene doping research is to develop techniques to detect the DNA of the 
vector used to deliver the transgene. In the case of viral gene therapy vectors, the 
transgene would most likely not contain introns, as these would significantly increase 
the size of the DNA strand for insertion, possibly making the gene too large for the viral 
capsid (162). Monitoring for the DNA sequence of two adjoining exons within the 
target gene, minus the endogenous introns, could demonstrate the presence of the 
vector. Using a plasmid based gene therapy approach would circumvent the size 
restriction, therefore the transgene could contain the normal introns that would be 
present in the host genome, complicating a direct detection strategy. However, the 
plasmid vector would contain exogenous genetic elements such as the multiple cloning 
site, which is used to insert genetic material into recombinant plasmids, and possibly the 
genes specific for the antibiotic resistance proteins. Based on these theories, polymerase 
chain reaction (PCR) based approaches are being used in an attempt to detect gene-
doping events (163). One possible drawback to the PCR based approach is obtaining a 
sample for testing purposes. This would most likely need to be a biopsy, as the vector 
would be injected intra-muscularly. This sampling technique would not be accepted by 
athletes, and therefore the genetic detection method, although promising, would not be a 
likely approach unless the vector ends up in the circulatory system (162). 
 
An alternative approach to detecting gene doping is to use protein profiling techniques, 
such as LC-MS and MALDI-MS, to assess whether the expression of the transgene 
perturbs the host’s serum or plasma proteome. Of the two mass spectrometry based 
techniques, LC-MS was the method chosen in this work to identify changes in the 
serum proteome, after tryptic digestion of proteins into peptides. 
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3.1.4 Application of LC-MS to serum protein biomarker discovery. 
LC-MS has become a major tool for identifying new biomarkers of disease, due to its 
ability to both identify and quantify multiple proteins in complex matrices such as 
serum and plasma (125). The main disadvantage to using LC-MS for analysing 
tryptically digested serum proteins is that in-source ion suppression caused by abundant 
peptide species masks the signal from lower abundant peptides. Therefore high 
abundant proteins must be removed from the sample prior to digestion and LC-MS 
analysis (125). As discussed in Section 1.8.1, a common technique employed to remove 
these high abundant proteins is to use immuno-depletion methodologies. Immuno-
depletion systems deplete proteins by targeting a specific epitope within a three 
dimensional structure, therefore requiring the proteins to be folded correctly, making the 
technique dependent on protein stability. Furthermore, the antibody-antigen interaction 
is also species specific, meaning specific devices are needed to remove high abundant 
proteins in serum or plasma from each species. Immuno-depletion is a low throughput 
technique, where samples are extracted sequentially through spin devices or HPLC 
columns. The sequential extraction process requires the complete release of the targeted 
proteins prior to reuse, to avoid sample-to-sample extraction differences. The 
effectiveness of the release of bound proteins was assessed by Gundry et al, where they 
demonstrated that using the manufacturers standard operating procedure did not result 
in complete release of the target proteins (164). Biomarker discovery experiments need 
large numbers of samples to obtain a statistically relevant cohort to submit to 
bioinformatics analysis. Therefore the ability to extract large numbers of samples in a 
high throughput and reproducible manner is essential, which would not be feasible 
using immuno-depletion devices. These considerations therefore call into question the 
applicability of immuno-depletion for sample treatment prior to biomarker identification 
experiments. 
 
The ACN depletion strategy, described in Chapter 2, demonstrated the ability to 
reproducibly deplete high abundant and high molecular weight proteins, whilst retaining 
lower abundant proteins in solution. This approach was also capable of detecting 
medium abundance proteins such as IGF-I in a single LC-MS/MS analysis. Work by 
Polson et al demonstrated that ACN was efficient at removing the vast majority of 
protein in plasma from a multitude of species, including human, dog, rat and mouse 
(133). The ACN protein depletion technique developed in chapter 2 exploits the 
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chemical properties of proteins dissolved in serum, making it species independent. The 
approach was also demonstrated to be highly reproducible, with high throughput 
potential and therefore should be suitable for large-scale mass spectrometry based 
biomarker discovery experiments.  
 
3.1.5 LC-MS based biomarker discovery and bioinformatics  
Nanoflow LC-MS analysis of large numbers of serum extracts generates immense 
amounts of data which, depending on the resolution of the MS system, could generate 
between 4 and 40 million individual m/z and intensity values over a single analysis. 
These very large datasets, coupled with the complexity of the serum proteome, means 
detecting changes in peptide levels over multiple analyses by eye would be an almost 
impossible task. Furthermore, in order for biomarker experiments to generate 
statistically significant results, large sample cohorts need to be analysed (165), 
significantly increased the data load. 
 
Bioinformatics techniques, such as ANNs, have been employed to datamine MALDI 
and Surface enhanced laser desorption/ionisation (SELDI) data to detect small changes 
in protein biomarker levels in complex samples (166). The combination of MALDI and 
ANNs has also been applied to the identification of protein biomarkers to GH 
administration in a murine model (144). In this study, Boateng et al used a stepwise 
ANNs approach to identify specific m/z ions capable of discriminating between GH and 
placebo treated mice. The specificity and sensitivity of the ANN model was 100% and 
86% (correct assignments of true negatives and positives respectively). One drawback 
of using MALDI or SELDI based mass spectrometry for biomarker discovery 
experiments is their inability to unambiguously characterise the protein relating to the 
m/z ion that was identified as important by the bioinformatics software. This must be 
done retrospectively, using tryptic digestion and MS/MS based peptide fragmentation 
(166) and linking tryptically derived peptides back to an intact protein identified in the 
original study is a difficult task.  
 
The applicability of ANNs for biomarker discovery using a MALDI/SELDI based 
approach has been proven (123,166). However, ANNs have not previously been used 
for biomarker discovery experiments using an LC-MS based sample analysis, possibly 
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due to the fact that LC-MS data are significantly more complicated than those generated 
using MALDI or SELDI approaches. ESI further increases data complexity, because a 
single peptide can have multiple charge states, as well as a retention time, therefore 
generating higher dimensional (n = 3/4) information. This increased data complexity 
could adversely affect the ability of the ANNs approach to identify changes in serum-
based protein biomarkers within a given dataset. However, if successful, the subsequent 
characterisation of the protein biomarker would be more efficient, as the m/z of 
candidate peptide ions could be selected for targeted LC-MS/MS analysis and their 
parent protein identified using database searching. 
 
3.1.6 Chapter overview  
A plasmid based gene therapy vector was chosen for the project because it requires a 
low technology base to produce and is the safest form of gene therapy, as DNA does not 
elicit an immune response. Furthermore, collaborators on the project (The Royal Free 
Hospital University College London) had previous experience in using both GH gene 
therapies (167) and in the administration of rhGH to humans as part of previous WADA 
grants (168). Their Home Office licence enabled them to perform new administrations 
of plasmid gene therapies to mice (Appendix III), which would be required for this 
study.  
 
In summary, this chapter reports an assessment of the effectiveness of the ACN 
depletion method for the removal of high abundant and high molecular weight proteins 
from murine serum prior to analysis by LC-MS. The ACN depletion method and LC-
MS analysis approach was then used to analyse serum samples from the GH gene 
therapy experiments performed at the Royal Free hospital in London.  
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3.2 MATERIALS AND METHODS 
3.2.1 Chemicals 
Acetonitrile (ACN, LC grade) was purchased from Romil (Cambridge, UK) and 18.2 
MΩ water was produced by a Maxima water purifier (Elga, High Wycombe, UK). 
Ammonium bicarbonate, dithiothreitol (DTT), iodoacetamide and formic acid were 
purchased from Sigma Aldrich (Poole, UK). Acetic acid was purchased from BDH 
(Poole, UK). Trypsin gold was from Promega (Southampton, UK). Pooled murine 
serum was purchased from Harlan SeraLabs (Bicester, UK).  
 
3.2.2 Assessment of the effectiveness of the ACN depletion method for removal of high 
abundant murine serum proteins prior to tryptic digestion and LC-MS/MS analysis. 
The ACN depletion method (described in Section 2.2.4) was applied to a pooled murine 
serum sample (20 μL) and analysed using an IDA based nanoflow LC-MS/MS analysis 
(described in Section 2.2.7.2). The acquired MS/MS spectra were then searched against 
the National Center for Biotechnology Information (NCBI) database, using a murine 
species filter, in order to identify proteins remaining in the supernatant after ACN 
depletion. The NCBI database was used in place of the Swissprot database as it 
contained a higher coverage of the murine proteome. 
 
3.2.3 rrGH construct preparation (performed by staff at RFUCL). 
RNA was purified from the rat pituitary gland and used for first strand cDNA synthesis. 
The cDNA was amplified by PCR and sub-cloned into the pGEM-T bacterial cloning 
vector (167). The insert contained the entire open reading frame and the majority of the 
3’UTR for presomatotropin. Restriction sites incorporated at the 5’ end of each PCR 
primer facilitated restriction digests and subsequent ligation into the mammalian 
expression vector pcDNA 3.1 (Figure 3.2). A “negative” plasmid was also prepared in 
the same way but with the start codon mutated in order to disrupt the translation of the 
protein. The sequence was verified by DNA sequencing and plasmids prepared by 
standard methods. Plasmid numbers were increased using a bacterial system, and 
subsequently purified. Purified plasmids were re-suspended in PBS for administration 
(1 mg/mL).  
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Figure 3.2. Plasmid used for gene therapy administrations to the murine.  
 
Initially, the amount of +ve and –ve plasmid prepared was only sufficient for 
administration to 10 mice. The first batch of construct was prepared for a proof of 
principle in-vivo experiment to assess if the LC-MS and ANNs approach could detect 
differences between mice administered the two different plasmids and a third placebo 
group administered with only PBS. This initial gene therapy administration was 
designated “Batch 1”, and future batches were numbered incrementally up to Batch 5.  
 
3.2.4 Construct administration to animals (Performed by staff at RFUCL). 
Gene therapy was administered to C57BL/6 mice in batches of 30, which included 10 
animals of each group; positive (+ve) plasmid, negative (-ve) plasmid and PBS control.  
 
3.2.4.1 Administration of construct to Batch 1(Performed by staff at RFUCL)..   
Each adult male C57BL/6 mouse received a total of eight injections containing either 
PBS, +ve plasmid or –ve plasmid. Injections were performed in the hind limbs of each 
animal, with three in the gastrocnemius muscle and the last injection in the 
corresponding tibialis anterior muscle. Each injection was 30 µl in volume, and in the 
case of plasmid treated mice, the dosing solution contained plasmid at 1 mg/mL in PBS 
(a total of 240 µg plasmid per animal).  
 
The body weight of each animal was monitored prior to administration, at one week and 
immediately prior to serum sample collection. This was performed to identify if the 
gene therapy would manifest through weight gain in the +ve plasmid treated animals. 
 
82 
Blood samples were taken from each mouse under terminal anaesthesia (urethane) via 
the heart puncture technique. Blood was left to stand for 30 minutes, before 
centrifugation at 1000x g for 10 minutes. Serum was aliquoted into separate 20 μL 
volumes and immediately frozen on dry ice and stored at  -70˚C. 
 
Serum was taken at 2.5-week post-dose with the aim of allowing up or down-regulation 
of protein biomarkers associated with the production of the GH protein by the +ve 
plasmid. The first batch of administrations was prepared in late 2005, and the samples 
delivered to Quotient Bioresearch in early January 2006. Upon delivery, all samples 
were stored at –70°C until thawed for sample analysis.  
 
3.2.4.2 Administration of construct to Batch 2 (Performed by staff at RFUCL). 
Following the successful demonstration of the LC-MS and ANNs approach to 
biomarker discovery (Section 3.3.3), a larger preparation of both +ve and –ve plasmid 
was generated as described in Section 3.2.3. The new plasmid stock was administered to 
a second set of 10 mice as described in Section 3.2.4.1. The second administration took 
place in June 2006, and samples arrived at Quotient Bioresearch in early July. 
 
3.2.4.3 Administration of construct to Batches 3-5 (Performed by staff at RFUCL). 
The final three batches of gene therapy samples were generated between September and 
October 2006, and were delivered to Quotient Bioresearch at the end of November 
2006. The body weight of animals in batches 2-5 were monitored prior to 
administration, at 1 and  2 weeks post administration and at serum sample collection. 
 
3.2.5 ACN depletion and LC-MS analysis of gene therapy Batch 1. 
Batch 1 contained a total of 10 +ve plasmid, 10 -ve plasmid and eight PBS control 
samples. Samples were randomised and 20 μL taken for ACN depletion and tryptic 
digestion. The LC-MS analysis method used for Batch 1 involved an IDA based 
approach. The nanoflow LC separation method used was as described in Section 2.2.6, 
and full scan m/z data were acquired from m/z 400-1600 using a scan speed of 4000 
amu/second. The three most abundant ions in the survey scan were selected for an 
enhanced resolution scan (250 amu/second), however only one was selected for MS/MS 
fragmentation and full scan analysis at 4000 amu/second (m/z 100-1700) to reduce the 
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MS cycle time. The total duty cycle for this LC-MS/MS method was in the region of 
three seconds, including all scan modes and instrument pauses between modes. 
Following LC-MS/MS analysis of all the ACN depleted serum samples, only the full 
scan MS analysis data were used as it demonstrated a more representative data sampling 
technique. 
 
3.2.6 ACN depletion and LC-MS analysis of gene therapy Batches 1-5 
The four remaining gene therapy Batches were stored at –70 °C until all samples could 
be ACN depleted and analysed in as short a time period as possible, in order to reduce 
the introduction of Batch-to-Batch extraction differences. A small number of samples 
from Batch 1 (n=18) were also available for analysis; Appendix IV contains information 
on all samples in the large analysis (totalling 135). The ACN depletion method was 
modified slightly from that described in Section 2.2.4, with 10 μL of sample taken as 
apposed to 20 μL. A lower volume of serum was taken to enable repeat analysis of 
samples at a later date, as taking 20 μL would leave too little serum for biomarker 
verification experiments. The volumes of water and ACN added to the serum were 
modified to account for the reduction in starting volume (20 μL of water, and 45 μL of 
ACN). All five Batches were ACN depleted and analysed over a total of 22 days (Table 
3.1), during which the nanoflow LC-MS system was running for 14 days. Of the 135 
samples analysed by LC-MS, two were removed due to the data being unsuitable for 
submission to ANNs, where the LC-MS trace demonstrated a significantly different 
profile over the 95 minute analyses. 
 
Table 3.1. Dates on which the gene therapy batches were ACN depleted and analysed 
by LC-MS. 
 
Date Batch Samples 
27-29th November 2006 2 30 
4-6th December 2006 3 28 
8-9th December 2006 1 18 
13-15th December 2006 4 29 
16-18th December 2006 5 28 
 
The outcome of the LC-MS/MS analysis of ACN depleted serum digests from Batch 1 
(3.2.6) indicated that the full scan LC-MS was the most appropriate data format for 
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submission to ANNs, as it was the most representative analysis technique. Therefore the 
LC-MS analysis method was modified to acquire only full scan data (m/z 400-1600) 
using a slower scan speed (1000 amu/second). The duty cycle of the full scan LC-MS 
method was similar to the method described in 3.2.6, and totalled approximately 2.5 
seconds. In order to compensate for the reduction in starting material compared with 
Batch 1 (10 as apposed to 20 μL), twice as much sample was injected onto the LC-MS 
system (4 μL as opposed to 2 μL). 
 
3.2.7 Transformation of LC-MS data for stepwise ANNs analysis  
The Statistica 7.0 (StatSoft Inc. Tulsa, USA) ANNs software package required data to 
be in a two-dimensional format, with a single value for each discrete input, and no 
missing input values. Therefore three-dimensional LC-MS data (time, m/z and intensity) 
needed to be converted into two-dimensional data (m/z and the summed intensity for 
each m/z input). In order to remove the peptide retention time as a data component, all 
spectra acquired during the peptide elution period (5-74 minutes) were summed using 
Analyst software (version 1.4.1) to give a single spectrum. The summed spectral 
information was then exported from Analyst as a text file and the data imported into 
Excel (Microsoft, USA). The m/z values were originally recorded to two decimal places, 
and were transformed into integer m/z values using the round function. Intensities of 
each rounded m/z value were summed using the Excel conditional summing tool, which 
summed all intensity values corresponding to each rounded m/z value. The combination 
of the round and conditional summing functions was capable of converting three-
dimensional LC-MS data into information compatible with the ANNs software package.  
 
3.2.8 Stepwise ANNs analysis 
Transformed data from each of the two analyses (Batch 1 and Batches 1-5) were 
separated into three different groupings: 1) +ve plasmid and –ve plasmid, 2) +ve 
plasmid and PBS control, and 3) –ve plasmid and PBS control. The aim of the ANNs 
analysis was to train an ANN model to classify samples into their respective groups, for 
example identifying whether a specific mouse was treated with the either the PBS 
control or the +ve GH plasmid. In the case of PBS control Vs. +ve plasmid, data 
submitted to the ANN model were specified as either 1 (PBS control) or 2 (+ve 
plasmid). The ANNs software would then train a model that would assign blinded 
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samples as either 1 or 2, and assess its accuracy by comparison of the predicted value 
with the sample’s correct state. 
  
The LC-MS data were analysed using a process called stepwise ANNs analysis, a 
technique developed by Nottingham Trent University for use in combination with the 
statistical software package Statistica 7.0. In the stepwise approach, an ANN model was 
trained for each of the 1200 discrete inputs (m/z 400 to 1600). Subsequent stepwise 
events trained ANNs models using the ions identified in previous cycles, in combination 
with newly selected m/z inputs from the remaining dataset. The Statistica ANNs 
software settings included a learning rate of 0.1 and a momentum value of 0.5 for each 
training step and model were generated using 50 random sample cross-validation 
bootstrap events (144,166). Each bootstrap involved randomising the data into three 
subsets: training (60%), validation (20%), and test (20%), with each model being 
assessed on the accuracy of predicting the state of the blinded test samples (as 1 or 2).  
 
The stepwise ANNs approach identified an optimum subset of ions, which most 
accurately modelled the input data. Ions identified by stepwise ANNs from the three 
datasets were selected for population predictions analysis. 
 
3.2.9 Population predictions analysis 
Ions identified as important in the stepwise ANNs process were used as selected inputs 
for training a new ANN model for population predictions analysis. This involved 50 
cross-validation events and the output values assigned to each sample in the test set was 
averaged to obtain a mean predictive value for a given sample over the 50 bootstraps. 
Comparing the mean predictive value for a sample against the expected value enabled 
an assessment of the accuracy of the model. The mean predictive values from the 
analysis were then sorted from 1 to 2 and the sample identities unblinded, which then 
enabled the assessment of the number of correct state assignments, false positives and 
false negatives. In order to demonstrate the spread of the ANNs predictions capabilities, 
the standard error of the mean was calculated for each sample. Receiver operating 
characteristic (ROC) curves were also calculated for the 50 prediction cycles, which 
enabled the assessment of the sensitivity and specificity of the model, along with the 
area under curve value (AUC). 
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3.2.10 Investigation into the reproducibility of the nanoflow LC-MS method. 
An experiment was devised to test the reproducibility of the nanoflow LC-MS system 
for generating m/z and intensity values from an identical murine serum digest over a 
number of days.  Murine serum was ACN depleted and digested before separating into a 
number of identical aliquots and stored at –20 °C before analysis. Five sequential 
injections of each aliquot were made onto the LC-MS system on five occasions over a 
number of weeks, and analysed using the same nanoflow LC-MS method as used for the 
analysis of the gene therapy samples.  
 
A sixth experiment involved performing six injections of the digest along with 30 
individual serum extracts. Each injection of the common serum digest was followed by 
the analysis of five murine serum digests. The final experiment was devised to assess 
whether injecting a common, or “QC” sample at regular intervals could help to control 
instrument drift during a nanoflow analysis of a large sample cohort. The total time 
taken for the sixth experiment was in the region of 60 hours, comprising of 36 95-
minute LC-MS analyses.  For all the six sets of injections, spectra were summed over 
the entire peptide elution time period (5-74 minutes), converted into the ANNs 
compatible format, and subjected to PCA analysis. 
 
3.2.10.1 PCA analysis of serum digest spectra 
Data from all six experiments were submitted to PCA analysis (Statistica 7.0). 
However, due to the data input limit of 1000 data variables, only m/z and intensity 
values from 400 to 1400 were analysed. Although 200 data points were missing from 
the analyses, this region of the spectra was the area that contained the least information, 
and therefore the loss was considered acceptable. The data derived from principal 
components 1 and 2 were plotted in order to display data inputs that explained as much 
of the variation in the data set as possible. 
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3.3 RESULTS AND DISCUSSION 
3.3.1 Characterisation of proteins present in ACN depleted murine serum. 
The data acquired from a 1D nanoflow LC-MS/MS analysis of an ACN depleted murine 
serum digest were searched against the NCBI database (as of 09/2006) using the Mus 
musculus species filter. The top protein hit was Fetuin A, also known as alpha-2-HS 
glycoprotein, a 35 kDa protein (Table 3.2). Two proteins were identified that exceeded 
100 kDa in molecular weight - alpha-2-macroglobulin, and preprocomplement 
component C3. Searching for additional data on these two proteins on Expasy.org 
identified that the mature form of the proteins are cleaved into smaller subunits, which 
could explain why they were detected in the ACN depleted serum digest.   
 
The average molecular weight of the identified proteins was 38 kDa, indicating that the 
ACN depletion was effective at enriching low molecular weight proteins from mouse 
serum. The proteins identified in the 1D LC-MS/MS analysis were compared against a 
list of proteins detected in an extensive mouse serum proteome identification 
experiment (169). Only four of the 38 proteins identified after ACN depletion were not 
present in both lists (apolipoprotein N, parotid secretory protein, keratinocyte 
differentiation-associated protein and Chemokine-binding protein 2). Fully one third of 
all proteins present in the supernatant after ACN depletion were apolipoproteins, which 
included APO A1, A2, A4, C1, C2, C3, D, E and N, similar to that seen in ACN 
depleted human serum (Section 2.3.4). This again could suggest that the method is 
specific for concentrating proteins from the apolipoprotein family. However, as was 
seen in the human serum analysis, the high abundant and high molecular weight protein 
APO B100 (1 mg/mL and 512 kDa) was not detected in the ACN depleted murine 
serum, therefore suggesting it was precipitated from the serum. These data indicated 
that the ACN depletion method was applicable for removing high abundant proteins 
from murine serum prior to tryptic digestion and LC-MS analysis.  
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Table 3.2. Proteins identified in a 1D LC-MS/MS analysis experiment on an ACN 
depleted murine serum digest. All proteins except Chemokine-binding protein 2 are 
common serum / plasma proteins (stated as secreted on expasy.org). 
 
Protein  Accession Protein Name Score Mass % Coverage
1 gi|2546995 Fetuin  880 35303 36.1 
2 gi|191885 Apolipoprotein A-IV 684 42986 46.5 
3 gi|12846616 Heamoglobin 651 14953 76.2 
4 gi|15421856 Apolipoprotein C-III  608 8890 46.5 
5 gi|5915682 Serum albumin 511 65892 26.8 
6 gi|26345182 Apolipoprotein A1 504 27922 51.9 
7 gi|22135640 Carboxylesterase N 433 60573 27.8 
8 gi|6678083 Alpha-1-antitrypsin 1-6 378 43514 29.3 
9 gi|148747546 Contrapsin 270 44742 20.8 
10 gi|6753100 Apolipoprotein C-II  246 8303 21.6 
11 gi|7305599 Transthyretin  198 54507 57.8 
12 gi|193446 Vitamin D-binding protein  172 21379 11.9 
13 gi|7304897 Apolipoprotein A-II  166 8863 41.2 
14 gi|6680856 Corticosteroid-binding globulin 165 42277 9.8 
15 gi|6753798 Coagulation factor II  162 71649 8.9 
16 gi|673431 Complement factor D 152 25457 26.7 
17 gi|127531 Major urinary proteins 11 and 8 130 17720 35.8 
18 gi|19527214 Apolipoprotein N 128 28232 14.7 
19 gi|114775 Beta-2-microglobulin 112 11687 27.7 
20 gi|19527216 Apolipoprotein F 110 17515 6.7 
21 gi|16418335 Leucine-rich alpha-2-glycoprotein 109 33875 12 
22 gi|309122 Preprocomplement component C3 106 184179 2.4 
23 gi|575657 Apolipoprotein D 99 19430 20.1 
24 gi|9055252 Inter alpha-trypsin inhibitor, heavy chain 4 96 72133 1.4 
25 gi|59858561 Major Urinary protein 24 86 18818 21.5 
26 gi|127532 Major urinary protein 3 83 19006 12.5 
27 gi|58037247 TREM like-1 79 23171 10.2 
28 gi|13384648 Biotinidase 75 56117 2.6 
29 gi|114041 Apolipoprotein E 66 33968 6.8 
30 gi|6678672 Lecithin cholesterol acyltransferase 66 47242 4.3 
31 gi|6680704 Apolipoprotein C-I 58 6993 20.5 
32 gi|200904 Serum amyloid A1 48 11753 7.9 
33 gi|554264 Parotid secretory protein 45 22690 34.5 
34 gi|12963823 Pro-platelet basic protein 44 12586 9.7 
35 gi|74199751 Keratinocyte differentiation-associated protein 44 9218 14.3 
36 gi|53819 Parvalbumin 41 11799 12.7 
37 gi|199086 Alpha-2-macroglobulin 38 163100 0.9 
38 gi|14547939 Chemokine-binding protein 2 37 43255 3.7 
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3.3.2 Body weights of mice during gene therapy administration. 
3.3.2.1 Body weights of mice from Batch 1 
The mice used in Batch 1 of the gene therapy administration experiments were weighed 
prior to administration of plasmid or placebo, one week afterwards and immediately 
before performing the terminal bleed (Figure 3.3).  
Average body weight changes of mice during administration
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Figure 3.3. Average body weights of the mice in Batch 1 at t=0, 1 week and 2 weeks 
post administration of gene therapy plasmids and PBS control, error bars demonstrate 
one standard deviation.  
 
The body weight data shown in Figure 3.3 suggests that the GH +ve plasmid treated 
animals demonstrated a greater overall increase in average body weight than the two 
control groups at 2.5 weeks post administration. It was not possible to perform any 
detailed statistical analysis on the results of the body weights as the raw data values 
were not supplied. These data suggest that expression of the GH protein in the GH +ve 
plasmid cohort was having a physiological effect by increasing the body mass of the 
+ve plasmid treated mice. 
 
 
3.3.2.2 Body weights of mice from Batches 2-5 
The mice in Batches 2-5 were weighed at t=0, 1 week, 2 weeks and 2.5 weeks post-
administration, and the average weights of the mice at each of the four time points were 
calculated (Figure 3.4).  
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Figure 3.4. Average body weights for mice from Batches 2-5 at t=0, 1 week, 2 weeks 
and 2.5 weeks post-administration of gene therapy plasmids and PBS control. 
 
Body weight data for the GH –ve plasmid and PBS treated animals in Batches 2-5 
displayed similar increases in weight over time as seen in Batch 1. However, the mice 
treated with the GH +ve plasmid did not differ from that seen in the –ve plasmid and 
PBS control animals (Table 3.3). Again, no raw data was supplied along with the graph, 
therefore statistical analysis of these results was not possible.  
 
Table 3.3 Average body weights of mice in the two administration groups (Batch 1 and 
Batches 2-5). 
Average body weights (g) Batch 1  Average body weights (g) Batches 2-5 
Time (weeks) +ve plasmid -ve plasmid PBS control  Time (weeks) +ve plasmid -ve plasmid PBS control 
0 25.5 25.8 25.4  0 23.75 23.65 23.8 
1 25.8 26.3 25.6  1 24.8 24.6 24.8 
2.5 27.5 27.1 26.8  2.5 25.8 25.6 26 
% Increase from T=0  % Increase from T=0 
1 101.2 101.9 100.8  1 104.4 104.0 104.2 
2.5 107.8 105.0 105.5  2.5 108.6 108.2 109.2 
 
 
The body weight data indicate that the first administration resulted in a 7.8% increase in 
body weight after administration of the GH +ve plasmid compared with a 5% increase 
in the other two cohorts. The GH +ve plasmid treated mice in the second administration 
group (Batches 2-5) displayed an 8.6% increase, however, a similar increase was also 
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seen in the other two groups (8.2 and 9.2%). This suggests that the second preparation 
of GH +ve plasmid did not generate a viable GH vector and therefore failed to increase 
circulating GH levels in the GH +ve plasmid treated mice.  
3.3.3 Stepwise analysis of LC-MS data from Batch 1. 
Visual inspection of the data from the LC-MS/MS analysis of samples in Batch 1 
resulted in a single data file being rejected as it was significantly different to all the 
other samples. The removal of a single LC-MS/MS file left 27 for submission to 
stepwise ANNs analysis. Spectra from 5-74 minutes were summed and the m/z and 
intensity values exported to Excel. The conditional summing tool was applied to 
generate data sufficient for submission to stepwise ANNs analysis. The transformed 
LC-MS data were split into three groups; +ve plasmid Vs. -ve plasmid, +ve plasmid Vs. 
PBS control, and –ve plasmid Vs. PBS control, and a total of 6 stepwise cycles were 
applied to each dataset and the ions identified as discriminatory were tabulated (Table 
3.4).  
 
Table 3.4. Stepwise ANNs results from Batch 1. Data shows m/z values and predictive 
accuracy in parentheses. The first ion in the +ve Vs. –ve comparison (1146 m/z,*), 
corresponds to the [M+2H]2+ ion of the murine IGF-I T1 peptide. 
No. of steps +ve Vs. Control 
(m/z) 
+ve Vs. -ve 
(m/z) 
-ve Vs. Control 
(m/z) 
1 1274 (69%) *1146 (77%) 404 (74%) 
2 1373 (90%) 1471 (82%) 1582 (87%) 
3 752 (92%) 549 (91%) 1335 (83%) 
4 793 (92%) 909 (97%) 527 (90%) 
5 471 (90%) 505 (95%) 1371 (93%) 
6 1259 (87%) 596 (92%) 891 (90%) 
 
Interrogating the stepwise ANNs results shows that the highest prediction accuracy was 
obtained from the +ve versus -ve plasmid samples, with a stepwise accuracy of 97% 
after four stepwise cycles. A predictive accuracy of 92% was obtained for the +ve 
plasmid versus the PBS control sample group after the addition of three ions. The ANNs 
stepwise analysis enabled the identification of a group of LC-MS derived m/z ions 
values that demonstrated good predictive capabilities, which warranted further 
investigation.  
 
3.3.4 Predictions profile of data from Batch 1. 
Ions identified as having discriminatory characteristics by the stepwise ANNs analysis 
were used to generate a new model in order to create prediction profiles for the three 
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groups (Figures 3.5 A, B and C). Figure 3.5A indicates that the model correctly 
identified 9 out of 9 +ve plasmid samples and 8 out of 8 PBS control samples. The 
models generated for the +ve versus -ve plasmid model also showed good 
discrimination between the treated and untreated populations with identifying 8 out of 9 
+ves and 8 out of 10 -ves (Figure 3.5B). However, the model was unable to distinguish 
–ve plasmid samples from controls. 
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Figure 3.5. Predictions performance of models generated using ions identified as 
important for discrimination between A) +ve plasmid (2, blue bars) Vs. PBS control (1, 
red bars), B) +ve plasmid (2, blue bars) Vs. -ve plasmid (1, red bars) and C) -ve plasmid 
(2, blue bars) Vs. PBS control (1, red bars). Error bars for each graph indicate standard 
error of the mean from the predictions analysis for each sample.  
 
The analysis of the initial Batch of gene therapy samples generated some promising 
results, however the data were obtained using small data sets (10 or less samples per 
group). The analysis of a larger data set of five Batches of gene therapy samples should 
generate a more robust and statistically valid result, as there would be up to 50 samples 
per group. On the basis of the promising results observed from the first Batch of gene 
therapy administrations, the remaining four administrations were scheduled.  
 
3.3.5 Stepwise analysis of LC-MS data from Batches 1-5. 
A total of 135 samples, from all five Batches of gene therapy administrations, were 
available for depletion. After LC-MS analysis, 133 data files were suitable for 
submission to ANNs analysis for biomarker identification purposes. The 133 samples 
consisted of 41 GH +ve plasmid samples, 47 GH –ve plasmid samples and 45 PBS 
controls. The data were split into the same groupings as discussed in Section 3.3.4 and 
submitted to stepwise ANNs analysis. The ions identified by the stepwise process and 
their respective accuracies are displayed in Table 3.5.  
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Table 3.5. Stepwise ANNs results from Batches 1-5. Data shows m/z values and 
predictive accuracy in parentheses. 
 
No. of steps PBS control v positive 
(m/z) 
Negative v positive 
(m/z) 
PBS control v negative 
(m/z) 
1 820 (62%) 516 (56%) 995 (64%) 
2 890 (56%) 407 (62%) 1586 (61%) 
3 922 (56%) 979 (64%) 1589 (58%) 
4 1023 (52%) 1152 (66%) 1181 (60%) 
5 1167 (44%) 1308 (56%) 1294 (52%) 
6 1523 (58%) 909 (65%) 1071 (64%) 
7 1095 (63%) 1078 (70%) 1430 (72%) 
8 953 (61%) 1174 (73%) 1561 (70%) 
 
The stepwise analysis of the large sample set failed to generate models capable of 
discriminating between the different gene therapy administration groups (GH +ve plasmid, 
GH –ve plasmid and PBS control) with a high degree of accuracy. An investigation was 
initiated into the cause of the failure of the LC-MS and ANNs analysis of the entire GH 
gene therapy sample cohort. The body weight data suggested that the +ve GH plasmid 
used in Batches 2-5 may not have generated a viable GH vector as noted earlier, and 
this may explain the failure of the ANNs model. Another explanation could be the 
reproducibility of the analytical method.  
 
The ACN depletion method had previously been demonstrated to be a highly 
reproducible extraction technique, therefore the reproducibility of the nanoflow LC-MS 
method was considered to be a possible source of error. In order to investigate the 
reproducibility of the nanoflow LC separation, the retention time of a high abundant and 
ubiquitous peptide in the ACN depleted serum digests was identified in samples 
throughout the five Batches. The peptide chosen for this analysis was the T2 tryptic 
peptide (TVQDALSSVQESDIAVVAR) from the apolipoprotein C3 (APO C3) protein. 
LC-MS/MS data relating to the identification of this peptide are shown in Figure 3.6.  
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Figure 3.6. Nanoflow LC-MS/MS analysis of a tryptically digested, ACN depleted 
murine serum sample. A = TIC. B = extracted ion chromatogram for APO C3 T2, peak 
at 41.31 minutes. C = full scan MS spectra of the T2 peptide displaying the [M+2H]2+ 
and [M+3H]3+ ions. D = enhanced resolution ion displaying 13C isotopic cluster pattern 
of the [M+2H]2+ ion. E = Full scan MS/MS spectrum of the [M+2H]2+ peptide species, 
matching y3 to y14 ions. 
 
The MS/MS spectra of the APO C3 T2 peptide (Figure 3.6 panel E) was searched 
against the Swissprot database (with a murine filter) and achieved a mascot score of 113 
and an expect value of 7.6 e-11, indicating a very strong match for the peptide. The 
retention time of the T2 peptide was recorded in the first sample, the middle sample and 
the final sample in each Batch of ACN depleted gene therapy serum samples. The mean, 
standard deviation and %CV of the APO C3 T2 peptide retention times for each Batch 
of gene therapy samples were calculated and are displayed in table 3.6.  
 
Table 3.6. Retention time of the APO C3 T2 peptide in a nanoflow LC-MS analysis 
over a number of injections on different days. 
 
 28/01/06 28/11/06 04/12/06 08/12/06 13/12/06 16/12/06 
1st sample 40.53 40.53 41.83 40.88 40.37 40.2 
Middle sample 40.60 41.42 42.17 40.74 39.93 39.86 
Last sample 40.43 41.67 41.34 41.12 40.16 39.91 
Mean 40.52 41.21 41.78 40.91 40.15 39.99 
SD 0.09 0.60 0.42 0.19 0.22 0.18 
%CV 0.21 1.45 1.00 0.47 0.55 0.46 
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This analysis indicated that the chromatographic performance of the nanoflow LC 
method was highly reproducible with regards to a peptide eluting mid-way through the 
95 minute LC-MS analysis. The retention time of the peptide did not change 
significantly over the analyses of the five Batches of samples. The average retention 
time over the five Batches was 40.76 minutes and had a CV of 1.7% (n=18), proving the 
reliability of the nanoflow LC system for reproducibly generating solvent gradients at 
300 nL/min.  
 
The demonstration of the highly reproducible peptide retention time over a number of 
days indicates that the variability in the analysis of the large sample cohort was not due 
to the LC separation. Furthermore, when transforming data for ANNs analysis, all 
acquired spectra over the LC-MS analysis were summed, which would eliminate any 
peptide retention time shifts during the analyses.  
 
3.3.6 Investigation into the stability of the LC-MS response over time  
PCA analysis was performed on the transformed LC-MS data from the repeat analyses 
of an identical tryptically digested ACN depleted murine serum (Figure 3.7). The PCA 
analysis indicated that there were trends within the data suggesting that repeat injections 
of an identical sample over time generated different m/z and intensity profiles. 
Displaying the first two factors from the PCA analysis showed that it was possible to 
group injections into their injection sets. In each of the six sets, each sequential injection 
can be seen in the PCA data space as a clear progression within the principal 
components. Each set of analyses demonstrated a small intra-set shift in Component 1, 
but generally a larger shift in Component 2. The inter-set differences could be explained 
mainly with changes in Component 1. The biggest change was detected in the sixth 
analysis experiment, which shows a large difference in Component 2 over the six 
injections. 
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Figure 3.7. PCA analysis of identical murine serum digests over a number of days on 
the 4000 QTRAP mass spectrometer. Injections performed on each day are numbered 
and ringed. Six clear groupings can be seen relating to the day of injection. 
 
Closer investigations were performed on the raw LC-MS data from the six sets involved 
monitoring the retention time, and the peak area of the APO C3 T2 peptide. This 
analysis indicated that the retention time of the peptide showed no significant 
differences between sets as expected (data not shown). However, the intra and inter-set 
peak area of the T2 peptide changed significantly over the six sets (Figure 3.8).  
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Figure 3.8. APO C3 T2 peptide raw peak area in each set of nanoflow LC-MS analyses. 
 
The above figure clearly demonstrates that the APO C3 T2 peptide peak area in the first 
injection is always higher than the final injection in all six sets. Furthermore, large inter-
set differences can be seen in the MS response for the T2 peptide over the six batches. 
Expressing the T2 peptide peak area for each injection as a percentage of the initial 
injection enabled the assessment of the intra-set differences of the T2 peptide peak area 
(Figure 3.9).  
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Figure 3.9. Expression of the APO C3 T2 peptide peak area data displayed in Figure 3.8 
as a percentage drop from the first injection. 
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Figure 3.9 indicates that the APO C3 T2 peptide peak areas decreased as each injection 
was preformed. The reduction in peak area from the first to the fifth / sixth analysis was 
inconsistent, ranging from 22 to 73 percent. Interestingly, the lowest percentage drop in 
signal was seen in set 3, which started with the lowest overall peak area for the APOC3 
peptide (Figure 3.8). It was noted from laboratory records that the nanospray fused 
silica needle was changed after the third set, which could explain the sudden increase in 
peak area in set four. In fact sets 1 to 3 were using the same needle, as were sets 4 to 6, 
and the APO C3 T2 peptide peak area tended to drop consistently from set to set after 
installation of each needle. This drop in response is a particular problem when 
performing nano spray analyses as the lifetime of the fused silica needles is in the 
region of 80 hours before they need replacement.  
The LC-MS data from the sixth set were further analysed in an attempt to identify the 
source of the intra-set variance. Normalisation of the transformed data in the six 
injections was performed by expressing the intensity values for each m/z input as a 
function of the summed intensity from all the m/z values. The normalised intensity 
value for the first injection was subtracted from the other five samples in order to 
identify m/z ions that were changing in intensity with each successive injection (Figure 
3.10).  
 
Figure 3.10. Differences between the normalised values for samples 1 and 5 in the sixth 
set of repeat injections. The m/z values for peptides demonstrating the most differences 
have been labelled.   
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This analysis identified a number of m/z values that changed significantly as the 
analysis progressed. The m/z value that changed the most over the two analyses was m/z 
833, which had another m/z ion close in mass that also changed to a lesser extent (m/z 
829). These ions were derived from two peptides which had [M+3H]3+ and [M+2H]2+ 
charge states of m/z 829, 833, and 1242, 1250 respectively. The difference between 
these two peptides was an [M+H]1+ m/z difference of 16, which could possibly be 
attributed to an oxidation event, a chemical modification that can occur to methionine 
residues (170). The mass shift between the ions of m/z 829 and 833 ion is 4, which 
should be 5.33 if the peptide is triply charged. This discrepancy can be explaned due to 
the combination of the instrument’s low mass resolution and the fact that all 
experimental m/z values are converted into integers prior to submission for data 
analysis. 
 
Extracted ion chromatograms for m/z 829 and 833 were generated from the full scan 
LC-MS data and showed two high abundant and closely eluting peptides. An IDA based 
analysis of a murine serum digest was performed and these two peptides were selected 
for MS/MS fragmentation (Figure 3.11).  
 
Figure 3.11. Data from an IDA based analysis of tryptically digested ACN depleted 
murine serum. The left-hand panes indicates data from the normal version of the 
APOA2 T7 peptide, with the methionine residue indicated by the red arrow in the 
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MS/MS spectrum. The right-hand panes display data for the oxidised version of the 
peptide, with the red arrow displaying the methionine residue, which is 16 Da higher 
than the corresponding peak in the normal peptide.  
 
Database searching of the MS/MS spectra acquired for the two MS/MS spectra 
indicated that they came from the the normal and oxidised forms of the T7 tryptic 
peptide (SAGTSLVNFFSSLMNLEEKPAPAA) from APOA2  (Figure 3.12). 
 
 
Figure 3.12. Mascot results from the LC-MS/MS data file, displaying matches for both 
the normal and oxidised peptide forms. 
 
Berg et al demonstrated that oxidised forms of peptides elute earlier than their normal 
counterparts (170). The data in Figure 3.11 clearly show that the oxidised form of the 
APO A2 T7 peptide elutes earlier than the normal form, further confirming the oxidised 
peptide hypothesis. In order to track the rate of the oxidation of the APO A2 T7 peptide, 
the peak areas of both the oxidised and normal peptides in the ACN depleted murine 
serum were calculated in each of the six samples from the sixth set (Table 3.7). 
 
Table 3.7. Peak areas of oxidised and normal APO A2 T7 peptide in a tryptically 
digested serum sample over a 30 hour period on the autosampler at 8 °C. 
 
Sample Normal Oxidised Ratio (normal:oxidised) 
1 9.74E+10 1.23E+11 1  :  1.26 
2 7.94E+10 8.96E+10 1  :  1.12 
3 6.29E+10 7.82E+10 1  :  1.24 
4 5.08E+10 7.49E+10 1  :  1.47 
5 4.17E+10 6.78E+10 1  :  1.62 
6 4.15E+10 7.44E+10 1  :  1.79 
 
 
The presence of high levels of the oxidised form of APO A2 in the original injection 
indicated that extensive oxidation of the protein had taken place either in- or ex-vivo as 
the oxidised form appeared in higher quantities than the normal protein. Pankhurst et al 
demonstrated that methionines in APO A2 in human serum became oxidised both 
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before and after serum was taken (171). Evidence of additional oxidation ex-vivo 
oxidation was also found in our dataset where the proportion of the oxidised APO A2 
peptide increased over time as the sample remained in the autosampler Table 3.7. These 
data suggest that the tryptically digested serum extracts acquired post-extraction 
modifications, even when cooled to 8ºC.  
 
The demonstration of modifications occurring to peptides in the autosampler suggests 
that extracting large numbers of samples for nanoflow LC-MS analysis would introduce 
time dependent changes prior to analysis. In this study, the mouse GH gene therapy 
samples were ACN depleted in groups of up to 30 samples and analysed over a total of 
22 days. This long analysis time could have introduced significant intra and inter-batch 
variation through a combination of the acquisition of peptide modifications, whilst on 
the autosampler, and instrument response drift over time. These possible variations in 
the dataset would further impact on the inherent biological variation of the serum 
proteome from 133 different mice and could explain why the LC-MS and ANNs 
analysis of the large Batch failed to produce a suitable model for discriminating 
between the different groups. 
 
3.3 SUMMARY 
The use of LC-MS/MS and database searching demonstrated that the ACN depletion 
method had similar extraction characteristics for both murine and human serum. 
Therefore, the ACN depletion method was suitable for extracting proteins from murine 
serum for LC-MS based biomarker discovery experiments. The application of LC-MS 
and ANNs to the detection of biomarkers capable of discriminating between GH +ve 
and GH –ve Batches, as well as between +ve GH and PBS control samples, appeared to 
be successful on the first Batch of gene therapy samples. A new preparation of the GH 
+ve and GH –ve plasmids were generated to produce a larger and more statistically 
relevant set of serum samples. These samples were produced over a large time period 
(June 2006 to November 2007) and were stored to be analysed in as short a time period 
as possible. The analysis of a larger Batch of samples by LC-MS and ANNs did not 
return improved results over the initial Batch. Three possible hypotheses were identified 
for the inability to develop a suitable ANNs model. 
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The first hypothesis was a possible failure of the second batch of GH +ve plasmid to 
produce the target protein. This could explain why no body weight increases were 
detected in animals in the later batches compared with the PBS and GH –ve plasmid 
groups.  
 
The second hypothesis was identified as the MS system showing insufficient 
reproducibility over a number of days. This issue was considered as a major problem for 
future analyses of large sample sets, and some degree of quality control and/or 
normalisation would be needed to control for the day-to-day changes in MS response. 
This might be achieved through the addition of internal standard proteins or stable 
isotope labelled peptides. 
 
A third hypothesis was identified as a modification of tryptically digested peptides in 
samples stored in the autosampler over a prolonged period of time. Data were presented 
on how the levels of an oxidised form of the APO A2 T7 peptide increased in samples 
stored in a cooled autosampler. The finding that peptides were acquiring modifications 
over time raises questions as to whether the application of nanoflow analyses can be 
performed on large sample sets for biomarker identification. Extensive controls would 
be needed to be put in place to account for sample modifications, such as limiting the 
size of sample numbers per batch to reduce analysis time, or alternatively to 
significantly decrease LC-MS analysis times to minimise the time samples are stored on 
the autosampler. 
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 CHAPTER 4. APPLICATION OF MASS SPECTROMETRY AND 
BIOINFORMATICS ANALYSIS TO THE IDENTIFICATION OF 
BIOMARKERS OF RHGH ADMINISTRATION TO THE HUMAN. 
 
4.1 INTRODUCTION 
Chapter 3 describes the application of LC-MS and ANNs to the identification of peptide 
ions specific for discriminating between three classes of treated mice (GH positive 
plasmid, GH negative plasmid and placebo). However, the administration of a similar 
GH gene therapy is not possible in the human and therefore an alternative proof of 
principle approach was needed to establish the potential of MS and ANNs to detect 
biomarkers of gene doping. The approach adopted in this study was the administration 
of the end protein product (rhGH), and the use of a similar LC-MS based approach to 
biomarker discovery, as for the murine gene therapy administration. The application of 
LC-MS to identify biomarkers of rhGH administration could also identify new targets to 
further aid in the detection of rhGH abuse, a task that WADA has been striving to 
achieve for a number of years. 
 
4.1.1  Current approaches for detecting rhGH abuse 
The detection of the abuse of rhGH in sports is analytically challenging due to a number 
of factors.  Firstly, rhGH and endogenous GH (22 kDa) are structurally identical (172), 
and secondly GH has a short half life and a pulsatile release pattern which makes the 
window of detection very narrow (173). Concentrations of circulating GH are also 
dependent on factors such as nutritional intake and exercise, where the concentration of 
GH in blood can increase up to seventy-fold in response to acute exercise (174,175). 
Furthermore, any excess beyond spontaneous episodic increases must also exclude the 
presence of diseases such as acromegaly (176). Therefore, an elevated GH 
concentration is not specifically related to the administration of rhGH.   
 
Current approaches for detecting the abuse of rhGH employ two ELISA based detection 
methods. The first measures the levels of the different GH isoforms (non-22 kDa vs 22 
kDa), where a high ratio of 22-kDa to non-22-kDa (17, 20 kDa) GH is used to indicate 
rhGH abuse (172).  The second technique is based on monitoring a number of 
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downstream GH biomarkers, with IGF-I, IGFBP-3 and PIIINP being the most important 
candidates (14,177,178).  Immunoassays were developed for monitoring these proteins 
in serum for clinical use, and have since been employed with the aim to detect rhGH 
abuse. The three rhGH biomarkers are up-regulated when humans have been 
administered with rhGH, and the combination of all three proteins have shown to 
significantly increase the length of time rhGH abuse can be detected (179).    
 
These immunoassays are highly sensitivity and demonstrate good analytical 
reproducibility. However, a major problem with using immunochemistry based 
techniques to detect rhGH abuse is that testing laboratories are dependent upon the 
availability of suitable reference standards and commercial immunoassay kits, whilst 
changes in the performance of kits might result in the need to re-establish reference 
intervals (63). Furthermore, different immunoassay kits can generate significantly 
different values for the same sample, as has been shown with IGF-I ELISA kits (180). 
Krebs et al used five commercially available assays to quantify IGF-I in a pooled serum 
sample. The measured concentrations in the five assays were 277, 279, 298, 350 and 
390 ng/mL, demonstrating that significant differences are often seen between ELISA 
kits for the same analyte.  
 
4.1.2 Application of mass spectrometry to serum and plasma protein biomarker 
discovery. 
In recent years, there has been increasing interest in the use of mass spectrometry for 
biological applications such as the identification of biomarkers of disease, disease 
progression, response to therapy, and monitoring biomarker levels in serum and plasma 
(181-183). A drawback of the mass spectrometric analysis of tryptically derived 
peptides is that the technique generates immense amounts of data, making the 
application of bioinformatics essential for identifying characteristic biomarker patterns 
within such complex datasets (123).  Artificial neural networks (ANNs) are a powerful 
statistical data-mining tool and have been utilised for the prediction of biologically 
important molecules in complex systems (184).  ANNs has previously been used, in 
conjunction with MALDI-MS, to identify serum based biomarker ions capable of 
detecting the administration of porcine GH to a murine model (144).  Proteomic 
profiling using MALDI-MS with protein chip technology and bioinformatics, has also 
 
106 
been used to identify novel serum protein biomarkers of rhGH administration in humans 
(185). In the study by Chung et al, samples from a WADA funded project (GH-2000) 
were used to identify haemoglobin alpha as a biomarker of rhGH abuse. However, this 
finding was not validated by reanalysing a larger sample set, and therefore the protein 
cannot be confirmed as a true biomarker of rhGH abuse.  
 
The current downstream rhGH biomarkers have been identified through hypothesis 
driven experiments, where the serum and plasma levels of these proteins were identified 
using classical immunochemical based assays. Additional rhGH related serum or 
plasma based biomarkers could be identified using mass spectrometry based 
proteomics, and any discovered biomarker added to the existing panel to increase the 
ability to detect rhGH abuse. 
 
4.1.3 WADA’s efforts in detecting rhGH abuse in humans 
Researchers funded by WADA have performed multiple rhGH administrations to 
humans in an attempt to develop protein-based assays capable of detecting rhGH abuse. 
Samples from these studies are often made available to other WADA funded 
researchers, and two sample sets were acquired for this project. The first sample set 
comprised a total of 48 serum samples, of which 24 were obtained from eight 
individuals dosed with rhGH, the remaining samples were from the same individuals, 
but in a placebo treated state (168). A diagrammatical representation of the study 
administration protocol is displayed in Figure 4.1.  
 
Figure 4.1. Schematic of rhGH administration performed at Royal Free UCL.  
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The samples from this rhGH administration project would initially be used for training 
an ANN model to detect biomarkers related to rhGH administration. A second rhGH 
administration project generated 215 serum samples, of which 40 were from rhGH 
treated individuals. Samples from the second project would then be used for biomarker 
validation purposes, which is described further in Chapter 5. 
 
4.1.4 LC-MS instrumentation for analysis of tryptic peptides 
The LC-MS analysis of the murine gene therapy samples did not identify a panel of 
biomarker ions capable of discriminating the three groups with a high degree of 
accuracy. A number of possible reasons for this were outlined in Section 3.3.6, which 
identified changes in instrument response, peptide modification within the autosampler, 
and possible failure of the plasmid as potential causes for failure.  
 
Before selecting the instrumentation for the analysis of the extracted serum samples 
from the administration of rhGH to humans, the data generated for the gene therapy 
administration study were investigated further: in particular the raw LC-MS data files 
obtained from the analysis on the 4000 QTRAP MS system. The data were acquired 
using a scan rate of 1000 amu / second (from 400 to 1600), which enabled simultaneous 
measurements of intensity for m/z values with increments of 0.08 units, totalling 15,000 
possible measurements per spectrum. These data were then transformed for ANNs 
analysis, which summed approximately 12 m/z intensity measurements into each of the 
1200 integer values (m/z 400-1600). Ideally, submitting a larger number of m/z 
datapoints per summed spectrum would have been more appropriate, for example at 
increments of 0.2 m/z, however this would have involved summing only 2 or 3 m/z 
intensity measurements per data point, making the output more prone to influence from 
instrument noise in the spectra.  
 
The 4000 QTRAP mass spectrometer is a low resolution MS system, and relies on a 
linear ion trap analyser for full scan analysis. Ions held within the trap can be scanned at 
three different speeds: 250, 1000 and 4000 amu/s, where slower scan speeds have 
higher resolution, but with a significantly increased instrument duty cycle. Therefore, 
the 4000 QTRAP is only capable of acquiring improved MS data quality by sacrificing 
data quality in the guise of reduced number of spectra per LC-MS analysis. An MS 
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system with increased mass accuracy and resolution would therefore need to be used to 
improve data quality, such as a TOF system which are regularly used for the analysis of 
tryptically digested proteins (186). 
 
4.1.5 Chapter overview  
This chapter describes the application of mass spectrometry and ANNs to the detection 
of serum biomarkers of rhGH administration. Serum samples from a high quality, well-
controlled rhGH administration to humans were obtained where a given sample’s rhGH 
or placebo treated state was assured. Peptide ions identified by ANNs as being capable 
of discriminating between rhGH and placebo states were investigated in an attempt to 
characterise their protein of origin.  
 
4.2 MATERIALS AND METHODS 
4.2.1 Chemicals 
Acetonitrile (ACN, LC grade) was purchased from Romil (Cambridge, UK), water was 
produced by an option 4 water purifier (Elga, High Wycombe, UK). Dithiothreitol, 
iodoacetamide, ammonium bicarbonate, and formic acid were purchased from Sigma 
Aldrich (Poole, UK). Acetic acid was purchased from BDH, (Poole, UK). Trypsin gold 
was purchased from Promega (Southampton, UK). Recombinant human growth 
hormone (rhGH) (Norditropin PenSet 24™) for injection and placebo (excipients with 
no rhGH) were supplied by Novo Nordisk (Denmark). 
 
4.2.2 Comparison of the 4000 QTRAP and the QTOF Premier  
In order to assess the capabilities of a TOF analyser for generating higher quality mass 
spectral data, a tryptically digested, ACN depleted human serum sample was analysed 
using both a 4000 QTRAP and a QTOF Premier (Waters, UK). Sample (2 μL) was 
injected onto the 4000 QTRAP and analysed using an IDA based analysis (as described 
in Section 2.2.7 and 2.2.8.2). This analysis generated data on all peptides at 1000 amu/s 
and data on specifically selected peptides at 250 amu/s. An additional analysis was 
performed where the survey scan used a scan rate of 4000 amu / second. The same 
extract was then analysed on a Waters QTOF Premier for comparison. 
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4.2.2.1 Analysis of serum extract on the Waters QTOF premier 
An ACN depleted and tryptically digested human serum sample extract was injected (1 
μL) onto a Symmetry C18 5 μm, 0.18 x 20 mm trap column (Waters) at a low rate of 5 
μL/minute and washed for six minutes. The trap column was switched in-line with an 
Atlantis C18 3 μm, 0.075 x 100 mm analytical column (Waters). Tryptic peptides were 
separated over a 55 minute gradient which involved 2% ACN to 55% ACN in 45 
minutes, then to 90% ACN in 10 minutes (all at 0.1% formic acid, v/v), using a flow 
rate of 300 nL/minute. Mass spectrometry analysis was performed using positive ion 
ESI with 3.5 kV applied to the needle, and full scan spectra were acquired from m/z 400 
to 1600 every 0.5 seconds. 
 
4.2.3 Administration of rhGH to human subjects (Performed by staff at RFUCL). 
All work described in this Section (4.2.3) was performed at the Royal Free Hospital. 
Following approval by the Royal Free Hospital Ethics Committee, eight male subjects 
aged 24.3 (± 4.5) years, weight 84.6 (± 13.1) kg and height 180 (± 6) cm, were 
randomly assigned to either a rhGH or placebo group (168).  A dose of rhGH 
(Norditropin PenSet 24TM) at 0.075 IU kg-1 or equivalent volume of PBS was 
administered daily for two weeks by subcutaneous abdominal injection.  After a 4-week 
washout period, the subjects were switched between placebo and rhGH treatment for 
another 2-week administration programme.  At the end of each 2-week administration 
period, subjects undertook a single bout of one-legged weigh-lifting exercise 16-20 
hours after the last injection. A catheter was inserted into a forearm vein and blood 
samples were collected before commencing exercise, immediately afterwards and 2.5 
hours after completion of exercise.  This generated three blood samples for each of the 
eight individuals in both the rhGH and placebo treated states, therefore generating six 
samples per individual and 48 samples in total. Blood was left to stand at 25 °C for 30 
minutes and centrifuged at 1000x g for 10 minutes.  The serum was collected into 
transparent glass tubes (10 mL), immediately frozen on dry ice and stored at -80˚C.  
Serum IGF-I levels were determined using a solid phase, enzyme-labelled 
chemiluminescent immunometric assay (Siemens, Germany) (168).  
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4.2.4 ACN depletion, digestion and LC-MS analysis of human serum samples. 
At the time of the LC-MS analysis, samples from only seven of the eight individuals (42 
of the 48 serum samples) were available for biomarker identification purposes. Serum 
from rhGH (n=21) and placebo (n=21) treated states was extracted using the optimised 
ACN depletion method described in Chapter 2 Section 2.2.4. Samples were randomised 
before extraction, and separated into two equal sized batches of 21 after evaporation. 
The first set of 21 samples were reconstituted, reduced, alkylated, digested and analysed 
by LC-MS 24 hours before the second set, in an attempt to reduce the time samples 
were stored on the autosampler. After digestion, aqueous formic acid solution (2.5 μL) 
1% (v/v) was added to each sample prior to analysis on a nanoAQUITY LC linked to a 
QTOF-Premier mass spectrometer (Waters, UK). Only full scan data were recorded in 
order to acquire the best possible data quality for submission to ANNs. Sample (1 μL) 
was injected onto the LC-MS system and analysed as described in Section 4.2.2.1. 
 
4.2.5 Processing of data from the LC-MS analysis 
Each LC-MS analysis described in 4.2.2 generated a file in the region of 2 gigabytes of 
data because each spectrum contained in the region of 112,000 m/z data points, and 
there were a total of approximately 7200 spectra recorded over the 60 minute analysis. 
The LC-MS data were converted into an ANNs compatible format, as described in 
Chapter 3. To achieve this task, spectra from the LC-MS file were summed from 12.5 to 
55 minutes, which corresponded to the peptide elution time period. The resulting 
spectrum was background subtracted, smoothed and the m/z values rounded to 
increments of 0.2. Ion intensities from the spectra were then summed to give a single 
value for each incremental m/z value, using the conditional summing tool in Excel 
(Microsoft, USA). The transformed LC-MS data were submitted to stepwise ANNs 
analysis. 
 
4.2.6 Stepwise analysis and model evaluation. 
Data were analysed using a stepwise approach developed by NTU in combination with 
the statistical software package Statistica 7.0 (StatSoft Inc. Tulsa, USA). The data were 
randomly divided into three subsets: training (60%), test (20%) and validation (20%), 
and trained using random sample cross validation (144,166).  In the stepwise approach, 
all the selected inputs were treated as a single input variable in the model, and 
 
111 
subsequently trained and tested with random sample cross validation.  This identified 
the optimum subset of ions that most accurately modelled the data.  The model was then 
interrogated to determine the response profiles of the optimum subset marker ions, and 
sample predictions were monitored and ranked to derive the population structure.  
Model performance was further evaluated by ROC curve analysis and measuring AUC 
values.   
 
4.2.7 LC-MS/MS characterisation of biomarker ions identified by LC-MS and ANNs 
analysis. 
Because the initial LC-MS analyses were performed using only full scan data collection, 
additional LC-MS/MS analyses were needed for biomarker ion identification purposes. 
This was performed on the existing sample extracts from an individual (both treated and 
untreated), where the six ions identified by the ANNs experiment were selectively 
targeted for LC-MS/MS analysis. Serum extract (2 μL) was injected and the peptides 
separated using a 95 minute method on an Ultimate 3000 LC system (Dionex, San 
Fransisco, CA, USA) coupled to a 4000 QTRAP with a NanoSpray II ® ion source 
(Applied Biosystems / MDS Sciex, Concord, ON, Canada). The MS/MS method 
involved fragmentation of biomarker peptide ions with 45 eV of energy, a linear ion 
trap fill time of 150 ms and a scan speed of 4000 amu / second. 
 
4.3 RESULTS AND DISCUSSION 
4.3.1 Comparison of QTRAP and QTOF mass spectral data 
The T4 tryptic peptide (DALSSVQESQVAQQAR) from apolipoprotein C3 (APOC3) 
was selected in order to compare data generated by the QTOF and QTRAP mass 
spectrometers. This peptide was selected as it demonstrated good signal using both MS 
analysers. The APOC3 T4 peptide has an expected m/z value of 858.97, and the 
experimentally acquired 13C isotopic cluster pattern of the peptide’s [M+2H]2+ charge 
state is displayed in Figure 4.2, which shows data from the three QTRAP scan rates and 
the QTOF analysis. The data acquired on the 4000 QTRAP using the 1000 and 4000 
amu/s setting were not capable of completely resolving the 13C isotope variants of the 
APO C3 T4 peptide, although complete resolution was achieved at 250 amu/s. The 
QTOF analysis demonstrated significantly superior data quality than the 4000 QTRAP, 
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where complete resolution was achieved using a significantly shorter duty cycle. The 
QTOF data acquisition rate was over four times as fast as the that used on the 4000 
QTRAP for the murine study (2 spectra per second compared with one spectrum every 
2.4 seconds). 
 
Figure 4.2. 13C Isotopic patterns for the [M+2H]2+ charge state of the APO C3 peptide 
DALSSVQESQVAQQAR. The top three windows show data acquired on the 4000 
QTRAP at 250, 1000 and 4000 amu/s. The bottom window shows data from the TOF 
analysis.  
 
Furthermore, the QTOF was capable of generating 92 measurements per integer m/z 
value, which enabled an increased number of data points per summed spectra to be 
submitted to ANNs analysis (0.2 m/z increments as apposed to integer). Therefore it was 
decided to use the QTOF system for the human serum analysis work. 
 
4.3.2 Determination of serum IGF-I levels in individuals dosed with rhGH (Performed 
by staff at RFUCL). 
Serum IGF-I concentrations were determined by immunoassay (Immulite™) following 
sample collection at the Royal Free Hospital. The immunoassay derived concentrations 
of IGF-I in the serum of subjects following each of the two test periods are shown in 
Figure 4.3. The results show significant increases in serum IGF-I levels following rhGH 
administration, however no increase in IGF-I was detected during the exercise bout on 
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each sampling day (data not included). An increase in circulating GH was detected in 
both rhGH and placebo treated individuals after exercise (168). Therefore the results 
demonstrate that monitoring serum IGF-I levels is sufficient to detect rhGH abuse, 
independent of any increases in endogenous GH due to exercise. However, research has 
shown that monitoring IGF-I in isolation is not sufficient to prove doping with rhGH, 
and additional markers are required (179). 
 
 
Figure 4.3. Concentrations of IGF-I (nM) in the rhGH and placebo treated individuals 
from the Royal Free UCL study. Each bar is the mean value from three samples, and 
error bars indicate 1 standard deviation.  
 
4.3.3 LC-MS peptide fingerprints of serum. 
A representative summed spectrum was obtained from an ACN depleted and digested 
serum extract (Figure 4.4), which displays multiple ions as expected for a highly 
complicated matrix.  
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Figure 4.4. A typical LC-MS spectrum of summed data acquired from 12.5 to 55 
minutes during the LC separation. Inset shows zoomed in region of m/z 600 to 650, 
demonstrating the high complexity of the spectrum. 
 
The reproducibility of the m/z ion intensity values observed in the combined LC-MS 
spectra was investigated after being transformed as described in Section 4.2.5. The 
mean ion intensity and standard deviation were calculated for each of the 6000 m/z 
channels across the 42 LC-MS analyses and demonstrated good reproducibility. The 
1500 most intense ions had a %CV value of 37.7%, which could be attributed to a 
combination of experimental error and natural variances in endogenous serum protein 
concentrations between the individual subjects. Previous investigations using ACN 
depletion of serum proteins and a quantitative SRM based LC-MS/MS analysis 
(Chapter 2) demonstrated highly effective depletion of albumin and good 
reproducibility of low molecular weight protein enrichment. The reproducibility of the 
m/z ion intensities indicates the ACN depletion method, combined with tryptic digestion 
and LC-MS analysis, is suitable for biomarker discovery experiments. 
 
4.3.4 Stepwise analysis of LC-MS data. 
Stepwise analysis of the transformed data from the LC-MS analysis of ACN extracted 
serum samples identified the optimum subset of variables, which were capable of 
correctly predicting whether a sample was rhGH or placebo treated.  A set of single 
input models was developed using the first marker from the mass spectrometric profile. 
This set consisted of 50 sub-models trained for 50 different randomly extracted cross-
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validation data sets. The mean squared error (MSE) and percentage of validation 
samples correctly classified were determined for these data along with standard errors 
and confidence intervals. The stepwise analysis of the LC-MS peptide data was 
performed for total of 10 cycles, and identified six ions (m/z 741.2, 1138.2, 801.2, 
752.6, 1028.4, 1259.4) that correctly classified 93% of all samples. Table 4.1 displays 
the masses and the predictive capabilities achieved for each round of stepwise analysis. 
 
Table 4.1. Ions identified by stepwise ANNs as being important for separating rhGH 
and placebo treated groups. 
  
 Stepwise cycle 
 1 2 3 4 5 6 7 8 9 10 
m/z 741.2 1138.2 801.2 752.6 1028.4 1259.4 1036.0 1038.4 480.0 769.6
% 
Accuracy 84 83 89.5 93 91 93 92 93.5 91 87 
 
 
An ANNs model was trained using only the first six identified biomarker ions, because 
after the sixth ion was added, the predictive accuracy did not significantly improve. 
However the tenth ion (769.6) was identified as the precursor m/z value of the 
[M+3H]3+ ion of the IGF-I T1 tryptic peptide. The reason for the failure of the addition 
of signal corresponding to an IGF-I peptide to increase the predictive accuracy was not 
ascertained, possibly due to the signal obtained from the IGF-I peptide in full scan MS 
mode being very low and more prone to ion suppression effects.  
The average predicted values from the test set were ranked and plotted (Figure 4.5).  
The sample population structure for rhGH (grey bars) and placebo (white bars) treated 
samples shows correctly predicted rhGH treated (ANNs prediction > 1.5) and placebo 
controls (ANNs prediction < 1.5).  
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Figure 4.5. Sample predictions with a six ion LC-MS model for peptides. The white 
bars are the placebo samples and the grey bars indicate rhGH treated samples. ANNs 
output values below 1.5 should be placebo samples whilst values above 1.5 indicate 
rhGH treated samples. Error bars display the standard error of the mean. 
 
The population profiles of the individual samples showed that they were classified into 
their respective groups (rhGH and placebo) with high confidence. The sensitivity and 
specificity of this model were 90% (19 of 21 rhGH treated) and 95% (20 of 21 controls) 
respectively.  
 
4.3.5 Model performance and interrogation. 
Model performance was further evaluated by ROC curve analysis and yielded an AUC 
value of 0.99 (Figure 4.6). An AUC of 1 indicates a model having equal sensitivity and 
specificity with perfect classification. The ANNs models were further interrogated to 
determine the responses to variations in each individual biomarker ion in order to 
determine whether they showed an increase (up-regulation) or decrease (down-
regulation) in intensity with regards to rhGH administration. The LC-MS data showed 
that the signal for the m/z 741.2 biomarker ion increased in the treated (mean of 14410 ± 
2175, 15.0 %CV, n=21) compared with the placebo (mean of 10814 ± 1486, 13.7 %CV, 
n=21) samples.    
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Figure 4.6. ROC curve from the predictions analysis from the six-ion ANNs model. 
 
 
4.3.6 Characterisation of LC-MS biomarker ion 741.2. 
An additional stepwise ANNs analysis was performed on summed spectra in a narrower 
LC-MS retention time window of 25 to 40 minutes, which again identified m/z 741.2 
ion as being the most important for discrimination between the placebo and rhGH 
treated states (83% accuracy), further confirming its relevance. Extracted ion 
chromatograms of the ions identified in the ANNs analysis were generated. Peaks were 
observed in all traces, with more than one peak visible in all traces (data not shown). 
Attempts were made to characterise all m/z ions identified using ANNs by LC-MS/MS 
analysis and protein database searching, however only the first ion (m/z 741.2) returned 
a protein match of any significance. Extracted ion chromatograms for m/z 741.2 
indicated two significant peaks, with average retention times of 32.3 and 32.7 minutes 
(± 30 seconds over the whole 42 LC-MS analyses which took approximately 96 hrs). 
An example chromatogram is displayed in Figure 4.7. The spectra under the both of the 
peaks at approximately 32.1 and 32.5 minutes in Figure 4.7 were combined, and 
contained a large number of ions relating to peptides, further demonstrating the high 
complexity of the tryptic digest (Figure 4.8). 
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Figure 4.7. Extracted ion chromatogram for m/z 741.2 from the QTOF analysis of a 
tryptically digested human serum extract. 
 
 
Figure 4.8. Combined spectra of the two peaks displayed in Figure 4.7, the top spectra is 
from the peak at 32.1 minutes and the lower from 32.5 minutes. Ions relating to the m/z 
741.2 ion can be seen in both spectra. 
 
Inspection of the 13C isotope cluster pattern of the peptide responsible for the m/z 741.2 
ion demonstrated that the peptide was quadruply charged, as the differences in the m/z 
values of each additional 13C within the cluster were approximately 0.25 (Figure 4.9). 
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Deconvolution of the 13C isotopic clusters for the first and second eluting peptides 
indicated that they had very similar masses of 2958.5 and 2959.5 Da respectively.  
 
 
Figure 4.9. 13C isotopic cluster pattern of the peptide contributing to the 741.2 m/z 
signal in Figures 4.7 and 4.8. The earlier eluting peak (left panel) gives a single mass 
difference when each 13C cluster is deconvoluted.  
 
The single Da difference in mass between these two peptides was believed to be 
attributed to a deamidation event, in which the amino group of an asparagine residue 
(16 Da) has been substituted for a hydroxyl moiety (17 Da) via a cyclised succinamide 
intermediate (187). The deamidation hypothesis was further strengthened by the 
reported observation that the analysis of a mixture of normal and deamidated peptides 
by reversed phase liquid chromatography results in the modified peptide eluting later 
than the normal peptide (170). This is consistent with the LC-MS data which showed 
two peptide peaks for m/z 741.2 (Figure 4.7), with the later eluting peptide having a 
single Da mass increase (Figure 4.9). To identify the protein associated with the m/z 
741.2 peptide, a full scan product ion MS/MS spectrum of the two peptides was 
performed by re-analysing an aliquot of both rhGH treated and placebo samples from 
one individual on the 4000 QTRAP. MS/MS analysis generated similar spectra for both 
LC peaks (Figure 4.10).   
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Figure 4.10. Spectra from the peaks at 45.89 and 47.25 minutes (spectrum 1 and 2 
respetcively) from the targeted LC-MS/MS analysis performed to characterise the 741.2 
m/z ion. The asterisks in spectrum 2 indicate the deamidated b ions, which are 1 m/z 
value higher than their normal counterparts in spectrum 1. 
 
The MS/MS spectra from the analysis were submitted to a Mascot search for 
identification using the Swissprot database (01-04-08), including a deamidation event as 
a variable modification. Spectra from both peaks were successfully identified as the T4 
tryptic fragment (LQELHLSSNGLESLSPEFLRPVPQLR) from the protein leucine-rich 
alpha-2-glycoprotein (LRG). The peaks at 45.89 and 47.25 minutes gave Mascot scores 
of 41 and 55 respectively (p<0.05). The T4 tryptic peptide of LRG has a single 
asparagine in its sequence, which is immediately followed by a glycine, which is 
believed to significantly increase the possibility of a deamidation event in the 
asparagine residue side chain (187). The possibility of a deamidation at the NG region 
of the peptide can be confirmed in the MS/MS data, as all the y ions are the same in the 
two spectra and the b5 ion, however the b10 and b11 ions demonstrate a single m/z shift 
between. These two ions contain the NG residues, therefore confirming the later eluting 
peak as having acquired a deamidation. 
 
4.3.7 In silico based identification of additional LRG tryptic peptides 
In order to further establish the identification of LRG as a possible rhGH-associated 
biomarker, the original LC-MS data set was investigated to extract additional 
information on tryptic peptides arising from this protein. An in-silico tryptic digestion 
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of the protein sequence was performed and yielded two additional LRG peptides 
ENQLEVLEVSWLHGLK (T7) and DGFDISGNPWICDQNLSDLYR (T21). In 
addition, peptides used to identify LRG in the 2D LC-MS/MS analysis of a tryptically 
digested human serum ACN extract (Section 2.3.7.2) were investigated to assess 
whether these extra tryptic peptides would be proteotypic (Figure 4.11).  
 
 
Figure 4.11. Peptides used to identify LRG in the 2D LC-MS/MS experiment. The three 
peptides used for further study of LRG in the 42 LC-MS data files (T4, T7 and T21 
highlighted in the red boxes) were identified with mascot scores of 73, 120 and 111 
respectively.  
 
These three selected peptides (T4, T7 and T21) comprise 20% coverage of LRG’s 312 
amino acid sequence and include 26 of the first 84 amino acids (T4), and 21 of the last 
56 amino acids (T21), showing well spread sequence coverage. The area under the two 
peaks relating to the T4 peptide was calculated for all the original 42 LC-MS analyses 
using Masslynx 4.1 software. A paired student t-test performed on the peak area values 
of the two T21 peptides, separated into the two populations (placebo and treated) and 
gave values of p=0.0015 and p=0.00016 for the normal and deamidated peptide 
respectively. Peak areas of the two additional peptides from rhGH treated and placebo 
states gave similar t-test values to the m/z 741.2 peptide (p= 0.0057 and p=0.0002 for 
T7 and T21 respectively).  Similar t-test values for the three tryptic peptides add further 
weight to the identification of LRG as a possible biomarker of administration of rhGH 
to humans. Furthermore, the ratio of the peak areas of the three LRG peptides over the 
42 LC-MS analyses had %CV values of 20, 32 and 37%, and considering no internal 
peptide markers were present to correct for ion suppression, this suggests the peak area 
values obtained for each peptide within a given sample were closely related.  
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4.3.8 Quantitative assessment of LRG related peptides in the 42 LC-MS data files. 
LC-MS is a quantitative technique, and generating extracted ion chromatograms for 
specific m/z ions will result in peaks related to target analytes which can be integrated to 
obtain quantitative information. Peak areas were calculated for each of the three 
peptides (with both T4 peak areas combined) in all analysed samples. The average peak 
area value for the three samples from each individual (rhGH and placebo treated states) 
were calculated and displayed together with the equivalent IGF-I concentrations 
identified by immunoassay (Figure 4.12). 
 
 
Figure 4.12: Comparison of IGF-I ELISA results in nM, and LRG peptide peak area 
values expressed as a mean for the 21 treated and 21 placebo samples analysed by LC-
MS. Error bars indicate one standard deviation.  
 
The analysis of the quantitative data for IGF-I indicates a clear separation between 
treated and placebo states, but the data for the three LRG peptides show some degree of 
overlap. However, the LRG peptide data for each individual, in the placebo and rhGH 
treated state are displayed in Figure 4.13. The products of the three peak areas were 
calculated and the mean of the three samples for each state expressed with one standard 
deviation (Figure 4.13). The comparison of LRG peptide peak areas in the placebo and 
treated state indicates that after 14 days of rhGH administration, the protein increases in 
concentration for six of the seven subjects. To assess whether the combination of LRG 
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and IGF-I improves the discrimination of placebo and treated states, the values of both 
proteins in the treated state were expressed as a percent increase from the mean of the 
placebo values. This was performed for the IGF-I quantitative data and LRG, and the 
sum of the two data sets was also included (Figure 4.14). 
 
Figure 4.13. Product of LRG T4, T7 and T21 tryptic peptide peak areas displayed as a 
mean value for each individual in the placebo and rhGH treated state. Error bars 
indicate one standard deviation. 
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Figure 4.14. IGF-I and LRG peptide product values in the treated state (for each subject) 
expressed as a percent increase from the placebo state. The black bars show the sum of 
the IGF-I and LRG increases over placebo state for each individual.  
 
The data presented in Figure 4.12 and 4.13 indicate that monitoring serum levels of 
LRG will not be sufficient to completely discriminate between rhGH and placebo 
treated individuals. However, the combination of LRG with IGF-I data (Figure 4.14) 
appears to increase the separation of the two states in six of the seven subjects tested. 
      
4.3.9 Structure and function of Leucine-rich α-2-Glycoprotein.  
LRG is a common serum glycoprotein, of unknown function. Its amino acid sequence 
includes a large number of leucine repeats which are common in amphipathic proteins 
such as apolipoproteins, membrane derived or membrane associated proteins (188). 
Recently LRG has been identified as a possible serum and plasma based biomarker to 
human lung (189,190) and pancreatic cancers (191). LRG has also be been identified as 
being upregulated as part of the acute phase inflammation reaction in hepatocyte cell 
lines (192), and was also amongst a number of proteins up-regulated in the serum of 
hepatocellular carcinoma patients after radiofrequency ablation therapy (193). Whilst 
LRG appears to be linked to a large number of diseases, no real validation processes 
have been performed in large sample sets. Furthermore, the proteins exact function is 
still to be elucidated. 
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A concurrent project performed at Quotient Bioresearch, involving the application of a 
nanoflow LC-MS/MS and SRM based analysis, detected an increase in the plasma LRG 
concentration after the administration of testosterone to the Equine (194). Testosterone 
is a well known anabolic steroid, and rhGH has been shown to have anabolic properties 
(195). Therefore the fact that LRG increased after the administration of both these 
compounds suggests that LRG could be used as a general marker of the abuse of 
anabolic agents.  
 
4.4 SUMMARY 
A comparison of the analysis of tryptically digested proteins using the 4000 QTRAP 
and QTOF instruments demonstrated that the latter was capable of generating data of 
asignificantly superior quality. This increased data quality also included a higher data 
sampling rate, therefore enabling a more representative set of spectra to be generated for 
each analysed sample. The downside of using the QTOF instrument was the immense 
amount of data that were collected, and it was necessary to carry out data reduction 
before the mass spectrum could be submitted for stepwise ANNs analysis. However, the 
reduced data set generated an ANNs model capable of successfully discriminating 
between rhGH and placebo dosed individuals.  
 
The work described in this chapter demonstrated that LC-MS, in combination with 
ANNs have potential as a diagnostic tool for predicting rhGH administration in human 
subjects, with good sensitivity and specificity. The ANNs predictive performance for 
LC-MS data sets demonstrated good discriminatory capabilities for assigning randomly 
selected samples to either a rhGH or a placebo treated state. LC-MS/MS analysis and 
database searching was applied to characterise ions identified by ANNs as 
discriminatory. This process identified a peptide from the serum protein LRG as a 
possible biomarker to rhGH administration. Additional peptides for LRG identified by 
in-silico digestion were also demonstrated to be rhGH dependent. This work is believed 
to be the first successful application of ANNs to LC-MS data for biomarker 
identification purposes, and a co-authored manuscript was published using this and 
MALDI data in Proteomics: Clinical applications (2009).  
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CHAPTER 5. DEVELOPMENT OF A HIGH THROUGHPUT LC-MS/MS 
METHOD FOR QUANTIFYING IGF-I AND LRG, BIOMARKERS OF 
RECOMBINANT HUMAN GROWTH HORMONE ABUSE 
5.1 INTRODUCTION 
The physiological action of GH is translated through the protein insulin-like growth 
factor-I (IGF-I) (53). This protein is a well established biomarker of rhGH abuse, 
however concentrations of IGF-I vary greatly within a given population, especially with 
age, where its concentration drops 35% per decade (63). Therefore measuring this 
protein alone is ineffective for doping control purposes. Furthermore, serum IGF-I 
concentration is used to clinically confirm acromegaly (196), therefore high IGF-I 
concentrations can be indicative of a disease state, not just GH doping. Research into 
detecting rhGH abuse has been a major drive of the WADA, and has lead to the 
identification of the bone growth marker procollagen III N-terminal peptide (PIIINP) 
and insulin-like growth factor binding protein 3 (IGFBP-3) being used as additional 
biomarkers (63). The combination of IGF-I, IGFBP-3 and PIIINP has resulted in a 
possible test for rhGH doping, however the technique uses three separate antibody 
based assays, two of which include the use of radioactive isotopes (179).  
 
The identification of LRG as a putative biomarker to rhGH administration was made 
through the application of LC-MS and ANNs (Chapter 4). The experiment involved the 
use of 42 serum samples from seven individuals, 21 of which were taken after the 
administration of placebo and 21 following the administration of rhGH (168). The 
sample cohort was not sufficiently large enough to conclusively validate the protein as a 
biomarker of rhGH abuse. Therefore a larger, independent sample set would need to be 
sourced for further validation. WADA have financed a total of 19 GH related research 
projects since 2001, which has generated a large number of sample cohorts that could be 
available for validating the LRG protein. Serum samples from one such rhGH 
administration study were available for analysis.  
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5.1.1 Sample cohort from additional rhGH administration study in humans (Performed 
by staff at RFUCL). 
A WADA funded rhGH administration study, performed at Royal Free UCL, included 
15 individuals, eight of whom were dosed with rhGH for 14 consecutive days. The 
remaining individuals were dosed with placebo for 14 days as a control. Three blood 
sampling periods were scheduled, where all 15 individuals performed acute exercise 
bouts prior to taking blood five times spread over a 60 minute period  (Figure 5.1). 
  
 
Figure 5.1. Schematic of rhGH administration to 15 individuals. Five samples were 
collected for each individual at each time point (T1, T2, T3). After week 4, 8 
individuals were dosed daily with 0.1 U of rhGH for 2 weeks, which was the only time 
rhGH was administered to any individual.  
 
The main aim of the rhGH administration study was to identify if acute exercise 
influenced serum concentrations of IGF-I and PIIINP. The results of the study have not 
yet been published, however, data were presented at the meeting of the Physiological 
Society in 2006 at UCL (197). The study showed that both IGF-I and PIIINP increased 
significantly after repeated dosing with rhGH. However, only PIIINP increased 
following exercise (Figure 5.2). 
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Figure 5.2. Concentrations of IGF-I and PIIINP in samples from the rhGH 
administration study performed at Royal Free UCL. Serum concentrations of IGF-I and 
PIIINP increase significantly after 14 days of rhGH administration, but only PIIINP 
appears to increase after exercise. 
 
The second rhGH administration study contained 215 individual serum samples which, 
when combined with the first Royal Free UCL rhGH study, totalled 257 serum samples 
that could be used for strengthening the hypothesis that LRG is a biomarker to rhGH 
administration. The large increase in serum sample numbers from the initial biomarker 
identification experiment (described in Chapter 4), would require a significant increase 
in sample throughput if LRG is to be measured by an LC-MS/MS based assay. 
Furthermore, serum IGF-I concentrations have already been determined in both rhGH 
administration studies, which could be combined with the LRG quantitative data to 
assess whether multiplexed analysis can improve the detection of rhGH administration. 
 
An immunoassay for the quantitation of LRG in serum or plasma has recently been 
developed, which could be used to identify concentrations of LRG in treated and 
placebo states (198). However, tryptic digestion and liquid chromatography-tandem 
mass spectrometry (LC-MS/MS) with selected reaction monitoring (SRM) has 
developed into a technique that has selectivity and sensitivity equivalent to well 
established antibody based techniques (23). Furthermore, the technique has proven to be 
highly multiplexed in nature, enabling multiple proteins to be quantified in a single 
analysis (147).  
 
5.1.2 LC-MS/MS and SRM based analysis of serum IGF-I concentrations  
A recent study by Kirsch et al (156) demonstrated that LC-MS/MS and SRM detection, 
in combination with isotope dilution, can detect tryptic peptides from IGF-I and 
IGFBP3 in a single analysis. However, Kirsch et al spiked serum with both proteins at 
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concentrations significantly higher than physiologically expected. An LC-MS/MS assay 
for IGF-I would need to be highly sensitive due to IGF-I’s low serum concentration of 
approximately 150 to 270 ng/mL (65). Bredehoft et al demonstrated the ability to detect 
endogenous concentrations of IGF-I and two of its synthetic analogues using LC-
MS/MS. However, their extraction method involved a low throughput and expensive 
antibody based enrichment strategy (100). The ACN depletion method (described in 
Chapter 2), in conjunction with nano LC-MS/MS and SRM analysis, demonstrated the 
ability to detect, and therefore quantify, both LRG and IGF-I at endogenous 
concentrations in serum using an inexpensive and high throughput extraction technique. 
Therefore, the development of a high throughput quantitative analysis approach, in 
combination with the ACN depletion method, could enable the analysis of large sample 
cohorts.  
 
Quantitative LC-MS/MS assays for small molecules use internal standards to account 
for extraction efficiency and in-source ion suppression effects (199). These internal 
standards are generally deuterium labelled analogues of the target analyte, which have 
identical chemical properties and nearly identical retention characteristics on RP-HPLC 
based analyses. The application of synthetic tryptic peptides (labelled with 13C and 15N) 
to protein quantitation has demonstrated similar capabilities for ion suppression 
correction for nano LC-MS/MS based quantitative assays (23,147,156). However, these 
studies used LC run times between 30 and 60 minutes, which if applied to the combined 
rhGH sample cohort (257 samples) would take between 5 and 10 days of LC-MS/MS 
time to analyse. Data presented in chapter 3 indicated that samples left in an 
autosampler for a protracted period of time appeared to accumulate autosampler storage 
related modifications. Furthermore, instrument response clearly diminished with time 
using nano flow LC-MS analysis. In order to quantify LRG and IGF-I using an LC-
MS/MS approach, significant reductions in analysis time would be needed, along with 
the addition of stable isotope labelled (SIL) internal standard peptides to correct for 
instrument drift over time. 
 
5.1.3 Ultra-High Performance Liquid Chromatography (uHPLC) 
Developments in liquid chromatography instrumentation and column chemistry have 
lead to the commercialisation of ultra high-pressure capable systems. Waters released 
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the Acquity UPLC™ system in 2004, which was capable of pumping solvents at 
pressures of up to 15,000 psi. This high pressure capability enabled the use of sub 2 μm 
particle sized chromatographic media, increasing the number of theoretical plates, 
which dictates the efficiency of separation for any given column length at a specific 
flow rate. Column separation efficiency can be expressed as the “height equivalent to a 
theoretical plate” (HETP) using the Van Deemter equation (Equation 1)  
EQUATION 1     
 
Where, H = Plate height, A = Eddy / Diffusion term corresponding to the multiple paths 
an analyte can take through the packed column, B = Longitudinal diffusion term which 
equates to analyte band broadening, u = mobile phase linear velocity, C = mass transfer 
term is the speed of which a compound diffuses between the stationary and mobile 
phases. 
 
The key advantage that sub 2 μm particle size columns introduce, is the reduction in the 
A and C term as a result of the reduced diffusion distance of analytes into and out of the 
chromatographic media. The effect of particle size on HETP, and therefore column 
efficiency, can be compared using a Van Deemter plot, where a decrease in particle size 
significantly improves the separation characteristics (Figure 5.3). 
 
 
Figure 5.3. Van Deemter plots for 10, 5, 3.5 and 1.7 μm particle size chromatographic 
media displaying height of theoretical plates as a function of flow rate. Image taken 
from Waters website (www.Waters.com)  
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The use of uHPLC-MS/MS, in combination with sub 2 μm particle size 
chromatographic media, increases efficiency of separation, which is not affected by 
increased flow, and therefore allows faster run times. This has resulted in significant 
increases in throughput for small molecule based analyses (200). If this increase in 
resolution could be translated to peptide analysis, it could significantly reduce analyses 
times, enabling large numbers of samples to be analysed in a fraction of the time taken 
for a typical nanoflow LC-MS analysis.    
 
This chapter describes the development of a high throughput uHPLC-MS/MS 
methodology, and its initial application to the quantitation of Apolipoprotein A1 (APO 
A1) in undepleted human serum as a proof of principle approach. Following this 
successful demonstration, an uHPLC-MS/MS and SRM based analysis technique was 
used in combination with the ACN protein depletion method, to obtain quantitative 
information for both IGF-I and LRG in serum in a single analysis. IGF-I values 
obtained using a uHPLC-MS/MS based assay were compared to the immunoassay 
values from two GH administrations (168) and (201). Quantitative data were also 
submitted to ANNs analysis in an attempt to generate models capable of discriminating 
blinded rhGH treated and placebo samples. 
 
5.2 MATERIALS AND METHODS 
5.2.1 Chemicals 
Norditropin was a gift from Novo Nordisk (Bagsværd, Denmark), and was used for both 
rhGH administrations. Acetonitrile (ACN, LC grade) was purchased from Romil 
(Cambridge, UK), water was produced by an option 4 water purifier (Elga, High 
Wycombe, UK). Dithiothreitol, iodoacetamide, ammonium bicarbonate, and formic acid 
were purchased from Sigma Aldrich (Poole, UK). Acetic acid was purchased from 
BDH, (Poole, UK). The SIL internal standard (IS) peptide analogue of Apolipoprotein 
A1 T7 DYVSQFEGSALGK(13C615N2) was purchased from Sigma Aldrich. Olympus 
serum calibrators (ODR3022) and QC1 (ODC003) were purchased from Olympus 
Diagnostics, Lismeehan, Ireland. The IGF-I T1 tryptic peptide 
GPETLCGAELVDALQFVCGDR(13C615N4) was also purchased from Sigma Aldrich. 
Two LRG IS peptides, ENQL(13C615N)EVLEVSWLHGLK (T7) and 
DGFDISGNPWICDQNL(13C615N)SDLYR (T21) were purchased from Cambridge 
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Research Biochemicals (Billingham, UK). Trypsin gold was purchased from Promega 
(Southampton, UK). 
5.2.2 Development of a high throughput uHPLC-MS/MS analysis method. 
Initial method development used an ACN depleted human serum extract. The extract 
was tryptically digested and analysed using the nano LC-MS/MS and SRM method as 
described in Chapter 2, Section 2.2.6. The same serum extract was injected onto a 
Waters ACQUITY UPLC™ system linked to an Applied Biosystems API 5000 triple 
quadrupole mass spectrometer (Sciex, Ontario, Canada). The column used for the 
analysis was a Waters ACQUITY BEH C18 2.1 x 100 with 1.7 μm sized particles, and 
the flow rate a constant 700 μL/minute. A total of 10 SRM transitions were used for the 
analysis, which corresponded to peptides APOA1, A2, A4, C1, C2, C3, D, F, M and 
serum amyloid A (Table 5.1). A total of four injections were made where the LC 
gradient was changed with each injection following the analysis of the results from the 
previous injection. The four methods are outlined in Table 5.2, which includes the 
Nano-LC method data. 
 
Table 5.1. SRM transitions used to monitor apolipoprotein derived tryptic peptides. 
 
Protein Precursor ion m/z Product ion m/z 
APO A1 700.8 1023.6 
APO A2 1175.6 1221.5 
APO A4 704.4 794.5 
APO C1 516.8 620.3 
APO C2 858.9 1417.7 
APO C3 745.1 1149.7 
APO D 615.8 890.4 
APO F 849.4 972.6 
APO M 754.4 875.9 
SAA 726.6 803.7 
 
Table 5.2. LC method data for the five LC-MS/MS analyses, showing progression from 
a 95 minute nano LC-MS/MS method to a 5 minute uHPLC-MS/MS method. 
 
Nano LC uHPLC Method 1 uHPLC Method 2 uHPLC Method 3 uHPLC Method 4 
Time (%A) Time (%A) Time (%A) Time (%A) Time (%A) 
0 100 0 100 0 100 0 80 0 90 
3 100 8 40 4 40 3 55 3 55 
5 95 10 10 5 10 3.1 10 3.1 10 
60 40 12 10 6 10 4 10 4 10 
70 10 12.1 100 6.1 100 4.1 80 4.1 90 
82.5 10 14 100 8 100 5 80 5 90 
82.6 100         
95 100         
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5.2.3 Application of uHPLC-MS/MS and SRM analysis to quantify APO A1 in human 
serum. 
Five aliquots (2 μL) of five different human serum samples, two aliquots (2 μL) of each 
of the five Olympus APOA1 calibrators, and five aliquots (2 μL) of an Olympus QC 1 
serum sample were each added to 16 μL of 50mM ammonium bicarbonate, pH 8.2, 
containing 10 pmol of the AQUA peptide DYVSQFEGSALGK(13C615N2). Samples 
were vortexed to mix and reduced at 60 °C for 60 minutes after the addition of 2 μL of 
100 mM DTT. Alkylation was performed using 2 μL of a 100mM iodoacetamide 
solution in water at room temperature in the dark for 30 minutes, and left in the light for 
20 minutes to inactivate the remaining reagent. Trypsin digestion was performed by 
adding 3 μL of a 100 μg/ml Trypsin Gold solution and incubating overnight at 37 °C. 
Samples were then centrifuged at 12000x g for 5 minutes and 20 μL was transferred to 
an autosampler vial containing 20 μL of 10% ACN in 0.1% formic acid. The vials were 
vortexed to mix, and 5 μL injected onto the uHPLC system and analysed in duplicate. 
LC method parameters used for analysis were as described in Table 1 (uHPLC method 
4), and SRM transitions specific for APOA1, A2, A4, B100, C1, C2, C3, D, E, F, M, 
albumin, and serum amyloid A were included (Table 5.1). Peak areas were integrated 
using the Analyst 1.4.1 software package (Applied Biosystems/MDS Sciex). 
 
5.2.4 Determination of serum APO A1 concentrations on the clinical analyser 
The AU640 clinical analyser (Olympus Diagnostics, Lismeehan, Ireland) was calibrated 
using the same five point calibrators used for the uHPLC/MS/MS analysis. Four 
replicate analyses were performed for each of the five human serum samples and the 
QC 1 sample and APO A1 concentrations were interpolated from the established 
calibration curve. 
 
5.2.5 RFUCL rhGH administration experiment 1 
Eight male subjects aged 24 ± 5 years, and weight 85 ± 13 kg were randomly assigned 
to either the rhGH or the placebo group.  A daily dose of rhGH (Norditropin PenSet 
24TM) at 0.075 IU/kg, or equivalent volume of PBS, was administered for two weeks by 
subcutaneous abdominal injection.  After a 4-week washout period, the subjects were 
switched between placebo and rhGH groups for another 2-week administration 
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programme.  At the end of each 2-week administration period, subjects undertook an 
exercise test 16-20 hours after the last injection. A catheter was inserted into a forearm 
vein and blood samples were collected before, immediately after and 2.5 hours after 
completion of exercise.  Blood was left to stand at 25 ˚C for 30 minutes, and then 
centrifuged at 1000x g for 10 minutes before collection of serum.  Serum IGF-I 
concentrations were determined using a solid phase, enzyme-labelled chemiluminescent 
immunometric assay (Siemens, Tarrytown, USA).  Informed consent was obtained for 
each individual and procedures were performed according to the Declaration of Helsinki 
II.  Approval for administration of rhGH to humans was also obtained from the Local 
Ethics Committee of the Royal Free Hospital in London. 
 
5.2.6 RFUCL rhGH administration experiment 2 
Fifteen male subjects 27 ± 9 years, of body weight 89 ± 15 kg were selected and 
subjected to a 4-week initial exercise regime. Following the 4-week lead in, a blood 
sample was taken in the fasted state before commencing an exercise bout, and at 15, 30, 
60 and 90 minutes post-exercise. Following the original sampling point, eight subjects 
were randomly assigned for a daily treatment of 0.1 IU/kg of rhGH and the seven 
remaining subjects were administered with a PBS placebo injection. Daily treatment 
with either rhGH or placebo lasted two weeks before the experiment was repeated using 
the same sampling procedure, as described above. Following the second sampling 
sequence, no further drug or placebo administrations were given to the 15 subjects 
before a third sampling sequence was performed after a one-week washout period 
(Figure 5.1). Serum IGF-I concentrations were quantified using a Nichols institute 
IRMA assay (IRMA) (Nichols Institute Diagnostics, CA, USA), after acidified 
extraction with IGF-II displacement. Informed consent was obtained for each individual 
and procedures were performed according to the Declaration of Helsinki II. Approval 
for administration of rhGH to humans was also obtained from the Local Ethics 
Committee of the Royal Free Hospital in London. 
 
5.2.7 Preparation of rhIGF-I standard addition curve, and quality control samples. 
A standard addition curve of IGF-I was prepared by spiking recombinant human IGF-I 
(rhIGF-I; Sigma, Poole, UK) into pooled human serum. A starting concentration of 2 
μg/mL was diluted using the pooled serum to generate calibration standards of 1000, 
 
135 
500, 250, 125, 62.5, 31.25 and 15.625 ng/mL.  Four aliquots of each concentration were 
transferred to 500 μL, 96 well plates (Nunc, UK), and 15 aliquots of the pooled serum 
used to prepare the curve were generated to assess the concentration of endogenous 
IGF-I.  Four independently spiked quality control samples were prepared to measure the 
accuracy and precision of the assay, which included 50, 100, 500 and 1000 ng/mL. Four 
aliquots of each QC concentration were prepared for extraction. 
  
5.2.8 Extraction of serum samples for uHPLC-MS/MS analysis  
Aliquots (30 μL) of calibration standard, QC, and serum from the rhGH administrations 
(totalling 257 serum samples) were transferred to 500 μL 96 well microtitre plates 
(Nunc, UK). A number of samples from the larger rhGH administration experiment 
were analysed in multiple replicates, totalling 319 extractions in the experiment. All 
subsequent transfers of solutions were performed using 8-channel pipettes to minimise 
the introduction of handling errors. Water (60 μL), containing approximately 5 pmol of 
a SIL analogue of IGF-I T1 peptide, and 5 μg/mL of the LRG T7 and T21 labelled 
tryptic peptides, was added to each well and the solutions mixed using a bench-top 
vortex machine. ACN (135 μL) was added and the plate sonicated for 10 minutes 
(Ultrawave Ltd, Cardiff, UK). Samples were mixed by vortexing and the plate sonicated 
for a further 10 minutes before centrifuging at 3500 rpm for 10 minutes to pellet the 
precipitate. Supernatant (125 μL) was transferred to a 250 μL PCR 96 well plate 
(Abgene, Epsom, UK) and evaporated to dryness in a rotary evaporator (Genevac, 
Ipswich, UK). Digestion buffer (18 μL), consisting of eight parts of 50 mM ammonium 
bicarbonate and one part 100 mM DTT, was added to each well and the solution 
vortexed to reconstitute the dried extract. The plate was incubated at 60°C for 60 
minutes and left to stand to reach room temperature before addition of 2 μL of 100 mM 
iodoacetamide. Samples were incubated in the dark for 30 minutes before exposure to 
light. Trypsin (3 μL), at a concentration of 100 μg/mL in 50 mM acetic acid, was added 
to each well and digestion performed overnight at 37°C. Formic acid, 1% (v/v) (3 μl), 
was added to each well to quench the digestion reaction and 10 μL of sample transferred 
to a clean 96 well plate containing 10 μL of 1% formic acid (v/v). 
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5.2.9 uHPLC-MS/MS analysis for IGF-I and LRG. 
The 96 well plates were loaded onto the autosampler of an Acquity UPLC™ system 
(Waters, Manchester, UK), which was at a temperature of 5°C. Solvents used for the 
analysis were 0.1% formic acid in water (A) and 0.1% formic acid in ACN (B). The 
column used for the analysis was an Acquity BEH 300 A C18 1.7 μm 2.1 x 100 mm 
peptide separation column (Waters). Sample (10 μL) was injected onto the column with 
the mobile phase at 10% B at a flow rate of 700 μL/minute. A gradient elution of 
peptides was performed over three minutes, with B rising from 10 to 45%. The column 
was then washed using 90% B for one minute, before returning to initial conditions for 
one minute (totaling a 5-minute analysis). The LC system was interfaced with an 
API4000 triple quadrupole mass spectrometer (Applied Biosystems/Sciex, Concord, 
ON, Canada). Electrospray was performed using a Turboionspray™ source set at a 
temperature of 600ºC, a voltage of 5.5 kV and gasses one and two both set at 60 PSI. 
Table 5.3 contains the six transitions used to monitor the endogenous protein tryptic 
peptides and their IS peptides. All samples were ACN extracted, digested and analysed 
by uHPLC-MS/MS within a seven day period.  
 
Table 5.3. SRM transitions and dwell time parameters used for monitoring the two LRG 
and IGF-I tryptically derived peptides, and their labelled analogues. Precursor and 
product ion m/z values were obtained from their instrument-derived values, not 
theoretical values. 
 
Peptide Sequence Precursor 
Ion m/z 
Product
Ion m/z 
y or b 
ion No. 
Charge 
state 
Dwell 
(ms) 
LRG T7 ENQLEVLEVSWLHGLK 947.5 1181.8 y10 2 50 
LRG T7 IS ENQLEVLEVSWLHGLK 951.5 1181.8 y10 2 50 
LRG T21 DGFDISGNPWICDQNLSDLYR 1243.7 1680.0 y13 2 50 
LRG T21IS DGFDISGNPWICDQNLSDLYR 1246.8 1686.8 y13 2 50 
IGF-I T1 GPETLCGAELVDALQFVCGDR 769.7 881.4 y7 3 200 
IGF-T1 IS GPETLCGAELVDALQFVCGDR 773.0 891.4 y7 3 200 
 
5.2.10 ANNs analysis of LRG and IGF-I quantitative data 
The LRG peptide peak area ratios and the IGF-I concentration in ng/mL were submitted 
to ANNs analysis software (Statistica 7.0, StatSoft inc. Tulsa, USA) for the purpose of 
sample stratification. Every fifth sample (63 in total) was removed to generate a 
validation data set to test the models that were generated from the remaining 256 
samples. Three ANNs models were generated using LRG, IGF-I and both LRG and 
IGF-I data in order to compare the differences in their predictive capabilities. ANNs 
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analysis of the three data sets was performed using a multilayer perceptron with two 
hidden layers, a learning rate of 0.1 and momentum of 0.5. Sample data were randomly 
selected into three subsets: training (60%), test (20%) and validation (20%), and trained 
using random sample cross validation a total of 50 times. For predictive purposes, a 
value of 1 was assigned to placebo treated individuals whilst was rhGH treatment was 
designated as 2. For each cycle, the ANNs model generated an output value (either 1 or 
2) for each sample in the blinded test set. These predictive values were averaged over 
the 50 random sampling events and the value compared with the expected output. This 
enabled the accuracy, sensitivity and specificity of the model to be determined and also 
allowed the generation of ROC curves and AUC values. The trained ANN models were 
then used to classify each of the 63 samples in the validation data set as either placebo 
or rhGH treated. 
 
5.2.11 Quantitative analysis of LRG and IGF-I in murine rrGH gene therapy samples. 
Following the identification of LRG as the source of the m/z 741.2 ion in the ANNs 
analysis of human serum (Section 4.3.5), an attempt was made to determine if the 
concentrations of the equivalent protein in murine serum were GH related. The murine 
variant was identified in an LC-MS/MS analysis in Chapter 3 (Table 3.3), which 
included two tryptic peptides LEDSLLAPQPFLR and LQALSPELLAPVPR. The latter 
peptide was identified as the T4 tryptic peptide with a [M+2H]2+ species, giving an m/z 
value of 752.49, which was one of the ions identified by stepwise ANNs as important 
for discriminating between GH +ve plasmid and PBS control samples in Batch 1 (Table 
3.5). A SRM transition for the murine LRG T4 peptide was identified to quantify 
murine LRG in ACN depleted serum. In addition, a SRM transition for the murine IGF-
I T1 fragment was also identified. Samples from the gene therapy administration 
experiments, with over 20 μL volume remaining, were selected for extraction in 
combination with the SIL human IGF-I T1 AQUA peptide. The extracts were analysed 
using the same uHPLC method but with different SRM transitions (Table 5.4). In total, 
21 GH +ve plasmid samples, 16 GH -ve plasmid samples and 11 PBS samples had 
sufficient volume for extraction using the ACN depletion method (20 μL). 
Unfortunately no samples from Batch 1 were available for the IGF-I and LRG 
quantitative analysis. 
 
 
138 
 
Table 5.4. uHPLC-MS/MS method SRM transitions for the analysis of ACN depleted 
mouse serum from the gene therapy administration samples. The bold and underlined 
amino acid is stable isotopically labelled. The difference between the murine and human 
IGF-I T1 fragment (D to P) is also highlighted as red text. 
 
Peptide  Sequence Precursor Ion m/z 
Product 
Ion m/z 
IGF-I T1 Human  GPETLCGAELVDALQFVCGDR 769.7  881.4  
IGF-I T1 Human IS  GPETLCGAELVDALQFVCGDR 773.0  891.4  
IGF-I T1 Mouse  GPETLCGAELVDALQFVCGPR 763.7  863.4  
LRG T4 Mouse  LQALSPELLAPVPR 752.4  991.6  
 
5.3 RESULTS AND DISCUSSIONS 
5.3.1 Method transfer from nanoflow to uHPLC. 
The digested ACN depleted human serum extract was injected onto the nano LC-
MS/MS system and the SRM traces of 9 apolipoproteins and serum amyloid A (SAA) 
combined into a single chromatogram (Figure 5.4A). Equivalent chromatograms from 
the 95 minute nanoflow and 5 minute uHPLC analyses are displayed in Figures 5.4 A 
and B respectively. 
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Figure 5.4. Transfer of LC-MS/MS assay for 9 apolipoproteins and SAA from a 
nanoflow to an uHPLC system. A = 95 minute nanoflow analysis, B= uHPLC 5 
minutes. 
 
The transfer from a 95-minute nanoflow SRM analysis to a 5-minute uHPLC method 
was successfully performed, and demonstrated an approximate 20-fold reduction in run 
time, with no adverse effect on peptide peak separations. These data were published as a 
Waters application note (2008). The sensitivity of the high flow rate method was 
assessed and appeared to be between 10- and 20-fold lower than the nanoflow method. 
This loss in sensitivity was expected as the flow rate was increased from 300 nL/minute 
to 700 μL/minute – an increase of approximately 2000-fold. A peptide eluting in 60 
seconds at 300 nL/minute would be present in 300 nL, conversely a peptide eluting in 
six seconds at 700 μL/min would be present in 70 μL, a 200-fold increase in volume. 
MS signal in electrospray is based on analyte concentration in the source, therefore a 
10-fold drop in sensitivity is entirely acceptable for a 200-fold decrease in analyte 
concentration, and a 10-fold decrease in peak width. 
 
5.3.2 Quantitation of APO A1 in serum and comparison to clinical analyser. 
The APO A1 quantitation experiment involved a total of 80 injections onto the Acquity 
LC system within seven hours, demonstrating high throughput analyses. The analysis 
involved duplicate injections of each sample (two replicate digestions of each calibrator 
standard, five replicates of each serum sample). A standard curve of APO A1 was 
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performed by generating a ratio of endogenous peptide to the SIL peptide in each of the 
calibrator samples (Figure 5.5).  
 
Figure 5.5. APO A1 standard curve from uHPLC-MS/MS derived peak area data.  
 
The equation of the calibration line was used to quantify the concentration of APOA1 in 
the five human serum samples and the QC1 material, and these were compared with the 
values obtained from the clinical analyser (Figure 5.6). 
 
 
Figure 5.6. Concentration of APO A1 in the five serum samples and the QC1 standard. 
The calculated APO A1 serum concentrations using the two methods show very similar 
concentrations, indicating the methods are highly comparable (R2 of 0.97). 
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The analysis of serum APO A1 concentrations by both uHPLC-MS/MS and clinical 
analyser shows the application of uHPLC-MS/MS to serum protein quantitation is 
entirely appropriate.    
 
5.3.3 Development of an uHPLC-MS/MS method for IGF-I and LRG tryptic peptides. 
A method was developed that was capable of detecting IGF-I and LRG derived tryptic 
peptides, and their SIL analogues (Figure 5.7). All six peptides show good peak shape 
using a five-minute analysis, and only the SRM trace for the endogenous IGF-I peptide 
shows another significant but chromatographically resolved peak. The signal to noise 
ratio for the IGF-I T1 peptide was calculated as 14.2, which was sufficient for 
quantitative analyses. The percentage amino acid coverage of IGF-I and LRG using the 
selected peptides was calculated as 30 and 12%. In the case of the larger LRG protein, 
peptides were selected from both the N and C terminal ends, selecting peptides from 
both ends of the LRG protein would aid confirmation that the whole protein was 
influenced by rhGH administration, rather than a possible protein cleavage product. 
Confirmation that the correct peptides were being detected was performed using full 
scan product ion analysis of the peptide parent ions, with subsequent protein database 
searching. The result of the database search identified the IGF-I T1 peptide with a 
mascot score (p<0.05) of 90, and the LRG T7 and T21 peptides with scores of 69 and 
76 respectively. Further confirmation of the specificity of the uHPLCMS/MS method 
was obtained through the demonstration of an exact retention time match with the SIL 
peptide analogues for each endogenous peptide (Figure 5.7). The retention time of the 
six peptides over the 382 total analyses was assessed, and results ranged from a CV 
value of 0.029% for the IGF-I T1 IS peptide with the most variation of 0.189% for the 
LRG T7 IS peptide, which demonstrates the excellent robustness of the Waters Acquity 
UPLC™ system. 
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Figure 5.7. Extracted SRM chromatograms from the five-minute uHPLC-MS/MS 
analysis used to monitor LRG and IGF-I peptides. The upper and lower traces 
correspond to the endogenous and SIL peptides respectively.  
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5.3.4 Generation of an IGF-I standard addition curve in human serum. 
ACN depleted serum extracts were tryptically digested and analysed by uHPLC-
MS/MS and the LRG and IGF-I peptides successfully separated using a 5-minute 
analysis (Figure 5.7). Following uHPLC-MS/MS analysis, peptide peak areas were 
calculated using the AnalystTM classic quantitation package (Applied 
Biosystems/Sciex). The peak area of the IGF-I T1 peptide was expressed as a ratio to its 
IS peptide, and the average of the four replicates used to generate a calibration curve 
(Figure 5.8).  
 
Figure 5.8. Standard addition curve of IGF-I spiked into human serum, showing total 
IGF-I concentration. Data includes single injections from four replicate extractions, and 
%CV for each concentration is displayed in the adjoining table. 
 
 
The equation of the line was used to identify the x-axis intercept, which corresponds to 
the endogenous IGF-I concentration of the serum (125 ng/mL). This value was then 
added to the spiked concentration values in each of the calibration samples and QC’s. 
The standard addition calibration line demonstrated a linear fit from 15.6 ng/mL to 2000 
ng/mL with an R2 value of 0.9991, and an average %CV of the calibration standards of 
11%. The average %RE of the back-calculated IGF-I concentrations of the calibration 
standards was 6%. This indicates the highly reproducible nature of the ACN depletion 
technique and its applicability to serum protein quantitation. To assess the precision and 
accuracy of the technique, independently spiked QC samples were extracted and 
analysed. The equation of the standard addition line was used to back-calculate the 
concentration of IGF-I in the QC samples. The values assigned to the QC samples 
IGF-I conc 
(ng/mL) 
% CV 
15.625 10.8 
31.25 7.8 
62.5 12.5 
125 10.3 
250 5.7 
500 5.3 
1000 5.5 
2000 2.4 
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indicate the assay has good precision and accuracy (Table 5.5), with 13 of the 16 QC 
samples being within 20% of expected values. Furthermore, the back calculated 
concentration of the 15 extracted blanks was 131 ng/mL with a %CV of 17. This value 
demonstrates a %RE of 5 when compared with the x-axis intercept derived value of 125 
ng/mL for the pooled serum IGF-I concentration. 
 
Table 5.5. Values attributed to the QC samples (+ endogenous IGF-I concentration) 
using the extracted calibration curve and the equation of the standard addition line. Data 
in brackets shows the %RE from the expected value. 13 of the 16 QC samples are 
within 20% of their expected value. 
 
IGF-I concentration  
(ng/mL) 
Calculated IGF-I concentration  
(ng/mL) and %RE 
QC concentration + endogenous 1 2 3 4 
50 175 112 (-36) 186 (6) 252 (44) 167 (-4) 
100 225 234 (4) 169 (-25) 201 (-11) 202 (-10) 
500 625 661 (6) 534 (-15) 568 (-9) 560 (-10) 
1000 1125 1064 (-5) 1172 (4) 914 (-19) 933 (-17) 
 
5.3.5 Quantitation of IGF-I in the serum from the two rhGH administrations. 
 To assess the assay performance against an immunoassay technique, the concentration 
of IGF-I in the serum samples from the two administrations was calculated using the 
equation of the line from the standard addition curve. The uHPLC-MS/MS derived IGF-
I concentrations of the 257 serum samples was compared with their immunoassay 
derived values (Figure 5.9). Data in this graph included an extra 62 replicate extractions 
and analyses of serum samples from the second rhGH administration, totalling 319 
uHPLC-MS/MS measurements.  
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Figure 5.9. Correlation of uHPLC-MS/MS and immunoassay derived IGF-I 
concentrations (ng/mL) for the serum samples from both rhGH administrations. The R2 
values obtained for the first (0.6039) and second (0.7688) experiments indicate the two 
techniques give similar values, despite using significantly different approaches to 
protein quantitation. Data displayed is from 319 total uHPLC-MS/MS analyses, from a 
set of 257 serum samples. 
 
This comparison demonstrates that the mass spectrometric assay gives similar IGF-I 
values to established immunoassay techniques, with R2 values of 0.6039 and 0.7688 for 
the first and second administrations respectively. The IGF-I values from the first rhGH 
administration demonstrates a lower correlation than the second, possibly due to the fact 
that the two rhGH studies used different immunoassays to quantify IGF-I 
concentrations. The different immunoassays used to quantify serum IGF-I 
concentrations could explain the difference in the slope of the gradients for the 
correlation lines (0.29 and 0.68 for administration 1 and 2 respectively). A possible 
explanation for this difference could be due to the antibodies used within each kit giving 
different responses for similar IGF-I concentrations. The main discrepancies between 
the two administrations appear to be the levels of IGF-I in the treated groups, where the 
first administration values range from 600 to 1000, whilst the second administration 
values ranged from 310 to 680 ng/mL. Discrepancies between different IGF-I 
immunoassay kits have been demonstrated previously, where levels of IGF-I in two 
different matrices generated significantly different results (180). In the study by Krebs 
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et al, values of IGF-I in a pooled serum sample ranged from 277 to 390 ng/mL, whilst 
levels in lyophilised serum were 150 to 344 ng/mL. In this project, the uHPLC-MS/MS 
derived serum IGF-I levels in the rhGH treated individuals demonstrated better overlap 
between administrations 1 and 2 (160 to 675 ng/mL), than the immunoassay values. 
 
In order to confirm previous findings on the effect of rhGH administration on an 
individuals serum IGF-I concentrations, the mean uHPLC-MS/MS derived IGF-I 
concentration on a given day was calculated for all 21 subjects (Figure 5.10). This 
showed a significant increase in the concentration of IGF-I for all of the subjects 
administered with rhGH for 14 days, in both experiments. The second administration 
included a third sampling event, a week after the cessation of rhGH dosing, which 
shows that IGF-I concentrations return to pre-dose levels within a seven day period.  
 
Figure 5.10. Mean IGF-I concentrations in ng/mL for each individual on a given 
sampling day. The first administration involved only two sampling periods – after rhGH 
treatment and placebo. The second administration included a third sampling point, 7 
days after cessation of dosing. Red bars indicate sampling after 14 days of rhGH in both 
administrations. The six subjects on the right were not dosed with rhGH at any point. 
Error bars indicate one standard deviation (n=3 for admin 1, n=5 for admin 2). 
 
The significant rise in IGF-I concentrations from the rhGH dosing suggests that the use 
of the protein for detecting rhGH abuse is a compelling one, as dosing with rhGH for 14 
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days significantly increases IGF-I serum concentrations within any given individual. 
However, it must be noted that subject 2 whom was dosed with placebo in the second 
administration had endogenous IGF-I concentrations similar to subjects that were 
administered with rhGH. This suggests that using a serum IGF-I concentration threshold 
to determine an rhGH doping event is not feasible as a stand-alone test, due to the wide 
serum IGF-I concentration range within the population. 
 
5.3.6 Concentrations of LRG in the serum from the two rhGH administrations. 
The impact of rhGH dosing on LRG concentrations was assessed. The concentration of 
the protein was identified by comparison of endogenous peptide peak area to a known 
concentration of the SIL peptide. The serum LRG concentration values were treated in 
the same fashion as the IGF-I peptide data and are displayed in Figure 5.11.  
 
Figure 5.11. Mean values of the product of the LRG peptide peak area ratios for each 
individual on a given sampling day. Data are arranged in a similar fashion to Figure 
5.10. Red bars indicate sampling after 14 days of rhGH in both administrations. 
 
The serum concentrations of LRG appears to follow a similar pattern to IGF-I, with 14 
of the 15 treated individuals displaying a higher LRG concentration after rhGH 
administration. The relative increase of LRG related to the administration of rhGH was 
lower than that seen with IGF-I. Further, the serum concentrations of LRG appear 
relatively consistent within the 21 individuals. This suggests that the measurement of 
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LRG alone will not be sufficient to detect rhGH doping, and that a longitudinal testing 
approach might be more appropriate, where an individual’s basal LRG concentration is 
assigned. An increase in the serum LRG concentration over a specified threshold could 
then indicate rhGH abuse. The level of IGF-I would also need to increase to rule out any 
false positives. Before LRG can be used for anti-doping purposes, further validation 
would be required, such as monitoring its serum concentration at regular time points 
both prior to, and post, rhGH administration. This would enable the identification of its 
pharmacodynamic properties related to rhGH exposure.  
5.3.7 Combination of LRG and IGF-I data for discriminatory purposes. 
The product of the combined LRG peptide peak area and the IGF-I concentration 
(ng/mL) was generated for each individual for both the rhGH treated and placebo states. 
The value obtained for the treated state was then expressed as a % increase from the 
placebo state. This transformation was performed for both the combined LRG and IGF-I 
data, and for the IGF-I data alone. The comparison of the two datasets indicates that for 
14 of the 15 individuals treated with rhGH, the combination of LRG and IGF-I 
increased the separation of placebo and treated states (Figure 5.12) 
 
Figure 5.12. Values of rhGH treated states for each individual expressed as a % increase 
from the placebo state. White and black bars indicate uHPLC-MS/MS derived data for 
IGF-I and LRG only, with the red bars indicating combined data from the LRG and 
IGF-I data. 
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Following rhGH administration, the concentrations of IGF-I increased in all subjects 
(45 to 470% increase over placebo), and LRG increased in 14 of the 15 subjects (9 to 
140% increase over placebo). Summing the percentage values of the two proteins 
demonstrates that the combination of the two biomarkers increased the separation of the 
treated and placebo states over a single marker (120 to 580% increase over placebo). 
Four of the six individuals that only received placebo injections demonstrated small 
increases in IGF-I concentrations, however only one demonstrated marginally increased 
LRG concentrations. These increases are likely to be due to natural variations in the 
serum concentrations of the two proteins over the two-week period between sampling. 
However, combining the LRG and IGF-I values reduced the apparent increase in IGF-I 
in three of the four individuals. 
 
 
 
5.3.8 ANNs analysis of LRG and IGF-I values from both administrations. 
Previous work has shown that the combination of IGF-I, PIIINP and IGFBP-3 increased 
the ability to detect rhGH abuse (179). ANNs have been used to generate multivariate 
models capable of stratifying disease and healthy states. Therefore, the technique was 
applied to the uHPLC-MS/MS acquired LRG and IGF-I data in an attempt to generate 
models capable of discriminating doped and placebo samples. Three ANNs models 
were trained using LRG, IGF-I and a combination of LRG and IGF-I data (Figures 5.13 
A-C). These trained models were then used to classify the samples in the validation data 
sets as either rhGH or placebo treated (Figures 5.13 D-F).  
   
Figure 5.13A.     Figure 5.13B 
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Figure 5.13C     Figure 5.13D 
 
Figure 5.13E     Figure 5.13F 
Figure 5.13. ROC curves for the models generated during the ANNs analysis of the 
SRM generated protein quantitation data. A = training model for IGF-I only, B = 
training model for LRG only, C = training model for combined IGF-I and LRG data. D 
= ROC curve from analysing the validation set for IGF-I only, E = ROC curve from 
analysing the validation set for LRG only, F = ROC curve from analysing the validation 
set for both proteins. Each plot includes AUC, accuracy, specificity and sensitivity 
values. 
 
A comparison of the model training performances (Figures 5.13 A, B and C) shows that 
the addition of LRG to IGF-I improved the predictive capability over both IGF-I and 
LRG alone. The application of the three models to the validation data set shows that 
using LRG alone was not capable of discriminating between rhGH treated and placebo 
individuals (Figures 5.13 A and C). The IGF-I model demonstrated significantly better 
discrimination (B and E) with the validation set resulting in 100% Specificity and 92% 
sensitivity. However, the LRG and IGF-I model demonstrated the best overall 
predictive capabilities (C and F). The addition of LRG data to the IGF-I model 
improved the accuracy from 94 to 97%, and resulted in 100% of the rhGH treated 
samples being identified correctly (100% Sensitivity). This showed a 3% increase in 
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accuracy, a 4% drop in specificity, and an 8% increase in Sensitivity. Combining the 
two proteins increased the overall accuracy and the identification of true positives, but 
increased the false positive rate.  
 
The product of the LRG and IGF-I peptide peak areas was generated for each sample 
and the mean values calculated for each individual on a given day. The same 
transformation was performed for the IGF-I values and the values obtained in the rhGH 
treated state expressed as a percent increase from the placebo state. The combination of 
LRG and IGF-I increased the separation of the treated and placebo states for 14 of the 
15 individuals treated with rhGH compared with using IGF-I on its own. These two 
approaches have demonstrated that the addition of LRG protein to IGF-I values 
increased the ability to discriminate treated and placebo individuals. 
 
5.3.9 Quantitative analysis of IGF-I and LRG in murine gene therapy samples. 
The application of the ACN depletion method to the detection of LRG and IGF-I tryptic 
peptide was successful. The SRM analysis included transitions specific for both human 
and murine IGF-I T1 peptide variants. The peptides differ by a single amino acid, the 
human variant being GPETLCGAELVDALQFVCGDR, and the murine 
GPETLCGAELVDALQFVCGPR. The application of an SRM based detection 
technique was able to detect this difference (Figure 5.14). 
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Figure 5.14. Example LC-MS/MS SRM trace from an ACN depleted serum digest. The 
left traces show the murine IGF-I T1 peptide eluting at the same time as the human 
IGF-I T1 aqua peptide (2.41 minutes). The top right trace is specific for the unlabelled 
human IGF-I T1 peptide and shows no significant peak at T=2.41 minutes. The bottom 
right trace shows the peptide peak for the T4 peptide of murine LRG. 
  
The uHPLC-MS/MS analysis of the available gene therapy samples generated relative 
concentrations of both LRG and IGF-I. Identification of absolute concentrations of 
these proteins was not possible because the intact proteins were not sourced to generate 
standard curves for analysis. The IGF-I peak area ratio for each of the samples is 
displayed in Figure 5.15, and shows that the concentration of murine IGF-I did not 
appear to be increased following administration of the GH +ve plasmid, which would be 
expected if GH was being expressed. Figure 5.16 displays the average values for each 
group, and shows that there was no detectable increase in IGF-I in the GH+ plasmid 
samples. 
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Figure 5.15. Upper graph shows murine IGF-I T1 peptide peak areas expressed as a 
ratio to the AQUA peptide. Red bars are GH +ve plasmid samples, green bars are GH –
ve plasmid samples and the blue bars the PBS control samples. Lower graph shows 
mean peak areas of IGF-I in the GH +ve, GH –ve and PBS control samples. Error bars 
indicate one standard deviation. 
 
Serum concentrations of LRG were assessed using the peak area of the T4 peptide, as 
identified in the SRM trace in Figure 5.14. Relative concentrations of LRG in each 
sample are displayed in Figure 5.15 and the mean values for each group in Figure 5.16. 
The relative concentrations of LRG did not appear to increase in the GH +ve plasmid 
treated group, matching the results seen with the IGF-I concentrations in the same 
samples (Figure 5.15). 
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Figure 5.16. Upper graph displays LRG T4 tryptic peptide peak areas in the murine 
gene therapy samples. Red bars are GH +ve plasmid samples, green bars are GH –ve 
plasmid samples and the blue bars the PBS control samples. The lower graph shows 
mean peak areas of LRG in the GH +ve, GH –ve and PBS control samples. Error bars 
indicate one standard deviation. 
 
The analysis of the original Batch of GH gene therapy samples (Section 3.2.5) was 
revisited and the LC-MS full scan data interrogated to identify peak areas of the LRG 
T4 peptide, and therefore identify relative concentrations of the LRG protein (Figure 
5.17). The re-analysis of the LC-MS data from samples in Batch 1 suggests that the 
concentrations of LRG in the GH +ve plasmid treated mice were elevated relative to the 
other two groups. This finding, along with the mice weight gain data and the 
development of an ANN model capable of discriminating between GH +ve and PBS 
control, suggests that the initial preparation of gene therapy plasmid worked. The data 
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from the subsequent Batches (2-5) were generated from animals dosed with a new 
preparation of plasmid, the activity of the second plasmid could be questionable with 
regards to the ability to produce GH in the host animals.  
 
 
Figure 5.17. Mean peak areas for LRG peptide from the first GH gene therapy Batch. 
Error bars indicate one standard deviation. 
 
5.4 SUMMARY 
A high throughput (5-minute) LC-MS/MS analysis method for quantifying proteins in 
undepleted and ACN depleted serum was developed. This high throughput technique 
was used to quantify APO A1 in human serum and demonstrated very high correlation 
to concentrations identified using an established antibody based clinical analyser 
system. 
 
The ACN depletion method has been shown to reproducibly enrich serum for a number 
of low molecular weight proteins prior to nano LC-MS/MS analysis (Chapter 2). It was 
then successfully applied to identify LRG as a putative biomarker to rhGH abuse in 
humans (Chapter 4). This project has also demonstrated that ACN depletion, in 
combination with tryptic digestion and uHPLC-MS/MS with SRM detection, is ideally 
suited for the analysis of serum proteins in large sample cohorts. During this project, a 
total of 382 serum extracts were analysed, which included standard curve samples, 
QC’s, and 257 individual serum samples (including 62 repeats) from two rhGH 
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administrations. The %CV of the raw peak areas of the LRG T7, T21 and IGF-I T1 
internal standard peptides in the 382 analyses were calculated as 40.7, 50.8 and 36.3% 
respectively. This demonstrates the high reproducibility of the extraction method, the 
Waters Acquity injection system, and the triple quadrupole MS/MS system over a 
number of days. The absolute quantitation of IGF-I, a medium abundance and clinically 
important protein, in 319 serum samples has proved this approach to be highly robust. 
Furthermore, the comparison of the IGF-I concentrations derived using uHPLC-MS/MS 
was comparable with the immunochemistry-based values obtained in previous studies 
performed on the same serum samples. It would appear that this is the first report of a 
truly high throughput and absolute quantitative analysis of a medium abundance serum 
protein in a large sample cohort using uHPLC-MS/MS. 
 
ANNs analysis of the quantitative data for both LRG and IGF-I generated a model with 
a higher predictive capability than using IGF-I alone. This technique has been 
successfully applied to serum proteomic data, and was capable of discriminating 
individuals with metastatic melanoma from healthy individuals (166). The technique 
was also used to identify LRG as a putative biomarker to rhGH administration (Chapter 
4). The inclusion of other biomarkers, such as PIIINP and IGFBP-3, could further 
increase the models discriminatory power. The application of uHPLC-MS/MS to the 
detection of rhGH abuse has demonstrated that the measurement of multiple markers in 
a single assay improved the discrimination of placebo and treated states. The use of 
LRG as a biomarker to rhGH abuse will require more extensive validation, such as 
monitoring its levels pre- and post-administration in a more controlled experiment.  
 
The application of the ACN depletion and uHPLC-MS/MS to the murine rrGH 
administration samples showed that there was no detectable increase in concentrations 
of both IGF-I and LRG. If rrGH was being expressed by mice dosed with the +ve 
plasmid, and if the protein secreted into the circulatory system, the serum IGF-I 
concentration should have increased. The serum samples that were available for the 
uHPLC-MS/MS analysis were all generated from the second Batch of gene therapy 
plasmid, and this therefore adds weight to the hypothesis raised in Chapter 3 that the 
second preparation of rrGH plasmid was ineffective. Unfortunately samples from the 
first Batch of gene therapy samples were unavailable to confirm or disprove this 
hypothesis.  
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Recent work carried out at Quotient Bioresearch assessed the post-administration serum 
concentrations of LRG in the equine following daily dosing with rhGH over a number 
of days. This experiment showed that serum LRG concentrations demonstrated a 
sustained increase with rhGH administration, although levels dropped with continued 
administration, whilst the IGF-I levels remained high (202). This pharmacodynamic 
pattern might be similar in humans, but will need to be assessed. 
 
The uHPLC-MS/MS assay for IGF-I and LRG described in this Chapter could either be 
used in combination with the immunoassays for IGFBP-3 and PIIINP, or as a single 
multiplexed uHPLC-MS/MS assay for all four biomarker proteins. The analysis of all 
four proteins in a single analysis, combined with ANNs analysis could improve the 
sensitivity and specificity of the existing biomarker assay, and aid in the detection of 
rhGH abuse in athletes. 
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6. CONCLUSIONS 
The application of proteomics and bioinformatics technologies to the identification, and 
characterisation of protein biomarkers to the administration of recombinant human 
growth hormone has been demonstrated in this thesis. The same approach was applied 
to detect biomarkers to growth hormone gene therapy in a murine model, however this 
proved inconclusive. An ACN based extraction method was developed that was capable 
of removing high abundant proteins from both murine and human serum. The 
concentration of protein in the human serum extracts was identified using the Bradford 
assay, and showed that 99.6% of total protein content was removed, with a coefficient 
of variation of 15%. The protein content of the same extracts was also characterised 
using SDS-PAGE, and demonstrated that the ACN extraction method depleted all 
proteins over 75 kDa, whilst enriching for the low molecular serum protein fraction. 
ACN depleted human serum was then characterised using both HPLC-MS/MS (SRM) 
and HPLC-MS/MS (IDA) approaches. The SRM analysis enabled the quantitative 
determination of specific serum proteins within the extracts, and demonstrated that the 
low molecular weight fraction was rich in apolipoproteins. The application of SRM 
analysis also demonstrated the ability to detect IGF-I, a well-characterised biomarker to 
rhGH administration, at endogenous concentrations. The IDA based 2D LC-MS/MS 
analysis of a serum extract resulted in the identification of 85 proteins, 78 of which 
were present on a validated list of plasma proteins. The protein list included another GH 
related biomarker, IGF-II, and a tissue leakage protein, actin, which demonstrated the 
method did not only enrich for apolipoproteins.   
 
The ACN depletion method was used to extract samples from a GH gene therapy study 
that was performed at the Royal Free Hospital (UCL). The study involved three groups 
of 50 mice dosed with plasmid containing an active rrGH gene, a plasmid with an 
inactive rrGH gene or PBS only as a control. Sample extracts were tryptically digested 
and analysed on an Dionex Ultimate 3000 nano flow LC system linked to an Applied 
Biosystems 4000 QTRAP MS instrument. Peptide content was assessed by collecting 
full scan spectra from m/z 400–1600, and summing all the spectra obtained from the 
peptide elution period of each LC-MS file. Three dimensional MS data (m/z, intensity 
and time) were transformed into two dimensional data (m/z, and intensity) using the 
conditional summing tool in Excel. The transformed data were submitted to stepwise 
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ANNs analysis at Nottingham Trent University in order to identify peptide marker ions 
that could discriminate between the three populations. An initial Batch of gene therapy 
samples (~10 samples of each population), showed promising results, where the ANNs 
model demonstrated 100% accuracy for the discrimination of the animals treated with 
PBS and +ve plasmid. The ANNs model for +ve plasmid versus –ve plasmid group 
demonstrated 80% predictive accuracy but the model for the –ve plasmid versus PBS 
groups failed to discriminate between the two groups. When the entire cohort of gene 
therapy samples were analysed (totalling 133 mice), the early good results were not 
repeatable. The larger sample cohort resulted in ANNs models with a maximum 
predictive accuracy of 63%, 73%, and 72% for the +ve plasmid Vs PBS, -ve plasmid Vs 
+ve plasmid and –ve plasmid Vs PBS respectively. Investigations into the failure to 
generate a suitable ANNs model for the large sample cohort were performed, and 
involved analysing a serum extract over a number of days using the full scan LC-MS 
approach. The results from the analyses were compared using PCA analysis and 
demonstrated the ability to separate the same sample analysed on different days into 
distinct groups. This was believed to be due to the difference in instrument response 
over the separate analyses. Further investigation showed that the peptide extracts were 
accumulating modifications within the autosampler, in particular oxidations. This 
analysis suggested that analysing large datasets over a number of days required some 
form of normalisation, possibly through the use of an internal standard, or QC samples 
analysed throughout the analyses.   
 
The same experimental approach to biomarker identification was applied to serum 
samples obtained from a WADA rhGH administration study performed at Royal Free 
Hospital. The study involved collecting serum from eight individuals dosed with rhGH, 
and also placebo, in a cross-over study design. Individuals were dosed daily with 
placebo or rhGH for two weeks, with a four week washout before switching treatment. 
The ACN depleted serum extracts were analysed at the University of Cambridge Centre 
for Proteomics using a Waters Nano-acquity LC system and a QTOF Premier MS 
system. The QTOF Premier MS system demonstrated superior duty cycle times and data 
quality compared to the 4000 QTRAP that was used for the murine serum sample 
analysis. A total of 42 samples were analysed in a over approximately three days, to 
reduce the influence of instrument drift. Data from the LC-MS analysis of the human 
serum extracts were transformed into two dimensional data and submitted to stepwise 
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ANNs analysis to identify a subset of ions that could be used to discriminate between 
the rhGH and placebo individuals. A six ion ANNs model was generated that 
demonstrated an overall predictive accuracy of 93%. A total of ten stepwise processes 
were performed, with the tenth cycle identifying an ion that corresponded to the m/z for 
the [M+3H]3+ charge state for the IGF-I T1 peptide. In order to identify the source of 
the six peptide ions, a targeted LC-MS/MS product ion analysis was performed using 
each of the m/z ions identified by the ANNs model as being important for 
discriminating between the rhGH and placebo states. Using LC-MS/MS analysis and 
database searching, the first ion (m/z 741.2, accuracy of 84%) was subsequently 
identified as the T4 peptide originating from the protein Leucine-rich α-2-glycoprotein 
(LRG). Additional LRG derived tryptic peptides were identified using in silico 
digestion and the existing LC-MS dataset was re-visited to identify the peak areas of the 
LRG T7 and T21 peptides. The product of the area for all three peptides were calculated 
and demonstrated higher overall concentrations within six of the seven individuals 
treated with rhGH. Analysis of the XIC for the m/z 741.2 ion demonstrated two peaks 
that eluted very closely, but were chromatographically separated. It was determined that 
both peaks related to the T4 LRG peptide, and that this phenomenon was attributed to 
the peptide undergoing a deamidation event. For this reason, the T4 peptide was not 
used in further experiments, as deamidation is a spontaneous modification, and not 
easily controlled, and would therefore complicate quantitative analyses.   
  
To further validate LRG as being influenced by the administration of rhGH to humans, 
an additional rhGH administration sample cohort was obtained. These samples were 
then added to the original cohort, totalling 257 samples. A higher throughout analysis 
technique was developed in order to analyse the entire sample set without the influence 
of modifications obtained in the autosampler and instrument response drift. Increased 
throughput was achieved by using a Waters UPLC Aquity ultra high pressure capable 
LC system with an analytical column employing a 1.7 μm particle size. This enabled a 
reduction in overall run time from 95 minutes on the nano LC system to a 5 minute 
method, enabling significantly higher sample numbers to be analysed with a given time 
period. Using this high throughput approach demonstrated that the overall peptide 
separation characteristics were not affected, however the sensitivity was reduced 
between 10 and 20 fold. The 257 serum samples were analysed using an SRM based 
uHPLC-MS/MS approach, where LRG serum concentrations were quantified relative to 
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the SIL peptide standard. IGF-I serum concentrations were quantified in the 257 serum 
samples using a standard addition approach, and compared well to their previously 
determined immunoassay derived values. LC-MS/MS assigned concentrations of LRG 
and IGF-I, from the rhGH treated and placebo individuals, were used to train ANNs 
models for discriminatory purposes. The models were then used to assess a validation 
batch, and results showed that a model generated using both LRG and IGF-I protein 
information obtained the highest prediction capability.  
 
The ACN depletion method and uHPLC-MS/MS approach was applied to the available 
serum samples from the rrGH gene therapy experiments. The approach demonstrated 
the ability to detect and quantify IGF-I and LRG in murine serum, however no increase 
in either protein was identified in samples from the +ve plasmid population.  
 
Since finishing the experimental phase of this project, the Equine LRG protein 
equivalent was identified in Equine plasma, and was shown to increase upon 
administration of both testosterone (194) and rhGH (202). This finding suggests that 
LRG might be a biomarker to the administration of anabolic agents. 
 
The applicability of proteomics technologies and bioinformatics analysis to identify 
biomarkers to GH gene therapy in a murine model was inconclusive, however, this 
approach generated better results when applied to samples from a human rhGH 
administration. Further experiments added weight to the hypothesis that the identified 
protein is rhGH dependent. This outcome suggests that the approach taken within this 
thesis is fit for purpose, and could be applied to other situations such as the 
identification of biomarkers to disease. 
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7. FURTHER WORK 
The majority of further experimental work should focus on the validation of LRG as a 
biomarker to rhGH administration. This would require a number of experiments: 
 
1. Assessment of LRG serum concentration within the population. 
The function of the LRG protein is still unknown, and until recently, analytical 
methodologies for quantifying the protein in human serum were not available. In order 
to obtain the serum concentration range within the population, a large number of 
samples would need to be analysed. These would need to be taken from normal 
individuals as well as athletes to identify the normal distribution of LRG serum 
concentrations within the population.   
 
2. Pharmacodynamic properties of LRG with relation to rhGH administration 
The effect of rhGH on serum levels of LRG would need to be assessed by collecting 
serum samples both pre- and post-administration of a single dose of rhGH. This would 
identify for how long the protein is elevated post-dose, which would indicate how 
useful LRG would be for detecting rhGH abuse. Another experiment would need to be 
performed where rhGH was administered daily to individuals to see if LRG is elevated 
following continued dosing. The analysis of samples from the equine rhGH 
administration project suggested that concentrations of LRG dropped whilst rhGH was 
still being administered. This would need to be assessed within a human model. 
 
3. Improvement of the uHPLC-MS/MS assay to include additional rhGH biomarkers 
This would include targeting more rhGH biomarkers in the uHPLC-MS/MS assay. 
Additional SRM transitions would need to be identified to be able to detect proteins 
such as IGF-II, IGFBP3 and PIIINP. Quotient Bioresearch has already investigated this 
further and a new solid phase extraction based plasma and serum protein extraction 
method, capable of detecting IGF-I, IGF-II, IGFBP2 and IGFBP3 in a single five-
minute analysis, has been developed (203). However, this new method has so far been 
unable to detect peptides from PIIINP, and therefore further work to develop an 
analytical extraction method would be required to detect and quantify this protein. 
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quantitation of apolipoproteins in human serum. Rapid Comm. in Mass Spectrom. 2007, 
21, 3255-3260. (Wrote manuscript and performed all LC-MS/MS experimental work.) 
 
4. R.G. Kay, C. Barton, C. Velloso, P. Brown, C. Bartlett, A. Blazevich, R. Godfrey, G. 
Goldspink, R. Rees, D. Cowan, S. Harridge, C.J. Roberts, P. Teale, and C.S. Creaser 
High-throughput ultra-high-performance liquid chromatography/tandem mass 
spectrometry quantitation of insulin-like growth factor-I and leucine-rich α-2-
glycoprotein in serum as biomarkers of recombinant human growth hormone 
administration. Rapid Comm. in Mass Spectrom. 2009, 23, 3173-3182. (Wrote 
manuscript and performed all LC-MS/MS experimental work.) 
 
Additional peer-reviewed journals that I have been a contributing author during the time 
this project has been performed have been included.  
 
1. J. A. Mead, L. Bianco, V. Ottone, C. Barton, R. G. Kay, K. S. Lilley, N. J. Bond, and 
C. Bessant. MRMaid: the web-based tool for designing multiple reaction monitoring 
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(MRM) transitions. Mol. Cell Proteomics. 2008 8, 696-705. (Contributed through 
advising on SRM selection parameters and helped test MRMaid software iterations.)  
 
2. C. Barton, R.G.Kay. Protein analysis using proteotypic peptides and LC-MS: 
Choosing the right chromatographic separation for optimal coverage or throughput. 
Chromatography Today. 2008 1, 11-14. (Co-authored manuscript, supplied data for 
figures.) 
 
3. C. Barton, P. Beck, R.G. Kay, P. Teale, and C.J. Roberts. Multiplexed LC-MS/MS 
analysis of horse plasma proteins to study doping in sport. Proteomics, 2009 9, 3058-
3065. (Contributed through advising on LC-MS/MS analyses and method 
development.) 
 
4. P. Teale, C. Barton, R.G. Kay, A. Roberts, C.J. Roberts, and L. Hillyer. Targeted 
proteomics using LC-MS/MS for the analysis of doping in horse. Proceedings of the 
17th International Conference of Racing Analysts and Veterinarians, Antalya, Turkey, 
2009. (Contributed through advising on LC-MS/MS analyses and method development) 
 
5. P. Teale, C. Barton, P. Driver, R.G. Kay. Biomarkers: unrealized potential in sports 
doping analysis. Bioanalysis, 2009, 1103-1118. (Co-wrote manuscript.) 
 
6. C. Barton, R.G. Kay, W. Gentzer, F. Vitzthum and S. Pleasance. Development of 
high-throughput chemical extraction techniques and quantitative HPLC-MS/MS (SRM) 
assays for clinically relevant plasma proteins. J. Proteome Res. 2010, 9, 333-340. (Co-
wrote manuscript, performed ACN extractions and analysed all sample extracts.) 
 
All papers are included in Appendix V. 
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9 CONFERENCES AND PRESENTATIONS 
Event Related information Date Duration 
East Midlands Proteomics 
Workshop 
Oral presentation November 2006 1 day 
IMSC 2006, Prague  Presented poster August 2006 5 days 
Proteomics Method Forum Invited oral 
presentation 
June 2007 2 days 
Reid Bioanalytical Forum Oral presentation July 2007 4 days 
East Midlands Proteomics 
Workshop 
Delegate November 2007 1 day 
BMSS Robinson college LC-MS 
conference 
Oral presentation December 2007 2 days 
RSC: Analytical Challenges for 
Biopharmaceutical products 
Oral presentation April 2008 1 day 
HUPO, Amsterdam Presented poster August 2008 4 days 
International Symposium on 
gene doping in sport, Florence 
Presented poster October 2008 3 days 
East Midlands Proteomics 
Workshop 
Oral Presentation November 2008 1 day 
East Midlands Proteomics 
Workshop 
Delegate November 2009 1 day 
BMSS SIMSUG 2010 Invited Oral 
Presentation 
April 2010 2 days 
BSPR 2010 Oral Presentation July 2010 3 days 
 
 
Awards: 
Ed Houghton prize for best publication at Quotient Bioresearch 2007 (Kay et al 2007) 
Best short talk at East Midlands Proteomics Workshop November 2008  
Ed Houghton prize for best publication at Quotient Bioresearch 2008 (Kay et al 2008) 
Represented Chemistry department at Loughborough University Court April 2009 
 
Application note. 
R. G. Kay, P. B. Grace, P. Teale, and J. Hicks. Successful transfer of a 95-minute 
nanoflow LC-MS/MS analysis of serum proteins to a 5-minute UPLC-MS/MS method. 
Waters application note. 2008. (Wrote manuscript) 
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APPENDIX II PROTEINS IDENTIFIED IN A 1D AND 2D LC-MS/MS 
ANALYSIS OF ACN DEPLETED SERUM EXTRACT. 
No. Accession Protein Name Score Mass 
Unique 
Peptides
% 
coverage 
1D SRM 
IDA 
Validated 
PP (08) 
1 APOA1_HUMAN Apolipoprotein A1 9141 28078 14 66.7 ? ? ? 
2 APOA2_HUMAN Apolipoprotein A2 8283 8797 5 74 ? ? ? 
3 A1AG1_HUMAN 
Alpha-1-acid glycoprotein 
1 
7487 21546 
8 
41.3 ? ? ? 
4 APOC3_HUMAN Apolipoprotein C3 4383 8759 5 75.8 ? ? ? 
5 ANGT_HUMAN Angiotensinogen 4272 49729 11 57.7 ? ? ? 
6 FIBA_HUMAN Fibrinogen alpha chain  4165 95715 4 12.5 ? ? ? 
7 APOA4_HUMAN Apolipoprotein A4 3936 43376 21 62.4 ? ? ? 
8 ALBU_HUMAN Serum albumin 3769 66428 33 68.6 ? ? ? 
9 FETUA_HUMAN Alpha-2-HS-glycoprotein 3727 30849 9 54 ? ? ? 
10 APOC2_HUMAN Apolipoprotein C2 3481 8909 4 68.3 ? ? ? 
11 A2GL_HUMAN 
Leucine-rich alpha-2-
glycoprotein 
3189 34325 
13 
60.8 ? ? ? 
12 A1AG2_HUMAN 
Alpha-1-acid glycoprotein 
2 
3020 21922 
7 
46.3 ? ? ? 
13 SAA_HUMAN Serum amyloid A protein 2923 11675 5 63.9 ? ? ? 
14 A1AT_HUMAN Alpha-1-antitrypsin 2473 44296 11 42.6 ? ? ? 
15 HBB_HUMAN Hemoglobin subunit beta 2251 15971 9 82.3 ? ? ? 
16 THRB_HUMAN Prothrombin 2177 65266 10 21.7 ? ? ? 
17 ZA2G_HUMAN Zinc-alpha-2-glycoprotein 2063 32124 13 53.2 ? ? ? 
18 KAC_HUMAN Ig kappa chain C region 1841 11773 6 80.2 ? ? ? 
19 LAC_HUMAN Ig lambda chain C regions 1561 11401 5 80 ? ? ? 
20 APOM_HUMAN Apolipoprotein M 1384 21253 7 57.4 ? ? ? 
21 CO4B_HUMAN Complement C4-B or A 1312 84775 9 10 ? ? ? 
22 HPT_HUMAN Haptoglobin  1209 43321 10 40.4 ? ? ? 
23 A1BG_HUMAN Alpha-1B-glycoprotein 1096 51908 12 39.6 ? ? ? 
24 APOD_HUMAN Apolipoprotein D 1089 19290 6 45 ? ? ? 
25 APOF_HUMAN Apolipoprotein F 1085 17413 4 32.1 ? ? ? 
26 HPTR_HUMAN 
Haptoglobin-related 
protein 
949 37448 
2 
9.4  ? ? 
27 TTHY_HUMAN * Transthyretin 920 13818 5 63.9 ? ? ? 
28 LCAT_HUMAN 
Lecithin-cholesterol 
acyltransferase 
892 47053 9 34.1  ? ? 
29 TRFE_HUMAN Serotransferrin 721 75132 14 28.4  ? ? 
30 HBA_HUMAN Hemoglobin subunit alpha 707 15183 6 76.1 ? ? ? 
31 
IGHG1_HUMAN 
Ig gamma-1 chain C 
region 
623 36596 
10 
45.8  ? ? 
32 HEMO_HUMAN Hemopexin 622 49263 6 29 ? ? ? 
33 HBD_HUMAN Hemoglobin subunit delta 589 16159 3 44.9  ? ? 
34 IGHA1_HUMAN Ig alpha-1 chain C 546 38486 7 38.2  ? ? 
35 CO3_HUMAN Complement C3 506 184834 6 6.8 ? ? ? 
36 VTNC_HUMAN Vitronectin 454 52244 5 13.4 ? ? ? 
37 A2AP_HUMAN Alpha-2-antiplasmin 340 50418 6 21.4  ? ? 
38 APOC1_HUMAN Apolipoprotein C1 293 6630 3 38.6 ? ? ? 
39 CXCL7_HUMAN Platelet basic protein 288 10487 4 37.5   ? 
40 
AMBP_HUMAN 
Contains: Alpha-1-
microglobulin 
266 37090 
3 
10.8  ? ? 
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IDA 
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PP (08) 
41 
IGHG2_HUMAN 
Ig gamma-2 chain C 
region 
263 36489 
4 
33.4  ? ? 
42 VTDB_HUMAN Vitamin D-binding protein 234 51209 2 8.9   ? 
43 CERU_HUMAN Ceruloplasmin 218 119952 4 8.5   ? 
44 SAP_HUMAN   ** Proactivator polypeptide 180 59899 1 5.5    
45 A2MG_HUMAN Alpha-2-macroglobulin 176 160695 8 7.8   ? 
46 
CPN2_HUMAN 
Carboxypeptidase N 
subunit 2 
171 59140 
4 
13.9   ? 
47 SPRC_HUMAN SPARC 141 33496 4 16.2   ? 
48 
SRGN_HUMAN**
* 
Serglycin 134 14798 1 8.2  ?  
49 
RETBP_HUMAN 
Plasma retinol-binding 
protein 
123 21058 3 20.9  ? ? 
50 
KTDAP_HUMAN 
ψ              
Keratinocyte 
differentiation-associated 
protein 
113 8768 2 26.3  ?  
51 APOE_HUMAN Apolipoprotein E 96 34215 3 12  ? ? 
52 
IGF2_HUMAN 
Insulin-like growth factor 
2 
96 7817 
2 
47.7  ? ? 
53 IGJ_HUMAN Immunoglobulin J chain 94 16041 2 16.1  ? ? 
54 
IC1_HUMAN 
Plasma protease C1 
inhibitor 
94 53071 
2 
4.8  ? ? 
55 FA5_HUMAN Coagulation factor 5 93 248335 1 0.9  ? ? 
56 
ECM1_HUMAN 
Extracellular matrix 
protein 1 
92 60409 
1 
2  ? ? 
57 
LMAN2_HUMAN 
Vesicular integral-
membrane protein 
90 35800 
1 
3.1   ? 
58 HRG_HUMAN Histidine-rich glycoprotein 89 57623 3 10.3   ? 
59 B2MG_HUMAN Beta-2-microglobulin  87 11845 1 18.5  ? ? 
60 ACTG_HUMAN Actin, cytoplasmic 2 83 42108 2 13.1  ? ? 
61 
SHBG_HUMAN 
Sex hormone-binding 
globulin 
83 40696 
2 
6.2  ? ? 
62 LUM_HUMAN Lumican 82 37002 2 6.2   ? 
63 
SG3A1_HUMAN θ  Secretoglobin family 3A 
member 1 
76 8281 1 18.3  ?  
64 
SDPR_HUMAN 
Serum deprivation-
response protein 
75 47098 1 3.3  ? ? 
65 
CC126_HUMAN  ξ  Coiled-coil domain-
containing protein 126  
73 12642 1 8.6  ?  
66 
IGF1A_HUMAN 
Insulin-like growth factor 
1 
70 7649 
1 
30  ? ? 
67 
C1R_HUMAN 
Complement C1r 
subcomponent 
67 79696 1 2   ? 
68 LG3BP_HUMAN Galectin-3-binding protein 65 64188 
2 5.6  ? ? 
69 APOH_HUMAN Beta-2-glycoprotein 1 65 36230 1 6.1  ? ? 
70 
C4BPA_HUMAN 
C4b-binding protein alpha 
chain 
55 63724 1 2.3   ? 
71 
ITIH4_HUMAN 
Inter-alpha-trypsin 
inhibitor heavy chain H4 
55 97590 3 4.5  ? ? 
72 
TRML1_HUMAN 
#  
Trem-like transcript 1 
protein 
54 31526 2 11.9    
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73 
CMGA_HUMAN  
+ 
Chromogranin-A  53 49032 1 4.2    
74 DCD_HUMAN Dermcidin 53 9316 1 20.9  ? ? 
75 
ICAM2_HUMAN 
Intercellular adhesion 
molecule 2 
51 28790 1 3.6  ? ? 
76 
PGRP2_HUMAN 
N-acetylmuramoyl-L-
alanine amidase 
48 60550 1 3.1   ? 
77 BIN2_HUMAN Bridging integrator 2 48 62008 1 3   ? 
78 
ACTC_HUMAN 
Actin, alpha cardiac 
muscle 1 
45 42069 
2 
7.2   ? 
79 PLMN_HUMAN Plasminogen 45 88374 1 1.6  ? ? 
80 BTD_HUMAN Biotinidase 45 57512 2 6.5   ? 
81 
FHR3_HUMAN 
Complement factor H-
related protein 3 
44 36508 1 3   ? 
82 PI16_HUMAN Peptidase inhibitor 16 40 47347 1 4.1   ? 
83 CFAB_HUMAN Complement factor B 39 84312 1 1.8   ? 
84 CLUS_HUMAN Clusterin 38 50087 2 7.3  ? ? 
85 
KNG1_HUMAN   $ 
Kininogen-1 Contains 
bradykinin 
34 69852 
1 
1.4 
 
 ? 
 
* Transythretin is present as a covalently bound homo tetramer in plasma/serum  
** Saposin B is a 79 aa peptide processed from immature SAP_HUMAN 
*** Serglycin (131 aa) is secreted by macrophages and endothelial cells 
ψ KTDAP is a 77 aa protein expressed highly in skin, thought to be secreted  
θ Secretoglobin is an 84 amino acid protein thought to be secreted 
ξ CC126 protein is a 114 aa glycoprotein of unknown function thought to be secreted  
# Both peptides are from the extracellular domain of TRML1 protein 
+ Peptide was from GR-44 from Chromogranin A (known to be secreted into CSF). 
$ The peptide used to identify Kininogen was Bradykinin, a 9 aa serum peptide 
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APPENDIX III LETTER TO WADA REGARDING ETHICAL APPROVAL   
Dear Dr Steff  
With reference to your letter of the 4th October regarding our successful submission for 
funding for research into the detection of gene doping and your request for animal and 
ethical committee approval documents, I have been in communication with Professor 
Goldspink of The Royal Free Hospital, London, the member of the consortium 
providing animal and human samples for the research program. Regarding human 
samples, these will be obtained following administrations of Growth hormone / IGF-1 
carried out as part of an on-going WADA funded research project currently being 
undertaken by Professor Goldspink’s group and will require no further administration or 
sample collection procedures to be undertaken, WADA are already in possession of 
appropriate documentation for this study. As such we believe the appropriate approvals 
for the work have already been obtained and provided to WADA. Regarding animal 
administrations and sample collection all such work carried out within the UK is 
licensed and tightly regulated by the Home Office, a government department. Prior to 
granting an individual license (which must be renewed every four years) the licensing 
authority undertakes a generic ethical review. Ethical approval of individual projects is 
not required within this system. The Home Office do not allow a copy of the licence to 
be e-mailed/faxed from the Institution but the appropriate details for Professor 
Goldspink and his deputy can be found below.  
Project Licence:  
Professor Geoffrey Goldspink:  
Licence No: PPL 70/6097  
Expiry date: 14 June 2009  
Personal Licence PIL 70/11260  
Dr Shi Yu Yang, Veterinarian MVS, PhD  
Licence No: No expiry date  
Based upon the above we believe we already have in place all the necessary approvals 
to commence the research program described in our submission.  
Yours Sincerely  
Phil Teale 
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APPENDIX IV GH GENE THERAPY SAMPLE INFORMATION. 
GH +ve plasmid GH +ve plasmid GH +ve plasmid 
Sample heam ? Batch sample heam ? Batch sample heam ? Batch 
1.1.1  1 2.1.1  1 3.1.1  1 
1.1.2  1 2.1.2  1 3.1.2 Y 1 
1.2.1 Y 1 2.2.1  1 3.2.1  1 
1.2.2  1 2.2.2  1 3.2.2  1 
1.3.1 Y 1 2.3.1 Y 1 3.3.1  1 
1.3.2  1 2.3.2  1 3.3.2 Y 1 
1.4.1  1 2.4.1 Y 1 3.4.1  1 
1.4.2  1 2.4.2  1 3.5.1 Y 1 
1.5.1  1 2.5.1 Y 1    
1.5.2  1 2.5.2  1    
1.1.1  2 2.1.1  2 3.1.1  2 
1.1.2 Y 2 2.1.2  2 3.1.2  2 
1.2.1 Y 2 2.2.1  2 3.2.1  2 
1.2.2 Y 2 2.2.2 Y 2 3.2.2 Y 2 
1.3.1 Y 2 2.3.1  2 3.3.1  2 
1.3.2 Y 2 2.3.2 Y 2 3.3.2  2 
1.4.1 Y 2 2.4.1 Y 2 3.4.1  2 
1.4.2  2 2.4.2 Y 2 3.4.2 Y 2 
1.5.1  2 2.5.1 Y 2 3.5.1  2 
1.5.2 Y 2 2.5.2  2 3.5.2 Y 2 
1.6.1  3 2.6.1  3 3.6.1 Y 3 
1.7.2  3 2.6.2 Y 3 3.6.2  3 
1.8.1 Y 3 2.7.1 Y 3 3.7.1  3 
1.8.2 Y 3 2.7.2  3 3.7.2  3 
1.9.1  3 2.8.1  3 3.8.1  3 
1.9.2 Y 3 2.8.2  3 3.8.2 Y 3 
1.10.1  3 2.9.1 Y 3 3.9.1  3 
1.10.2 Y 3 2.9.2 Y 3 3.9.2 Y 3 
   2.10.1 Y 3 3.10.1 Y 3 
   2.10.2  3 3.10.2 Y 3 
1.11.1 Y 4 2.11.1 Y 4 3.11.1 Y 4 
1.11.2 Y 4 2.11.2  4 3.11.2 Y 4 
1.12.1 Y 4 2.12.1  4 3.12.1 Y 4 
1.12.2 Y 4 2.12.2 Y 4 3.12.2  4 
1.13.1 Y 4 2.13.1 Y 4 3.13.1 Y 4 
1.14.1  4 2.13.2  4 3.13.2 Y 4 
1.14.2  4 2.14.1  4 3.14.1 Y 4 
1.15.1 Y 4 2.14.2 Y 4 3.14.2  4 
1.15.2 Y 4 2.15.1 Y 4 3.15.1 Y 4 
   2.15.2 Y 4 3.15.2 Y 4 
1.16.1  5 2.16.1  5 3.16.1 Y 5 
1.16.2 Y 5 2.16.2  5 3.16.2 Y 5 
1.17.1 Y 5 2.17.1 Y 5 3.17.1 Y 5 
1.17.2 Y 5 2.17.2  5 3.17.2  5 
1.18.1 Y 5 2.18.1 Y 5 3.18.1 Y 5 
1.18.2 Y 5 2.18.2 Y 5 3.18.2  5 
1.19.1  5 2.19.1  5 3.19.1 Y 5 
1.19.2 Y 5 2.19.2  5 3.19.2 Y 5 
1.20.1 Y 5 2.20.1 Y 5 3.20.1 Y 5 
1.20.2 Y 5 2.20.2 Y 5 3.20.2 Y 5 
Grey boxes indicate samples that were available from Batch 1 for the large cohort 
analysis.  
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